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Abstract 
There is an urgent need to identify markers of diagnostic and prognostic 
significance that can help in the development of novel cancer therapeutics. The 
principal aim of the present study was to evaluate nicastrin and EP300 as 
potential markers associated with breast cancer drug resistance. Nicastrin is a 
component of γ-secretase, an intermembrane complex of four proteins with 
roles in proliferation, cell adhesion and tamoxifen resistance. EP300 is a histone 
acetyltransferase and a transcriptional activator of E-cadherin which has been 
shown to regulate epidermal-to-mesenchymal transition and doxorubicin 
resistance via escape from drug-induced senescence. 
Using breast cancer cellular models in which nicastrin had been modulated or γ-
secretase activity impaired with an inhibitor, we have found an insignificant role 
of nicastrin in altering chemosensitivity to doxorubicin and paclitaxel. 
Similarly, we have used stably transfected breast cancer cell models in which 
EP300 was either over-expressed or down-regulated and a knocked-out EP300 
colon carcinoma cell model. We have confirmed EP300 role in regulating E-
cadherin levels in vitro, to alter paclitaxel sensitivity and the generation of drug 
resistance. Furthermore, EP300 silencing was associated with increased in vitro 
tumourigenicity and cancer stem cell-like properties, while its ectopic 
expression in mesenchymal breast cancer cells rescued the epithelial, 
differentiated, paclitaxel sensitive phenotype. 
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Gene expression profiling identified down-stream EP300 targets associated with 
drug resistance, epithelial-to-mesenchymal transition and cancer stem cells 
including ABCG2, BCL2, TNFRSF11B and TGFB2. Finally, 
immunohistochemical analysis of patient samples revealed a strong correlation 
between co-expression of EP300 and E-cadherin, particularly in metaplastic 
breast cancer, a rare aggressive form of invasive breast cancer with histological 
evidence of epithelial-to-mesenchymal transition which has a poor clinical 
outcome.  
Taken together, this study highlights the role of EP300 in mediating paclitaxel 
resistance by apoptosis evasion, probably via up-regulation of Bcl-2, and its link 
to regulation of epithelial-to-mesenchymal transition and stemness. 
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Chapter 1: General Introduction 
 
1.1 Breast cancer incidence 
Breast cancer is one of the leading causes of cancer-associated death among the 
female population worldwide (Downs-Holmes and Silverman 2011, Kotiyal and 
Bhattacharya 2014) and is the second most common cancer in the world 
(Murray and Lopez 1997). According to the World Health Organization it is by 
far, the most frequent cancer among women with 1.67 million new cancer cases 
diagnosed in 2012, corresponding to 25% of all cancers (Levaggi, Poggio et al. 
2014). Breast cancer incidence rates vary across the world ranging from 27 per 
100,000 in Middle Africa and Eastern Asia to 92 per 100,000 in Northern 
America (GLOBOCAN 2012, Zujewski 2015). At present, the majority of new 
cases, and the majority of breast cancer deaths, occur in less developed regions 
of the world (Ferlay, Soerjomataram et al. 2015). Breast cancer ranks as the 
fifth most common cause of death accounting for 522,000 cancer-associated 
deaths and it is the most frequent cause of cancer death in women in less 
developed countries (324,000 deaths, 14.3% of total) (GLOBOCAN 2012). 
Moreover, it is now the second most common cause of cancer death in more 
developed countries (198,000 deaths, 15.4%) after lung cancer (Ferlay, 
Steliarova-Foucher et al. 2013). The mortality rates is less than that for 
incidence worldwide because of the more favorable survival of breast cancer in 
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(high-incidence) developed regions, with rates ranging from 6 per 100,000 in 
Eastern Asia to 20 per 100,000 in Western Africa (IARC 2012).  
 
1.2 Molecular subtypes of breast cancer 
Breast cancer death is very much associated with the type and grade of the 
disease. Extensive genomic analysis of breast cancers differentiates four 
coherent groups (Cancer Genome Atlas 2012), similar to the intrinsic subtypes 
(Table 1.1) defined by gene expression profiling (Sorlie, Perou et al. 2001). 
Breast cancer subtypes can also be defined by multiparameter molecular tests 
such as the PAM-50 (Bastien, Rodriguez-Lescure et al. 2012) or 
MammaPrint/BluePrint (Bayraktar, Royce et al. 2014). 
Histologically, breast cancers can be broadly divided into: in situ (ductal and 
lobular) and invasive (or infiltrating) carcinoma according to the distinct micro-
anatomical structure of the normal breast (Li, Uribe et al. 2005). In situ 
carcinoma includes: ductal carcinoma in situ (DCIS) and lobular carcinoma in 
situ (LCIS). Invasive breast carcinoma may be either ductal or lobular in origin 
and comprises invasive ductal carcinoma (IDC) and invasive lobular carcinoma 
(ILC), respectively (Li, Uribe et al. 2005). These histological types of breast 
cancers are more elaborated in Chapter 6. Microarray-based gene expression  
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Table 1.1: Breast cancer intrinsic subtypes defined by immunohistochemistry 
Subtype Occurrence 
(%) 
ER PR HER2  
(ErbB2) 
CK5/6 EGFR Ki67 
Luminal A ~40 + (high) +/ -       - Any Any low  
Luminal B ~20 + (low) +/ -      + Any Any high 
HER2- enriched 10-15 - -      + Any Any Any 
Basal-like or 
Triple-negative 
15-20 - -      - CK5/6 or EGFR 
positive 
Any 
Normal breast-
like 
5-15 - -      - - - Any 
ER/ PR = Estrogen/ Progesterone Receptor, HER2 = Human Epidermal Growth Factor Receptor-2, EGFR = Epidermal Growth Factor 
Receptor,   ErbB2 = Erythroblastic Leukemia Viral Oncogene Homolog 2, CK5/6 = Cytokeratin 5/6 
 
profiling (performed on tissue microarrays), based on immunophenotyping 
using a six-marker panel, has identified five major biologically distinct intrinsic 
molecular subtypes (Table 1.1) having different clinicopathological features and 
variable prognosis (Voduc, Cheang et al. 2010, Guiu, Michiels et al. 2012).  
 
1.3 Breast cancer diagnosis and molecular profiling 
The diagnosis of breast cancer is based on clinical examination together with 
imaging, and is confirmed by pathological assessment (Senkus, Kyriakides et al. 
2015) as outlined in Table 1.2.  
Pathological diagnosis is performed by ultrasound or stereotactic guided core 
needle biopsy (CNB), fine needle aspiration cytology (FNAC) and sentinel 
lymph node biopsy (SLNB). A CNB is indicated before initiating any type of 
treatment and is mandatory if preoperative systemic therapy is intended  
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Table 1.2: Assessments for breast cancer diagnosis 
A. Assessment of general health status  
 History 
 Menopausal status 
 Physical examination 
 Full blood count 
 Liver, renal and cardiac (in patients planned for anthracycline and/or 
trastuzumab treatment) 
 function tests, alkaline phosphatase and calcium 
B. Assessment of primary tumour  
 Physical examination 
 Mammography 
 Breast ultrasound 
 Breast MRI 
 Core biopsy with pathology determination of histology, grade, ER, 
PR, HER-2 and Ki67 
C. Assessment of regional lymph nodes  
 Physical examination 
 Ultrasound 
 Ultrasound-guided biopsy if suspicious 
D. Assessment of metastatic disease  
 Physical examination 
 Other tests are not routinely recommended, unless locally advanced 
or when symptoms suggestive of 
 metastases are present 
MRI, magnetic resonance imaging; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal  
growth factor 2 receptor. (Senkus, Kyriakides et al. 2015) 
 
(Senkus, Kyriakides et al. 2015). An ultrasound-guided FNAC is preferable in 
evaluating lymph node status for the follow-up patients (Hammon, Dankerl et 
al. 2015). In newly diagnosed patients, FNAC is used with high accuracy, 
sensitivity and specificity to predict lymph node metastases (Ahn, Kim et al. 
2013). In patients with a clinically node-negative breast cancer, SLNB is 
adopted as a suitable approach to axillary staging (Lyman, Temin et al. 2014). 
Final pathological diagnosis is carried out according to the World Health 
Organization (WHO) classification (Lakhani, Ellis et al. 2012) and the tumour–
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node–metastases (TNM) staging system (Senkus, Kyriakides et al. 2015). The 
pathological report includes: the histological type, grade, immunohistochemical 
(IHC) evaluation of oestrogen receptor (ER) status (using a standardised 
assessment methodology, e.g. Allred or H-score) and, for invasive cancer, IHC 
evaluation of progesterone receptor (PR) and human epidermal growth factor 2 
receptor (HER2) gene expression. Proliferation markers, such as the Ki67 
labelling index, provide additional useful and valuable information with 
prognostic significance (Dowsett, Nielsen et al. 2011). 
The hormone receptor status defining the intrinsic subtypes of breast cancers is 
key to the pathological diagnosis of this deadly disease (Senkus, Kyriakides et 
al. 2015). The presence or absence of estrogen receptor (ER), progesterone 
receptor (PR) and Human epidermal growth factor receptor 2 (HER2) forms the 
main component of routine diagnosis of breast cancer from clinical specimens 
(Zoon, Starker et al. 2009). As described in table 1.3, this is accompanied by 
serum specific and gene expression profiling methods based on the purpose and 
stage of the disease (Table 1.3). These molecular diagnostic tests enables 
personalized diagnostic information as well as specific tailor-made treatment 
plans, and thereby minimizes not only the disease burden but also the 
generation of resistance.  
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Table 1.3: Methods for breast cancer diagnosis 
Assay Description Purpose Disease stage 
Tissue 
requirement 
A. Hormone receptor and protein expression methods     
ER LBA or IHC 
Guide for 
therapy and 
prognosis 
All stages, at 
initial diagnosis 
Fresh or FFPE 
(blocks or 
sections) 
PR LBA or IHC 
Guide for 
therapy and 
prognosis 
All stages, at 
initial diagnosis 
Fresh or FFPE 
(blocks or 
sections) 
HER2 IHC or FISH 
Guide for 
therapy and 
prognosis 
All stages, at 
initial diagnosis 
Fresh or FFPE 
(blocks or 
sections) 
HERmark™ 
For total HER2 expression and 
HER2 homodimers 
Guide for 
therapy and 
prognosis 
All stages, at 
initial diagnosis 
FFPE (blocks or 
sections) 
B. Blood or serum specific methods 
CellSearch® 
Computes circulating tumour 
cells of epithelial origin 
Early detection 
and prognosis of 
metastases 
Asymptomatic 
patients and all 
stages 
blood sample  
(7.5-ml) 
Biomarker 
Translation 
Test 
Detects and quantifies key 
biomarker levels 
Screening or 
early detection 
Asymptomatic 
patients 
blood sample  
(10-ml) 
C. Gene expression profiling methods 
MammaPrint™ 
Gene expression profiling (70 
genes) to predict clinical 
outcome of breast cancer 
Prognosis Stage 1 or 2 
3-mm3 fresh 
sample in RNA-
stabilizing 
solution 
OncoVue® Test 
Combines the SNP patterns of 
117 genes and individual 
history to predict breast cancer 
risk 
Screening 
Patients without 
family history, 
before 
radiologically or 
clinically detected 
Cheek cell 
collection by oral 
rinse 
GeneSearch™ 
breast lymph 
node 
Detection of gene expression 
markers: Mammaglobin and 
cytokeratin 19 by qRT-PCR 
Detects breast 
tumour cell 
metastasis in 
lymph nodes 
Node-negative, 
T1–T3 invasive 
carcinoma 
2–3-mm3 fresh 
sentinel lymph 
node biopsy 
Nipple fluid 
aspiration 
Evaluates DNA methylation 
status of breast epithelial cells 
via quantitative multiplex 
methylation-specific PCR 
Early detection 
High-risk 
patients, before 
radiologically or 
clinically 
detectable 
Small volume of 
aspirate from non-
lactating women 
DiaGenic 
BCtect® 
Analyzes gene expression 
signatures from peripheral 
blood 
Early detection 
Asymptomatic 
patients 
Blood sample 
Oncotype 
DX®* 
Measures ER, PR and HER2 
gene expression via qRT-PCR 
Prognostic and 
predictive value 
Early (stage I and 
II) 
FFPE (block or 
sections) 
Theros H/ISM 
and MGISM 
Measures two-gene ratio and 
five-gene expression index 
Prognostic and 
predictive value 
Stage 1, 2 and 3 
FFPE (block or 
sections) 
ER: Estrogen receptor; LBA: Ligand-binding assay; IHC: Immunohistochemistry; FFPE: Formalin-fixed paraffin-embedded; PR: Progesterone receptor; HER2: 
Human epidermal growth factor receptor 2 (Zoon, Starker et al. 2009) 
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The CellSearch® test is the only FDA-approved method currently used for the 
assessment of the circulating tumour cells (CTCs) aiding in the prognosis of 
patients with metastatic breast cancer. The prognosis of breast cancer based on 
this method relies on the isolation and identification of CTCs from the 
peripheral blood of the patient. The result of the test provides a strong, 
independent predictor of survival (Riethdorf, Fritsche et al. 2007). 
Gene expression based molecular profiling methods are used for various 
purposes, starting from early detection and screening of breast cancer, to the 
prediction and prognosis for breast cancer survival (Table 1.3). For example, 
MammaPrint® test is a 70-gene signature-based molecular diagnostic method 
used to assess chance of tumour recurrence. This is a powerful tool employed 
for the clinicopathologic risk assessment in patients with node-negative breast 
cancer. The 70 gene signature used in this microarray profiling method have 
independent prognostic value (Zoon, Starker et al. 2009). 
Oncotype DX® is used currently as the standard breast cancer screening test for 
the detection of early stage (I or II), node-negative, ER-positive invasive breast 
cancer. The test involves a qRT-PCR and microarray based 21-gene expression 
assay to report a recurrence score (from 0 to 100), indicating the probability of 
recurrence within 10 years of initial diagnosis. Patients are grouped as low, 
intermediate or high-risk group based on this recurrence score. This method can 
be used as a powerful molecular tool for identification of patients who can be 
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treated with chemotherapy and to determine the chance of recurrence of 
invasive subtype of breast cancer after treatment (Zoon, Starker et al. 2009). 
 
1.4 Management and treatment of breast cancer 
An early detection of breast cancer is essential for effective management and 
treatment of the disease in addition to reducing the mortality and morbidity 
(Chan, Wiseberg-Firtell et al. 2015). Breast cancer treatment is provided by a 
multi-disciplinary team specialized in the disease and include at least one 
surgeon, radiation oncologist, medical oncologist, radiologist and pathologist 
(Wilson, Marotti et al. 2013). The choice of treatment strategy be based on the 
tumour burden and/or location (size and location of primary tumour, number of 
lesions, extent of lymph node involvement) and biology (pathology, including 
biomarkers and gene expression), as well as the age and general health status of 
the patient (Senkus, Kyriakides et al. 2015). 
Strategies for breast cancer prevention encompass lifestyle modifications, such 
as avoidance of obesity, physical activity, and restraining alcohol intake, as well 
as surgical and therapeutic interventions (Cuzick, DeCensi et al. 2011). In early 
breast cancer, routine staging and risk assessment evaluations are directed at 
local and regional spread of disease (Figure 1.1) as the asymptomatic distant 
metastases are very rare (Harris, Fritsche et al. 2007, Senkus, Kyriakides et al. 
2015). In more advanced and malignant cases, the treatment and management 
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includes appropriate combination of surgical and therapeutic interventions 
based on the final diagnosis of the disease. The overall management and 
treatment of breast cancer includes: A. local treatment and B. adjuvant systemic 
treatment (Senkus, Kyriakides et al. 2015) and is discussed briefly as follows. 
Figure 1.1: Treatment algorithm for early breast cancer. CT = chemotherapy, BCS = 
breast-conserving surgery, ET = endocrine therapy and RT = radiotherapy. The figure has 
been modified from (Senkus, Kyriakides et al. 2015) 
 
1.4.1 Local treatments  
Local treatment of primary breast cancer comprises both surgical excision of the 
tumour as well as radiation therapy. Surgery includes breast-conserving surgery 
(BCS) and mastectomy (Figure 1.1).  
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Breast-conserving surgery (BCS) involves oncoplastic procedures for complete 
removal of the breast tumour keeping appropriate margins of surrounding 
healthy tissues (Franceschini, Martin Sanchez et al. 2015).  
Breast cancer treatment by mastectomy encompasses both the standard as well 
as nipple- and skin-sparing, and skin reducing procedures (Atiyeh, Dibo et al. 
2014, Franceschini, Martin Sanchez et al. 2015). Skin-sparing mastectomy 
enables the skin envelope to be preserved for use in the breast reconstruction 
(Senkus, Kyriakides et al. 2015). Unlike BCS, this is an aggressive treatment 
and is often accompanied by immediate reconstructive procedures 
(Franceschini, Martin Sanchez et al. 2015).  
Surgical removal of a discrete portion or "lump" of breast, usually in the 
treatment of malignant tumour or breast cancer is achieved by lumpectomy. The 
amount of tissue removed is limited, compared to a full-breast mastectomy.  
Breast reconstruction may be performed either immediately at the time of 
mastectomy or may be delayed until the patient has recovered the mastectomy 
and has completed the adjuvant therapy (Ananthakrishnan and Lucas 2008). 
Yet, a third option is an immediate-delayed reconstruction for patients who are 
at high risk requiring a post-mastectomy radiotherapy awaiting review of 
permanent sections resected during mastectomy. Postoperative radiation therapy 
(RT) is strongly recommended after breast-conserving surgery (BCS) (Early 
Breast Cancer Trialists' Collaborative, Darby et al. 2011). Post-mastectomy RT 
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(PMRT) is recommended for high-risk patients and employed for routine use in 
patients with one to three positive axillary lymph nodes (Ebctcg, McGale et al. 
2014).  
1.4.2 Adjuvant systemic treatments 
Adjuvant therapy for breast cancer is instilled in addition to the primary, main 
or initial therapy: to maximize the chance of long-term disease-free survival, to 
increase the effectiveness of main therapy and to prevent and/or reduce the 
relative risk of recurrence. Primary breast cancer patients receive systemic 
therapy in the adjuvant setting, preferably within 2-6 weeks post-surgery 
(Lohrisch, Paltiel et al. 2006). Factors determining the treatment 
recommendations for adjuvant treatment include: classic anatomic and 
pathologic factors, such as tumour size, tumour grade, and lymph node (LN) 
status (Hernandez-Aya and Gonzalez-Angulo 2013); patient’s biological age, 
general health status, co-morbidities and preferences (Lohrisch, Paltiel et al. 
2006); and predicted sensitivity to particular treatment types, expected benefits 
from their use and an individual’s risk of relapse (Senkus, Kyriakides et al. 
2015).  
The standardised recommended chemotherapy (Table 1.4) given in an adjuvant 
setting, can lead to substantial improvement of clinical outcomes in breast 
cancer patients (Hernandez-Aya and Gonzalez-Angulo 2013). 
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Table 1.4: Classical and current chemotherapy regimens in adjuvant breast cancer therapy  
Chemotherapy Regimen 
CMFa 6 cycles of C 100 X 14 + M 40 X 2 + 5-FU 600 X 2, given q 28 d 
ACa 4 cycles of A 60 + C 600, given IV q 21 d 
ECa 4 cycles of E 90 + C 600, given IV q 21 d 
FACa 6 cycles of 5-FU 500 X 2 + A 50 X 1 + C 500 IV X 1, q-3 wk 
FECa 6 cycles of 5-FU 500 X 2 + E 60 X 2 + C 500 IV X 1, q-4 wk 
AC→P 4 cycles of A 60 C 600 q-3 wk→12 cycles of P 80 q-wk 
AC→D 4 cycles of A 60 C 600 q-3 wk→4 cycles of D 100 q 3-wk 
FEC→D  3 cycles of F 500 E 100 C 500 q-3 wk →3 cycles of D 100 q 3-wk 
FEC→P 3 cycles of F 600 E 90 C 600 q-3 wk→8 cycles of P 100 q-wk 
Dose-dense 
AC→P 
4 cycles of A 60 C 600 q-2 wk→4 cycles of P 175 q-2 wk + filgastrim 
days 3–10 
Data are drug dose, mg/m2 x frequency per cycle: x 14 = days, 1–14 oral; x2 5 days, 1 and 8 IV; x1 = day 1 IV; q- = every. A = doxorubicin; 
C = cyclophosphamide; D = docetaxel; E = epirubicin; F = 5-fluorouracil (5-FU); IV = intravenous; M = methotrexate; P = paclitaxel. 
aClassical and chemotherapy regimens. (Hernandez-Aya and Gonzalez-Angulo 2013) 
 
Post-operative systemic adjuvant therapies are tailored according to the intrinsic 
sub-type of breast cancer (Table 1.1). As recommended in the latest St Gallen 
International Breast Cancer Conference 2015 (Coates, Winer et al. 2015), the 
sub-type specific adjuvant chemotherapy can be outlined in the following table 
(Table 1.5): 
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Table 1.5: Post-operative adjuvant systemic treatment for specific sub-types of breast cancer 
Clinical grouping Type of therapy 
1. Triple-negative Cytotoxic chemotherapy including anthracycline and 
taxanes 
2. ER negative and HER2-positive  
T1a node negative No systemic therapy 
T1 b,c node negative Chemotherapy plus trastuzumab 
Higher T or N stage Anthracycline→taxane with concurrent trastuzumab 
continued to 12 months 
3. ER positive and HER2-positive As above plus endocrine therapy appropriate to 
menopausal status as below 
4. ER positive and HER2-negative 
(luminal disease) 
 
Without markers of less endocrine 
responsiveness (luminal A-like) 
Endocrine therapy alone according to menopausal status 
Premenopausal low risk Tamoxifen 5 years 
Premenopausal other Tamoxifen 5–10 years or OFS plus tamoxifen or OFS 
plus exemestane 
Postmenopausal low risk Tamoxifen 5 years 
Postmenopausal other AI preferably up front; extended adjuvant therapy  
With markers suggesting lesser 
endocrine responsiveness  
(luminal B-like) 
Endocrine therapy as above plus adjuvant cytotoxic 
chemotherapy in many cases 
OFS = ovarian function suppression, AI = aromatase inhibitor. (Coates, Winer et al. 2015) 
 
1.4.3 Neoadjuvant systemic treatments 
Neoadjuvant therapy is recommended in locally advanced and ‘operable’ breast 
cancers, in particular when mastectomy is required due to larger tumour size. 
Primary systemic therapy, given prior to local treatment, in a neoadjuvant 
setting, may decrease the extent of surgery needed (Senkus, Kyriakides et al. 
2015). Preoperative systemic neoadjuvant therapy not only renders inoperable 
tumours resectable but also allows the down-staging of patients with operable 
breast cancer who desire breast conservation (Gralow, Burstein et al. 2008). 
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1.4.4 Endocrine therapy or hormone therapy 
Endocrine therapy, also known as hormone therapy, is indicated for estrogen 
receptor (ER)-positive breast cancers (Table 1.5). Hormone therapy slows or 
stops the growth of hormone-sensitive (i.e. estrogen-responsive) tumours by 
blocking the body’s ability to produce the hormone (estrogen) or by interfering 
with its action. Strategies to treat hormone-sensitive breast cancers (Table 1.6)  
 
Table 1.6: Endocrine therapy for breast cancer 
Strategy Class/Type of drug Mode of action Example 
(Brand) 
A. Blocking 
ovarian 
function 
Gonadotropin-releasing 
hormone (GnRH) agonists 
or luteinizing hormone-
releasing hormone (LH-RH) 
agonists 
interfering with signals from 
the pituitary gland that 
stimulate the ovaries to 
produce estrogen 
goserelin 
(Zoladex®) 
leuprolide 
(Lupron®) 
B. Blocking 
estrogen 
production 
Aromatase inhibitors (AIs) blocking the activity of 
aromatase enzyme by either 
temporary or permanent 
inactivation 
anastrozole 
(Arimidex®) 
letrozole 
(Femara®) 
exemestane 
(Aromasin®) 
formestane 
(Lentaron®) 
C. Blocking 
estrogen’s 
effects 
Selective estrogen receptor 
modulators (SERMs) 
interfering with estrogen’s 
ability to stimulate the growth 
of breast cancer cells by 
binding to estrogen receptors 
tamoxifen 
(Nolvadex®) 
raloxifene 
(Evista®) 
toremifene 
(Fareston®) 
  Other antiestrogen drugs functioning as an estrogen 
antagonist 
fulvestrant 
(Faslodex®) 
(Available at: http://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet)  
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include:  suppressing ovarian function of estrogen production by using 
gonadotropin-releasing hormone (GnRH) agonists (e.g. goserelin and 
leuprolide); blocking estrogen production by using aromatase inhibitors (e.g. 
anastrozole and exemestane); modulating estrogen function by using selective 
estrogen receptor modulators, SERMs (e.g. tamoxifen and raloxifene), and anti-
estrogen compounds (e.g. fulvestrant) (NCI 2012). 
 
1.5 Drug resistance in breast cancer  
Despite the increasing arsenal of anticancer agents and the advent of molecular 
targeted therapies, drug resistance in cancer is not uncommon (Raguz and 
Yague 2008). Chemotherapy failure not only limits the efficacy of the treatment 
(Holohan, Van Schaeybroeck et al. 2013) but also increases the burden of 
cancer death (Yague, Arance et al. 2007). In breast cancer, both intrinsic or de 
novo and acquired types of drug resistance are reported (Rexer and Arteaga 
2012, Oida, Matsuda et al. 2014). In the case of intrinsic resistance, before 
receiving chemotherapy, resistance-mediating factors pre-exist in the bulk of 
tumour rendering the therapy ineffective. Acquired drug resistance, on the other 
hand, can emerge during the course of the treatment for tumours that were 
initially responding to the same therapy. This eventually leads to treatment 
failure and ultimately to progression of the disease and tumour recurrence. 
Acquired chemotherapy resistance is attributed to various causes, viz., mutations 
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during treatment, and can occur through various other adaptive responses, e.g. 
elevated expression of the therapeutic target and activation of alternative 
compensatory signalling mechanisms (Holohan, Van Schaeybroeck et al. 2013). 
Acquisition of drug resistance has a clinically unfavourable outcome of multi-
drug resistance (MDR), as in such case, the tumour cells that were initially 
responding to the original combination of the drugs becomes resistant to new 
compounds having unrelated and different modes of action (Yague, Arance et 
al. 2007).  
In general, both pharmacokinetic (PK) factors viz., absorption, distribution, 
metabolism and elimination (ADME) of the drug, as well as pharmacodynamic 
(PD) properties of the compound may contribute to the development of 
resistance. For example, inadequate access of the drug to the tumour cell, poor 
infusion rate or influx, decreased drug uptake, excessive drug metabolism by 
detoxifying enzymes and efflux due to overexpression of drug transporters, all 
of which might contribute to the mechanisms underlying acquired resistance. 
The anticancer activity of a drug can also be limited by drug inactivation or lack 
of activation, alterations in the expression levels of the drug target, triggering of 
adaptive prosurvival responses, and importantly, changes in drug-induced 
apoptosis (Yague, Arance et al. 2007, Holohan, Van Schaeybroeck et al. 2013). 
In breast cancer, there is evidence of both de novo as well as acquired 
resistance, not only for traditional drugs, such as doxorubicin and paclitaxel, but 
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also for targeted chemotherapeutic agents such as tamoxifen. Prominent 
examples include doxorubicin resistance by overcoming drug-induced 
senescence (Zhou, Hu et al. 2014), tamoxifen resistance by overexpression of 
HER2/neu (HER2) and the estrogen receptor (ER) (Shou, Massarweh et al. 
2004), and trastuzumab resistance by cyclin E amplification/overexpression in 
HER2-positive breast cancer patients (Scaltriti, Eichhorn et al. 2011). In many 
instances, breast cancer therapy failure occurs mainly due to emergence of 
recurrent endocrine-resistant tumours, and attempts have been made to elucidate 
the mechanisms underpinning such resistance (Weinberg, Marquez-Garban et 
al. 2005, Raguz and Yague 2008). Altered growth factor signalling, mediated by 
EGFR and insulin-like growth factor I receptor (IGF-IR), are also responsible 
for the development of anti-estrogen resistance  (Raguz and Yague 2008). A 
recent evidence suggests the involvements of micro-RNAs in the regulation of 
multi-drug resistance (MDR) in breast cancer. Specifically, overexpression of 
the microRNA (miR)-106b~25 cluster leads to generation of doxorubicin 
resistance in breast cancer cells by overcoming doxorubicin-induced senescence 
(Zhou, Hu et al. 2014). 
It has also been suggested that the tumour microenvironment could play 
important roles in breast cancer therapy resistance, endocrine resistance (Andre, 
Berrada et al. 2010, Martinez-Outschoorn, Goldberg et al. 2011, Pontiggia, 
Sampayo et al. 2012, Holton, Bergamaschi et al. 2014). Elevated stromal gene 
37 
 
expression predicts resistance to neoadjuvant chemotherapy with the 
combination trio of 5-fluorouracil, epirubicin and cyclophosphamide (FEC), 
implying that stromal activation could be involved in chemotherapy resistance 
in breast cancer (Farmer, Bonnefoi et al. 2009). The relatively small proportion 
of stem-cell-like populations known as the tumour-initiating or progenitor cells 
also potentially exacerbate drug resistance (Vinogradov and Wei 2012). 
Importantly, breast cancer stem cells are reported to be highly resistant to both 
radiation therapy as well as chemotherapy (Kakarala and Wicha 2008). This 
emphasises the need for developing therapeutic strategies targeting cancer stem 
cells (Figure 1.2). 
 
Figure 1.2: Therapies targeting cancer stem cells (CSCs). CSC-directed therapeutic 
strategies include selective targeting of: surface markers of CSCs (red area), oncogenic and 
prosurvival signalling pathways triggered by CSCs (green area), ABC transporters (purple 
area) and tumour microenvironment nurturing CSCs (blue area). The figure has been 
modified from (Chen, Huang et al. 2013). 
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1.6 Cancer stem cell hypothesis and breast cancer 
Normal embryonic stem cells are endowed with two basic properties: the 
capacity to self-renew and the capacity to generate daughter cells that can 
differentiate in different cell lineages (Rodriguez Salas, Gonzalez Gonzalez et 
al. 2010, Seymour, Twigger et al. 2015). Likewise, cancer cells also contain a 
relatively small subpopulation of cells with stem cell properties. In breast cancer 
this subpopulation, also known as cancer stem cells (CSCs), is associated with 
malignant transformation and progression of the disease (Rodriguez Salas, 
Gonzalez Gonzalez et al. 2010) as well as chemotherapy resistance (Kakarala 
and Wicha 2008). The enhanced tumourigenicity as well as radiation and 
chemo-resistant properties imparted by the CSCs are attributed to their intrinsic 
characteristics. For example, the specific protective and hypoxic 
microenvironment or the CSC niche; elevated levels of anti-apoptotic and drug 
efflux or transporter proteins; activated prosurvival, oncogenic and anti-
apoptotic signaling pathways; and anchorage independence - all of these 
contribute to the highly tumourigenic and therapy-resistant traits of the CSCs 
(Reya, Morrison et al. 2001, Rodriguez Salas, Gonzalez Gonzalez et al. 2010, 
Vinogradov and Wei 2012). The intrinsic chemotherapy-resistant nature of the 
CSCs (Figure 1.2) make the cancer treatment more challenging and demand 
more attention to develop more sophisticated treatment strategies targeting 
CSCs. 
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Figure 1.3: Cancer stem cell-directed therapies may serve as a potential strategy to 
overcome chemotherapy resistance. In contrast to the conventional therapies that may 
shrink tumours by killing mainly cells with limited proliferative potential, therapies targeted 
against cancer stem cells might more effectively kill the cancer stem cells, rendering the 
tumours unable to grow or to maintain themselves. Thus, even if cancer stem cell-directed 
therapies do not shrink tumours initially, they may eventually lead to cures. The figure has 
been adapted from (Reya, Morrison et al. 2001). 
 
 
1.7 Epithelial-mesenchymal transition in tumourigenesis 
In epithelial cancers, tumour aggressiveness, invasion and metastasis are 
associated with epithelial-to-mesenchymal transition (EMT), induced by various 
factors. Cancer cells that have undergone EMT share molecular characteristics 
with CSCs (Kong, Li et al. 2011). Acquisition of an EMT phenotype renders 
tumour cells to develop the capacity to infiltrate surrounding tissues and 
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consequently enables them to metastasize in distant sites (Lee, Dedhar et al. 
2006). Progression of the tumour in most carcinomas is accompanied by EMT 
involving the acquisition of a mesenchymal phenotype, with concomitant loss 
of expression of epithelial markers and up-regulation of mesenchymal 
molecular markers, leading to increased cell motility and invasion (Mani, Guo 
et al. 2008, Kong, Li et al. 2011). During metastasis, initiated by an EMT, 
disseminated tumour cells (DTCs) apparently require self-renewal capability, 
similar to that exhibited by the embryonic stem cells (Mani, Guo et al. 2008). 
This is how EMT is related with the acquisition of a “cancer stem cell-like” 
phenotype otherwise known as “stemness”. At the cornerstone of EMT lies the 
transcription factors that drive this process and eventually confer to the tumour 
cells  an increased motility, invasiveness, and resistance to apoptosis and 
ultimately leading to drug resistance and treatment failure (Cheng, Chan et al. 
2007, Mani, Guo et al. 2008). 
 
1.8 Markers of breast cancer drug resistance, invasion and stemness 
The understanding of the key signaling and molecular mechanisms that regulate 
invasion and metastasis in epithelial cancers via processes such as EMT and 
stemness has led to the identification of molecules that help characterise the 
tumour despite their heterogeneity. The more sophisticated molecular biology 
and gene expression-based techniques facilitate the discovery of novel 
41 
 
biomarkers not only for early detection of tumours but also for identifying 
pathway-related druggable molecules to address the challenge of therapy 
resistance in cancer. In breast cancer, a very few of these markers like ER, PR, 
HER2 and E-cadherin, can be exploited clinically. Therefore, there is a clear 
need to identify and molecularly characterise novel markers that would assist in 
the prognosis and patient stratification and offer a more effective and tailor-
made treatment options to the patients. 
Attempts have been made to identify potential markers associated with breast 
cancer invasion and metastasis, stemness and apoptosis, and tumour suppression 
and drug resistance (Table 1.7), although very few are useful clinically. Among 
the established markers which are already used in clinical practice include: 
ER/PR/HER2, E-cadherin, CK5/6, CK19, Ki67, etc. More efforts are, however, 
given now-a-days on the identification of biomarkers associated with tumour 
metastasis, circulating tumour cells and cancer stem cells (CSCs). For example, 
established markers of CSC include those associated with: pluripotency factors, 
viz., OCT4, SOX2 and nanog; surface antigens, such as, CD44, CD133 and 
EpCAM; drug detoxifying enzymes like ABCG2 and ALDH1. Since breast 
cancer drug resistance is associated with EMT and CSC (Singh and Settleman 
2010), and due to the tumour heterogeneity, effective and early detection and 
management of breast cancer demands the use of specific markers to prevent 
relapse and treatment failure. 
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Table 1.7: Examples of existing and potential markers aiding in clinical diagnosis of breast 
cancer and patient stratification 
Markers targeting/ 
associated with 
Example Functional Role Reference(s) 
Breast cancer (BC) 
Subtyping (or 
immunophenotyping) 
ER/PR/HER2 
(ErbB2) 
BC diagnosis (Adamczyk, Niemiec et al. 
2012) 
 EGFR BC prognosis (Nicholson, Wright et al. 
1990) 
Drug Resistance and 
apoptosis 
Bcl-2 Prognosis and treatment 
decision 
(Nadler, Camp et al. 2008) 
EMT E-cadherin BC prognosis, invasion and 
metastasis 
(Yoshida, Kimura et al. 
2001) 
 Twist and 
vimentin 
Detection of circulating tumour 
cells (CTCs) in early and 
metastatic BC 
(Kallergi, Papadaki et al. 
2011) 
Invasion and 
Metastasis 
Ki67 Marker for invasion (Dede, Gumuskaya et al. 
2013) 
 Cytokeratin 
5/6 (CK5/6) 
Marker for invasion and 
metastasis 
(Hicks, Short et al. 2006) 
Stemness and/or 
chemosensitivity 
ABCG2 Marker for tumour-initiating 
cells (TICs), drug resistance and 
stemness 
(Sicchieri, da Silveira et al. 
2015) 
 ALDH1 Identification of TICs (Sicchieri, da Silveira et al. 
2015) 
 CD44 Identification of TICs (Sicchieri, da Silveira et al. 
2015) 
  Prognostic marker in early 
invasive breast cancer 
(Ahmed, Aleskandarany et 
al. 2012) 
  A marker for proliferation, 
angiogenesis, invasion, 
metastasis, and CSC 
(So, Lee et al. 2011) 
 CD133 A useful surrogate marker for 
predicting chemosensitivity to 
neoadjuvant chemotherapy 
(Aomatsu, Yashiro et al. 
2012) 
  A CSC marker for invasive 
ductal carcinoma 
(Mansour and Atwa 2015) 
 SOX2 a prognostic marker for 
detection of early recurrence 
(Finicelli, Benedetti et al. 
2014) 
Tumour Suppression p53 A strong prognostic molecular 
marker, together with HER2 
(Yamashita, Nishio et al. 
2004) 
  A prognostic marker in node 
negative breast cancer 
(Jung, Jeong et al. 2011) 
  A prognostic marker in 
inflammatory breast cancer 
(Gonzalez-Angulo, Sneige 
et al. 2004) 
Circulating tumour 
cells (CTCs) 
Cytokeratin 
19 (CK19) 
Detection of CTCs (Chen, Zou et al. 2010) 
 EpCAM Detection of CTCs (Zhao, Yang et al. 2013) 
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1.9 Key signalling pathways that regulate the EMT and the CSC 
phenotypes in breast cancer 
In breast cancer, passage through EMT is associated with the development and 
maintenance of breast cancer stem cells (BCSCs) (Kotiyal and Bhattacharya 
2014). Therefore, understanding the pathways regulating both EMT and CSC is 
key to the development of therapy targeting the BCSCs. Important pathways 
include: notch, Wnt, tumour necrosis factor-α (TNF-α)/ nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), transforming growth factor- 
β (TGF-β), extracellular signal related kinase (ERK)/mitogen-activated protein 
kinase (MAPK) and receptor tyrosine kinase (RTK) pathways (Huber, Kraut et 
al. 2005, Kotiyal and Bhattacharya 2014).  
Among these pathways, Wnt signaling activates and stabilizes the downstream 
signaling molecule β-catenin resulting in its accumulation and translocation into 
the nucleus where it regulates transcription of the target genes. This leads to 
subsequent accumulation of Snail and down-regulation of E-cadherin and 
eventually to the development of EMT (Wang and Zhou 2011). Wnt signaling 
can also cross-talk with the notch pathway that play a crucial role in 
determination of cell fate and maintenance of progenitor cells as well as 
proliferation, apoptosis and EMT (Kotiyal and Bhattacharya 2014). Activation 
of EMT through notch requires the co-ordination with the TGF-β pathway via 
Smad3, which subsequently enhance Slug expression to suppress E-cadherin 
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expression (Leong, Niessen et al. 2007). The TGF-β pathway regulates 
transcription of various EMT signature molecules: Snail, Slug and Twist (Wang 
and Zhou 2011). Cross-talking between TGF-β signaling and other signaling 
pathways like Notch, Wnt/ β-catenin, NF-κB and RTKs can also trigger EMT 
which further assists in maintaining the mesenchymal phenotype of metastatic 
tumour cells (Wang and Zhou 2011). 
 
1.10 Aims of the thesis 
The general aim of this thesis was to evaluate potential markers of drug 
resistance in breast cancer and to characterise them by molecular profiling, 
functional assays and immunohistochemical methods. Specifically, nicastrin 
and EP300 were selected in order to identify their potential roles in drug 
resistance, epithelial-to-mesenchymal transition (EMT) and the maintenance of 
a cancer stem cell (CSC)-like phenotype.  
The specific aims of the thesis were: 
1. To examine the effect of modulation of nicastrin on short-term drug 
sensitivity and long-term drug resistance against conventional 
chemotherapeutic agents including doxorubicin and paclitaxel. 
2. To study the effect of combining a γ-secretase inhibitor (GSI) with 
doxorubicin, etoposide and paclitaxel. 
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3. To investigate the potential role of EP300 in altering paclitaxel resistance 
by short-term drug sensitivity and long-term drug resistance assays in 
vitro. 
4. To evaluate the effects of EP300 modulation on the EMT and CSC 
phenotypic traits leading to paclitaxel resistance. 
5. To identify potential target molecules down-stream of EP300 to 
understand the potential mechanisms of paclitaxel resistance imparted by 
EP300 by studying the gene expression pattern in the MCF-7 
transcriptome. 
6. To validate the effects of EP300 down-regulation in breast cancer cells 
using colon carcinoma cell HCT-116 models with complete knock-out of 
the protein.  
7. To explore the possible correlation between EP300 and E-cadherin 
expression in breast cancer patients using clinical samples. 
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Chapter 2: General Materials and Methods 
A description of antibodies and oligonucleotides or primers is provided in the 
Appendices I and II, respectively. 
 
2.1  Cell culture and maintenance 
All cell culture procedures were carried out in a Class II laminar flow hood 
(BioMAT 2, MAT, Derby, U.K.), and cells were grown in a Galaxy 170R 
incubator at 37°C with 5% CO2 (RS Biotech, Ayrshire, U.K.). 
 
2.1.1 Maintenance of cells by passaging 
Tumourigenic breast cancer cell lines MCF‐7, MDA‐MB‐231, CAL‐51 
(German Resource Centre for Biological Material, DSMZ, Braunschweig, 
Germany), T47‐D, ZR‐75‐1, SKBR-3, BT-474, and BT-549 (Table 2.1) were 
cultured in DMEM (Gibco®) supplemented with 10% FCS and 100 U/ml 
penicillin, 0.1 mg/ml streptomycin and 2 mM L‐glutamine in 5% CO2 at 37°C. 
The TNBC cell HCC-1806 was subcultured 2-3 times per week in RPMI-1640 
medium (Sigma-Aldrich®) supplemented with 10% FCS and 100 U/ml 
penicillin, 0.1 mg/ml streptomycin and 2 mM L‐glutamine in 5% CO2 at 37°C.  
All the cells were obtained from the American Type Culture Collection (ATCC) 
unless otherwise mentioned (Table 2.1), and were subcultured and maintained 
by passaging as suggested by the ATCC. All tissue culture procedures were  
47 
 
Table 2.1: Cell lines used  
Cell Line Type/Abbreviation Source/Reference 
MCF-7 Breast cancer, epithelial ATCC 
T-47D Breast cancer, epithelial ATCC 
ZR‐75‐1 Breast cancer, epithelial ATCC 
SKBR-3 Breast cancer, epithelial ATCC 
BT-474 Breast cancer, epithelial ATCC 
BT-549 Breast cancer, mesenchymal ATCC 
MDA-MB-231 Triple-negative breast cancer 
(TNBC) 
ATCC 
CAL-51 Triple-negative breast cancer 
(TNBC) 
German Resource Centre for Biological 
Material, DSMZ (Braunschweig, Germany) 
HCC-1806 Triple-negative breast cancer 
(TNBC) 
ATCC 
MTMECs Minimally transformed human 
mammary epithelial cells 
William Hahn (Dana Farber, Boston) 
HCT-116 WT Colon carcinoma cell line, 
wild type (WT) 
Cancer Research Technology (London, UK) 
HCT-116 KOEP Knocked-out EP300 (KOEP) 
line of the WT HCT-116 
Cancer Research Technology (London, UK) 
 
performed in a laminar flow hood, using disposable sterile plastic-wares (e.g. 
Corning® cell-culture flasks, Falcon tubes, Stripette® Serological Pipets, etc.). 
Minimally transformed human mammary epithelial cells (MTMECs) were a gift 
from William Hahn (Dana Farber, Boston). These cells express TERT, SV40 
large T antigen, a constitutively active form of PI3K, p110α, and oncogenic Ras 
and have been previously described (Zhou, Hu et al. 2014). MTMECs were 
subcultured using HuMEC ready medium (GIBCO®) containing HuMEC basal 
serum-free medium, HuMEC supplement (1%), bovine pituitary extract (5% 
w/v), supplemented with 10% FCS and 100 U/ml penicillin, 0.1 mg/ml 
streptomycin and 2 mM L‐glutamine in 5% CO2 at 37°C. The colon carcinoma 
cell HCT-116 was subcultured 2-3 times/week using McCoy's 5A (modified) 
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medium (GIBCO®) supplemented with 10% FCS and 100 U/ml penicillin, 0.1 
mg/ml streptomycin and 2 mM L‐glutamine at 37°Cin the presence of 5% CO2. 
A HCT-116 derivative with EP300 knocked-out (Krubasik, Iyer et al. 2006), 
along with the wild type HCT-116, was purchased from Cancer Research 
Technology (London, UK). 
 
2.1.2 Freezing cells for long-term storage in the liquid nitrogen 
From a ~75% confluency 75 cm2 dish, cells were frozen in 3 vials of ~1 ml 
cryomedium (as a rule of thumb, although it can change depending of the type 
of cell) composed of 90% fetal calf serum, 10% DMSO. Briefly, cells were 
trypsinized, following quenching with medium containing 10% FCS, spun at 
1300 rpm for 3 min and the supernatants were aspirated off. Then cryomedium 
(normally between 0.5 -1.0 ml per cryotube) was added little by little with a 1 
ml Gilson resuspending the cells to avoid clumps and finally, the cells 
suspended in cryomedium were transferred to cryotubes (1 ml max). The 
cryotubes containing the cells were immediately transferred to a Mr Frostie 
(isopropanol replaced every 5 freeze-thaw cycles), and taken to the -80°C and 
left overnight. The cryovials were then transferred to liquid nitrogen (LN) 
vessel avoiding a sudden increase in temperature (i.e., by taking the tubes in dry 
ice during transit to LN facility). 
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2.1.3 Thawing cells 
During thawing cells, the cryovials were taken from the liquid nitrogen and put 
immediately in a 37°C water bath (if your liquid nitrogen tank is far away from 
your 37°C water bath, take the tubes and put them in dry ice during transit). 
Once thaw the tubes were immediately taken to the T/C hood, transferred to a 
15 ml Falcon and 5-10 ml culture medium was added very slowly and moving 
the tube (so that the DMSO gets out of the cell). The cells were treated gently 
avoiding vigorous pipetting, etc. and spun 3 min at 1300 rpm in a standard T/C 
centrifuge). The supernatant was aspirated and discarded, added fresh medium 
(5- or10 ml for a 25- or 75 cm2 culture flask) at 37°C with pipettes and 
resuspend avoiding clumps. The culture flask was then incubated at 37°C in the 
presence of 5% CO2. 
 
2.2  RNA interference (RNAi) to generate knocked-down cell lines 
Both transient and stable transfection methods were used to transfect shRNAs 
into breast cancer cells. Lipofectamine® (Invitrogen) was used to transduce 
shNCT in HCC-1806 cells and the lentiviral vector pGIPZ® (Thermo Scientific) 
(Figure 2.1 A and B) was used to stably transfect MTMEC and MCF-7 cells 
with shRNAs corresponding to consensus sequences for EP300 and CDH1. 
These cells were generated in Prof. Coombes' (nicastrin) and Dr. Yagüe's 
(EP300 and CDH1) labs prior to my arrival. 
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Figure 2.1: Vector mapping and constructs. (A) pGIPZ lentiviral vector, (B) detailed 
vector map of pGIPZ (C) pGIPZ sh constructs for EP300 
 
 
2.3  Generation of stably transfected cell lines by gene overexpression 
CAL-51 and MDA-MB-231 cells expressing E-cadherin, EP300 or the empty 
pcDNA3.1 vector (negative control) were generated by stable transfection. The 
detail method are described as follows. 
 
2.3.1 Cloning vectors used and their constructions 
Plasmids pcDNA3.1-p300 (plasmid # 23252) and hE-cadherin-pcDNA3 
(plasmid # 45769) (Figure 2.2) were obtained from Addgene (Addgene, MA, 
USA). Empty vector pcDNA3.1 was purchased from Invitrogen. All plasmids 
were cloned into E. coli DH5α and the QIAGEN plasmid purification kit 
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(Qiagen, Hilden, Germany) was used to isolate plasmid DNA as indicated in the 
manufacturer’s instructions. 
 
Figure 2.2: Schematic of the plasmid constructs used for transfection. The restriction 
enzyme cloning sites used for pcDNA3.1-EP300 and pcDNA3.1-hE-cadherin recombinant 
plasmid design are shown.  
 
 
2.3.2 Plasmid DNA isolation, restriction digestion and purification 
Plasmid isolation from E. coli DH5α was performed using the QIAGEN® 
plasmid purification kit (Qiagen, Hilden, Germany), according to 
manufacturer’s instructions. Where possible, plasmid preparations were 
prepared simultaneously using the same reagents.  
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2.3.3 Transfection methods 
Transfection using FuGENE6®  
CAL-51 and MDA-MB-231 cells were seeded in 75 cm2 flasks (Corning®) to 
reach 50-60% confluence on the day of transfection. Before transfecting, the 
medium was replaced by antibiotic-free medium and 2.2 ml of pre-warmed opti-
MEM was used to dilute 75 μl of the FuGENE6® (Promega, Mannheim, 
Germany) transfection reagent. After a 5-minute incubation at room-
temperature, the volume corresponding to 25 μg of linearised plasmid was 
added to the opti-MEM/FuGENE6 mix with transfection reagent: DNA ratio of 
3:1 as prescribed in the manufacturer’s instruction. Complex formation was 
allowed for 15 minutes at room temperature and finally the mixture was added 
to the 75 cm2 flasks.  
Transfection using GenJet®  
Since FuGENE6 transfection did not result to EP300 over-expression, ectopic 
over-expression of EP300 in CAL-51 and MDA-MB-231 cells was performed 
using GenJet® (SignaGen Laboratories). For this, cells were grown to 90% 
confluence in 25 cm2 flasks (Corning®) on the day of transfection. In order to 
allow the formation of optimal size of complex particles, serum-free DMEM 
with high glucose (4.5 g glucose/L) was used to dilute the DNA and GenJet® 
reagent. Α volume of 250 μl of medium was used to dilute 5 μg of DNA and 20 
μl of GenJet® reagent in two separate tubes for a 4:1 ratio of transfection 
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reagent:DNA. The diluted GenJet® reagent was then added to the diluted DNA 
solution, the mixture was vortexed and complex formation was allowed by 
incubation at room temperature for 15 minutes. Cells were then trypsinised, 
counted and the volume corresponding to 2.7x106 cells was centrifuged for 10 
minutes at 150 x g at room temperature. The supernatant was aspirated and the 
cell pellet was completely re-suspended in the 500 μl transfection complex and 
subsequently incubated at 37°C for 20 minutes. At the end of the incubation, 5 
ml of pre-warmed fresh complete growth medium was added to the cells and 
these were plated in the 25 cm2 flasks. Antibiotic selection was added two days 
post-transfection, as mentioned below. 
 
2.3.4 Antibiotic selection and cell culture post-transfection 
Two days post-transfection, the medium was changed to contain penicillin and 
streptomycin and G418® (geneticin) was added at a final concentration of 1 
mg/ml to allow selection for the transfected cells (both MDA-MB-231 and 
CAL-51). This was done for both FuGENE6® and GeneJet® protocols. 
 
2.4  Analysis of protein expression 
2.4.1 Preparation of cell lysates 
The medium was aspirated from culture plates. Cells were washed twice with 
ice-cold PBS (phosphate-buffer saline) keeping the plates on ice. Next, 1 ml 
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PBS was added to the plates and the cells were scraped off with cell scraper. 
The resulting cell suspensions were taken in Eppendorf® tubes (1.5 ml) and 
centrifuged at 10,000 x g for 1 min at 4°C.  
 
2.4.2 Total protein extraction 
The supernatant was aspirated and the pellet was lysed by using radio-
immunoprecipitation assay (RIPA®) buffer (Sigma-Aldrich) (150 mM NaCl, 
1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM 
Tris, pH 8.0). Protease inhibitor cocktail (catalogue no. P8340, Sigma, UK) 
and phosphatase inhibitor (phenylmethanesulfonyl fluoride solution) were 
added to RIPA just prior to use. The tubes were kept on ice for 10 min and 
vortexed after each 2 min. The lysates were cleared by centrifuging at 15000 x 
g for 10 min at 4°C, the supernatants were collected and transferred to a fresh 
tube and used immediately or stored at -80°C until needed. 
 
2.4.3 Nuclear protein extraction 
Cells were grown in 2x15 cm dishes until they reached ~75% confluence. The 
medium was aspirated off the culture plates. Cells were washed once with ice-
cold PBS (phosphate-buffer saline) keeping the plates on ice. Next, 4 ml 
Nuclear EZ® lysis buffer (QIAGEN) was added to the plates and the cells were 
scraped off with cell scraper from one dish and then up to 4 ml of the cell 
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lysates were collected and added to the second dish and scraped off in the same 
way as done for the former and taken in a 15 ml Falcon tube and kept in ice 
until all the cells were scraped off in this way, after which the Falcons were 
briefly vortexed and kept on ice for 5 min. Then the Falcons were spun at 500 x 
g for 5 min at 4°C and the supernatants were carefully discarded. The resulting 
pellets were resuspended using 0.5 ml of the EZ lysis buffer and topped up with 
3.5 ml of the same lysis buffer, vortexed and kept on ice for 5 min. Following 
this short incubation, the Falcons were centrifuged again at 500 x g for 5 min at 
4°C. After carefully discarding the supernatants, the pellets were resuspended in 
#200 µl of RIP mix containing RIPA buffer, Na3VO4 (1:400), 0.5 M NaF (1:10) 
and PMSF (1:100). The tubes were kept on ice for 10 min and vortexed after 
each 2 min. The lysates were cleared by centrifuging at 15000 x g for 10 min at 
4°C, the supernatants were collected in fresh 1.5 ml tubes and preserved at -
80°C until next manipulation. 
 
2.4.4 Estimation of protein concentrations by BCA assay 
The protein concentrations were quantified by BCA (bicinchoninic acid) assay 
using Thermo Scientific Pierce® BCA Protein Assay Kit (Prod#23227). The 
protein lysates or extracts were first diluted 1:5 using dH20 and this diluted 
samples were used to estimate the concentration.  
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2.4.5 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples were denatured in sample buffer containing SDS (Laemmli buffer) and 
heated at 95-100°C for 10 min. Then 20 µg proteins were loaded onto 10% 
SDS-polyacrylamide gels (SDS-PAGE) and run in running buffer (0.1% w/v 
SDS, 25 mM Tris, 190 mM glycine) at 90 V through the stacking part of gel 
then changed to 120-140 V through the resolving gel.  
 
2.4.6 Electroblotting by wet transfer method 
Next, the proteins were transferred to nitrocellulose membranes (BioTrace® NT) 
in transfer buffer (25 mM Tris, 190 mM glycine and 20% methanol) at 100 V 
for 90 min on ice. 
2.4.7 Western blot  
Following transfer, the nitrocellulose membrane containing the transferred 
proteins was rinsed with Ponceau to visualize the bands. The membrane was 
then blocked with 5% skimmed milk in PBS for 1 hr and then incubated at 4°C 
overnight with primary antibody against the respective proteins analysed 
(Appendix I). As a normalizer, β-actin (mouse mAb 6276, abcam, 1:10,000) and 
lamin-B were used for total and nuclear proteins, respectively. The day after, 
the membranes were washed (one quick wash followed by 2 subsequent washes 
each for 10 min) with 1xTBS-0.1% Tween 20. Then, the membranes were 
incubated with anti-rabbit (926-32213, IRDye® 800CW Donkey anti-Rabbit, LI-
57 
 
COR, Nebraska, USA) and anti-mouse (926-68072, IRDye® 680RD Donkey 
anti-Mouse, LI-COR, Nebraska, USA) secondary antibodies for 45-60 min. 
Finally, the membranes were washed with 1xTBS-0.1% Tween 20 twice and 
then with PBS, each for 10 min and the bands were visualized by using 
Odyssey® Infrared Imaging System. 
 
2.5  Analysis of mRNA expression (by RT-qPCR) 
2.5.1 mRNA Extraction 
Isolation of total RNA was performed using the RNeasy kit from QIAGEN 
(Manchester, UK). Briefly, cells were grown in 10 cm2 dishes and at 70-75% 
confluence, were harvested by scraping in 1 ml PBS solution. The resulting cell 
suspension was centrifuged at 9,500 x g for 1 min at 4°C, the supernatant was 
aspirated and the cell pellets were lysed by re-suspending in 600 μl RLT buffer 
(containing β-mercaptoethanol) and centrifuging in a QIAshredder® column for 
2 minutes at 12,500 x g. Next, an equal volume of 70% ethanol was added to 
the lysate, 700 μl of which was transferred to a QIAspin column® and spun at 
9,500 x g for 15 seconds. The flow-through was discarded and contaminants 
were washed off once in 700 μl of buffer RW1 buffer (by spinning at 9,500 x g 
for 15 seconds) and twice in 500 μl of RPE buffer (by spinning first at 9,500 x g 
for 15 seconds and then for 2 minutes), discarding the flow-through after each 
wash. After the last wash, any residual buffer was removed by another 
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centrifugation step at 12,500 x g for 1 minute. RNA was eventually eluted in a 
clean 1.5 ml tube by addition of 35 μl of RNAse-free water to the column by 
centrifuging at 9,500 x g for 1 minute. The concentration of the isolated RNAs 
were determined and finally they were preserved at -80°C for next 
manipulation.  
 
2.5.2 Quantification of mRNA by using NanoDrop® 
Total RNA concentration was measured using a NanoDrop ND1000 
spectrophotometer (Thermo Scientific, UK).  
 
2.5.3 Reverse transcription of RNA for cDNA synthesis 
Complementary DNA (cDNA) synthesis was performed by converting total 
RNA (a volume equivalent to 1 μg) using the high capacity RNA-to-cDNA 
master mix (Applied Biosystems, UK) with random primers in a thermal cycler. 
The cycling steps were as follows: primer annealing at 25°C for 5 minutes, 
reverse transcription reaction at 37°C for 2 hours, reverse transcriptase 
inactivation at 85°C for 5 minutes and cDNA incubation at 4°C until samples 
are recovered for storage at -20°C. 
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2.5.4 Real-time quantitative PCR (RT-qPCR) 
Quantitative PCR (qPCR) was performed in a 10 or 20 μl reaction volume on a 
7900HT Thermocycler (Applied Biosystems, Warrington, UK) using 1X SYBR 
Green PCR Master Mix (Applied Biosystems, Carlsbad, USA) and 3.5 pM of 
appropriate forward and reverse primers for each of the genes analysed 
(Appendix II). The RT-qPCR amplification conditions were set up as follows: 
10 min at 95°C, followed by 40 cycles of 60 s at 95°C, 30 s at annealing 
temperature (Ta) (60°C), 30 s at 72°C. GAPDH, RPLO and RPS14 were used as 
the normalizers. The PCR cycle number that generated the first fluorescence 
signal above a threshold (threshold cycle, CT; 10 standard deviations above the 
mean fluorescence generated during the baseline cycles) was determined, and a 
comparative CT method was used to measure relative gene expression. The 
primer efficiency was tested prior to the individual experiment for the set of 
primers and as required. 
 
2.5.5 Data analysis 
For all samples, relative quantitation of the tested genes was determined using 
the comparative CT method also referred to as the 2
−ΔΔC
T method (where ΔCT is 
the difference in CT between the gene of interest and the geometric CT value of 
the two housekeeping genes (RPS14 and RPLO). The PCR cycle number that 
generated the first fluorescence signal above a threshold (i.e., threshold cycle, 
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CT above the mean fluorescence generated during the baseline cycles) was 
determined. The average CT for each gene in each sample was normalized with 
respect to the CT values of two or three housekeeping genes tested (GAPDH, 
RPLPO and RPS14). The normalized amount of each tested gene was 
subsequently used to compare the relative amount of each tested gene in the 
different samples. The relative change in gene expression was estimated as the 
ratio of normalized CT relative for each sample relative to the normalized CT for 
the cells used as reference line to get the relative amount. Statistical significant 
differences between experimental groups were determined using a Student t-
test; statistical significance was set at a confidence level of >95% (P< 0.05). 
 
2.6  Assays of short-term drug sensitivity and long-term drug resistance 
2.6.1 Analysis of drug sensitivity by cell viability assay 
Sulphorhodamine B (SRB) assay was used to assess in-vitro short-term 
sensitivity of the cancer cells against chemotherapeutic agents. This is a 
colorimetric assay based on the ability of the SRB, which is an aminoxanthene 
dye (bright-pink), to bind with the basic amino-acid residues of the protein 
components (under mild acidic conditions by using two sulphonic acid groups) 
of the cells fixed with trichloroacetic acid (TCA) to tissue culture plates.  The 
stoichiometric binding of SRB gives an estimate of the amount of dye extracted 
from stained cells which is directly proportional to the cell mass. Cells were 
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counted and seeded (3000 cells per well) with three replicates in flat-bottomed 
96-well plates. The cells were allowed to adhere overnight, and then media 
containing the chemotherapy agent at different concentrations were added. At 
day 3, the cells were fixed by adding 100 μl per well of ice-cold 40% TCA to 
each well and incubated at 4°C for 60 min. The plates were washed five times 
under running tap water and stained with 100 μl per well SRB reagent, i.e., 
0.4% w/v SRB (Sigma-Aldrich, Poole, UK) in 1% acetic acid for 30 min. The 
plates were rinsed five times with 1% acetic acid and left to dry overnight. SRB 
was solubilised with 100 μl per well 10 mM Tris-base, shaken for 30 min and 
finally, the optical density was measured at 492 nm. 
 
2.6.2 Analysis of drug resistance by clonogenic assay 
Unlike SRB assay that measures short-term drug sensitivity of cells, the 
clonogenic assay is potentially an effective way to evaluate long-term resistance 
of the cells in-vitro against chemotherapeutic agents. In this assay, cells are 
exposed for a short period of time (3-5 days) to the drug and then fresh media 
are added to the culture plates are to allow the cells to grow in a drug-free 
interval for 3-4 weeks during which the cells generate visible clones that can be 
stained and counted. The number of the clones depends on the ability of the 
cells to offer resistance against the drug and this varies from cell to cell. In 
brief, cells (5×104-1.5X104) were seeded in triplicate in 25-cm2 culture flasks 
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and exposed to a single dose of the drug at various concentrations. After 21 to 
30 days, the media were aspirated and the flasks were washed off with distilled 
H2O and fixed with 100% methanol. Next the flasks were stained with 0.5% 
crystal violet (Sigma) in 25% methanol, washed again with distilled H2O and 
left to air-dry overnight or until completely dry. The colonies were counted and 
then the plates were solubilized with 33% acetic acid to measure relative optical 
density (OD) at 490 nm using a microplate reader (Sunrise®, Tecan). 
 
2.7  Analysis of population doubling time by sulphorhodamine B (SRB) 
assay 
The ability of the SRB to stain cellular protein can be employed to measure the 
population doubling time, i.e., the time by which the cell population doubles in 
number. This doubling time is an indication of how fast or slow a particular cell 
can grow as they are cultured in-vitro and obviously varies from one cell type to 
next. Various factors can affect the growth of cancer cells and hence measuring 
the doubling time gives a clue to the effect produced by the change of that 
factor on cells’ proliferation rate. As mentioned in the section 2.6.1, cells are 
counted and seeded (500-100cells/well, depending on the cell type) in six 96-
well plates in hexaplicate and one plate (Day 0) is fixed immediately on the 
same day after the cells are attached with 40% TCA. The other plates are fixed 
each day until day 5. After all the plates are fixed, they are removed of the 
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fixatives by washing under slow-running tap water and air-dried. Next, the 
plates are stained with SRB, rinsed off with 1% acetic acid and left for 
overnight drying after which they are solubilized with 10 mM Tris and the OD 
readings are read at 492 nM using a micro-plate reader.  
 
2.8  Caspase assay 
Caspase assay offers a direct measurement of different effector caspases 
(cysteine aspartic acid-specific proteases) that are involved in extrinsic and/or 
intrinsic apoptotic pathway. As caspase-8 and -9 are involved in extrinsic 
(receptor-mediated) and intrinsic (mitochondrial) apoptosis in mammalian cells, 
respectively, we measured the activation of these two caspases by using kits 
(Promega®). The Caspase-Glo® 8 and Caspase-Glo® 9 assays are homogeneous 
luminescent assays that measures caspase-8, and -9 activities, respectively. 
These two members of the cysteine aspartic acid-specific protease (caspase) 
family play key initiator roles in the extrinsic and intrinsic apoptotic pathways 
of mammalian cells (Adams 2003). The assay kits provide luminogenic 
caspase-8 and -9 substrates in a buffer system optimized for caspase activity, 
luciferase activity and cell lysis. The addition of a single Caspase-Glo® -8 and -
9 reagents in an “add-mix-measure” format results in cell lysis, followed by 
caspase cleavage of the substrate, and generation of a “glow-type” luminescent 
signal (produced by the luciferase reaction; Figure 2.3). The signal generated is 
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proportional to the amount of caspase activity present. The Caspase-Glo® (8 and 
9) reagents rely on the properties of a proprietary thermostable luciferase (Ultra-
Glo® Recombinant Luciferase), which generates the stable “glow-type” 
luminescent signal and improves performance across a wide range of assay 
conditions. 
 
Figure 2.3: Caspase-8 or -9 cleavage of the luminogenic substrate containing the LEHD 
sequence. Following caspase cleavage, a substrate for luciferase (aminoluciferin) is released, 
resulting in the luciferase reaction and the production of light. 
 
In brief, cells (10,000/well) were seeded in 96-well plates (white plates for the 
reaction and the usual transparent ones for SRB control), incubated overnight at 
37°C with 5% CO2 and treated with a selected range of paclitaxel concentrations 
(0, 10, 20, and 50 nM) for 24 hour in the same condition, i.e., incubating at 
37°C with 5% CO2. Next, the freshly prepared Caspase-Glo
® (Promega) 
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reagents were added and incubated at room temperature for 60 min (covering 
with foil, to protect from light) and the luminescent signals were read using a 
luminometer. The values obtained were normalized from the SRB controls and 
eventually the fold changes were compared with respect to the empty vector 
respective controls. 
 
2.9  Flow cytometry analysis by FACS 
2.9.1 Annexin V-FITC staining 
Apoptosis, or programmed cell death (PCD), is a normal physiologic process 
for removal of unwanted cells. However, in cancers, the potentially 
tumourigenic cells gain resistance against chemotherapeutic agents via evasion 
of apoptosis mechanism. Essentially, one of the earlier events of apoptosis 
includes translocation of membrane phosphatidylserine (PS) from the inner side 
of the plasma membrane to the surface. Annexin V, a Ca2+-dependent 
phospholipid-binding protein, has high affinity for PS, and fluorochrome-
labeled Annexin V can be used for the detection of exposed PS using flow 
cytometry. Here, we used the Annexin V FITC apoptosis detection kit (BD 
Pharmingen®) for investigating the apoptosis evasion mechanism of paclitaxel 
treated EP300 down-regulated cells using flow cytometry analysis. For this, 
cells were grown to 50-60% confluence in 10 cm Petry dishes and treated for 24 
hour with various concentrations of paclitaxel (Tocris®). The cells were then 
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trypsinised and peletted by spinning at 500 rpm for 5min. The cell pellets were 
then washed with PBS and spun at 500 rpm for 5 min twice. The resulting 
pellets were then resuspended with 1X AnnexinV-binding buffer (diluted from 
5X Annexin V binding buffer: 8 mL 5X Annexin V-binding buffer and 32 mL 
deionized water). The resuspended cells were then divided (100 µl) in 5 FACS 
tubes for each of the cells (empty vector control and EP300 knocked-down line) 
for the following conditions: unstained, PI (propidium iodide) stained and 
double-stained (Annexin V and PI), for cells treated with various concentrations 
of paclitaxel (0, 1 2.5, 5 and 10 nM) and also positive controls (untreated naive 
cells were boiled at 100°C). In each of the tubes (containing 100 µl cell 
suspension), 5µl of AnnexinV was added and the tubes were incubated for 15 
min. Following this, tubes labelled for Annexin V and PI and PI were treated 
with 5µl of PI (100 µg/ml) and incubated for another 15 min. When waiting for 
this incubation, FACS readings (using BD FACS Canto A®) were taken for the 
unstained samples after adding 400 µl of the diluted Annexin V binding buffer. 
Following the incubation, all other samples were prepared (by adding 400 µl of 
the diluted Annexin V binding buffer) and read out in the FACS machine and 
the data were recorded using proper gating parameters. For analysis, FlowJo® 
software used where signals were compensated manually.  
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2.9.2 CD44-APC and CD24-PE staining 
In order to assess the effect of EP300 on altering the stem cell behaviour, EP300 
knocked-down, knocked-out and overexpressed lines were used to sort for 
CD44high/CD24low sub-population, which are characteristic of cancer stem cells 
in various types of breast cancer including breast and colon (Ahmed, 
Aleskandarany et al. 2012). For this, cells were grown in ~90-95% confluence 
in 10-cm dishes after which they were harvested by trypsinising, counted and 
then divided into 5 FACS tubes for each of the following conditions: unstained, 
isotype controls (for CD44 /CD24 and for the negative control beads) , CD44 
and CD24 antibody and negative control (beads for compensation). For CD44 
and CD24 staining, CD44-APC and CD-PE antibodies (BD Pharmingen®) were 
used. After taking the cell suspension in the FACS tubes, FACS buffer (sterile, 
composition: 500 ml PBS + 0.5% BSA or serum + 2 mM EDTA) were added 
(100 µl/106 cells). Next, CD44 and CD24 antibodies (20 µl/106 cells) and 
isotype antibodies (5ul) were added and incubated for 30 min at 4°C. Following 
incubation, FACS buffer (1-2 ml per 106 cells) were added to each of the tubes, 
which were then centrifuged at 1500 rpm for 5 minutes and then resuspended 
with 500 µl FACS buffer. The samples were then taken to run the FACS. The 
FACS readings were analysed using the FlowJo® software.  
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2.10 Senescence-associated β-galactosidase (SA- β-gal) assay 
Drug-induced senescence is characterized by enlarged cell morphology, arrest 
of cell growth and activation of lysosomal β-galactosidase. This is one of the 
mechanisms by means of which cancer cells can develop chemoresistance as is 
described with respect to doxorubicin induced senescence by pass (ref) by 
triple-negative breast cancer cells. In order to explore if nicastrin down-
regulation can lead to by-pass of senescence, we used the ‘Senescence β-
Galactosidase Staining Kit® (Cell Signaling Technology). The kit detects β-
galactosidase activity at pH 6 in cultured cells and tissue sections. β-
galactosidase activity at pH 6 is present only in senescent cells and is not found 
in presenescent, quiescent or immortal cells. To perform the test, cells were 
seeded (10,000/well) in triplicates in 6-well plates and treated with 25 ng/ml of 
doxorubicin next day for 3 days after which the media was changed to make the 
cells drug-free and the cells were incubated until they got senescence-like 
appearance. Next, the plates were stained using the kit and the senescent cells 
were counted and percentage of senescent cells and plating efficiencies were 
calculated. When staining the cells, the growth medium from the cells were 
removed and the plates were washed once with 2 ml 1xPBS. The cells were 
then fixed with 1 ml 1xFixative Solution for 10–15 minutes at room 
temperature. While the plates were in the Fixative Solution, the Staining 
Solution was prepared (in polypropylene tubes) adding: a. 930 μl Staining 
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Solution, b. 10 μl Staining Supplement A, c. 10 μl Staining Supplement B, and 
d. 50 μl 20 mg/ml X-gal in DMF. Then the wells were washed twice with 2 ml 
1xPBS and 1 ml Staining Solution mix was added to all the wells in the plate. 
After staining, the plates were incubated overnight at 37°C and the next day, 
checked under a microscope (200 x total magnification) for development of 
blue colour. 
 
2.11 Mammosphere formation assay 
Mammosphere culture was used to assess capacity of breast cancer stem cells 
(BCSCs) to propagate in anchorage-independent growth conditions. For this 
assay, cells (100-200 cells/well) were seeded in duplicate in ultra-low 
attachment 24-well plates (Corning, NY, USA) in DMEM/F12 medium 
supplemented with 20 ng/ml epidermal growth factor (EGF, Sino Biologicals®), 
20 ng/ml basic fibroblast growth factor (bFGF, GIBCO) and B27 (GIBCO®). In 
order to prevent complete drying out, 500 µl of fresh medium was added every 
3-5 days until 3-4 weeks after which the spherical clusters of cells were counted 
as mammospheres and the %SFE (sphere forming efficiency) was calculated as 
per the following formulae: 
 
%SFE = Number of spheres counted/Total number of cells plated X 100 
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2.12 Soft agar assay for assessment of anchorage-independent growth 
Cells (5x104) were seeded in 0.3% agar in DMEM with 10% FCS (pre-warmed) 
on each well of 6-well tissue culture plates with a bottom layer of solidified 
0.6% noble agar in DMEM with 10% FCS. After the top layer of agarose 
solidified, the plates containing triplicate cultures for each cell type were 
incubated and maintained for 4 weeks at 37°C in an atmosphere of 5% CO2 and 
95% air, with 200 µL fresh medium added after each 3-5 days. After 4 weeks, 
colonies ≥ 50 µm in diameter were counted under a simple Nikon® microscope 
(Model: Eclipse, TS100; Japan) and photographed using EVOS FL Cell 
Imaging System® (Life Technologies, Paisley, UK). The colonies were also 
stained with 0.02% crystal violet in 75% ethanol followed by destaining with 
PBS and the coloured images of the clones were captured using the EVOS 
microscope as mentioned above.   
 
2.13 Derivation of drug-resistant cell lines 
Drug resistant cells HCT KOEPTx20 (i.e., EP300 knocked-out HCT-116 cell  
resistant to 20 nM of paclitaxel) were derived by selecting and culturing HCT 
KOEP (i.e., EP300 knocked-out HCT-116 cell) cells in McCoy’s 5A medium 
supplemented with 20 nM paclitaxel (Tocris®) following a “pulse” methodology 
as described before (Raguz and Yagüe 2010). Cells with enhanced drug 
resistance were generated from HCT KOEPTx20, via methods of drug 
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resistance screening. HCT KOEPTx20 cells in log phase were plated into 75-
cm2 culture flasks with 15 ml of McCoy’s 5A medium for 48 hours, and then 
washed twice with pre-warmed PBS, trypsinized, diluted. And then 5x106 cells 
were seeded into per 75-cm2 culture flask and cultured for 24 hours. Cells were 
rinsed with fresh medium, and then treated with various doses of paclitaxel (30 
nM and 40 nM) for 72 hours. Again, cells were washed twice with pre-warmed 
PBS and then cultured in fresh medium for 72 hours. Thus, enhanced drug 
resistant cells, HCT KOEPTx30 and HCT KOEPTx40, were obtained (Raguz 
and Yagüe 2010) and then maintained in McCoy’s 5A medium supplemented 
with 10% FCS and 10mL of PSG (Invitrogen). Drug resistant MCF-7 shEP300 
cells were also generated in a similar method as described above where cells 
were exposed to 20 nM paclitaxel by pulse methodology and the resistant cells 
eventually emerged and maintained the phenotype as confirmed by short-term 
drug sensitivity test (SRB staining for cell survival assay, section 2.6.1) using 
various concentrations of the drug (paclitaxel). 
 
2.14 Statistical analysis 
The graphical representations show the mean ± standard deviation of the data 
obtained. GraphPad Prism ver.6 (GraphPad, CA, USA) was subsequently used 
for statistical analysis of the results obtained. One-way ANOVA tests were used 
for multiple sample comparisons. A p-value p≤0.05 was considered as 
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statistically significant and indicated using an asterisk (*P<0.05). Increasing 
statistical significance is indicated with more asterisks (**P≤0.01, ***P≤0.001, 
****P≤0.0001). 
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SUPPLEMENTARY MATERIALS AND METHODS  
Plasmid isolation  
Plasmid isolation from E. coli DH5α was performed using the QIAGEN 
plasmid purification kit® (Qiagen, Hilden, Germany). For the Miniprep, single 
colonies of bacteria carrying each of the plasmids were picked from a streaked 
ampicillin plate and inoculated overnight at 37°C in a shaking incubator in 5 ml 
of Luria-Bertani (LB) medium. The bacterial cells were harvested by 
centrifugation at 6800 x g for 3 minutes and re-suspended in 250 μl of buffer 
P1. Alkaline lysis was then performed by adding 250 μl of buffer P2. After 
allowing the lysis reaction to proceed for 5 minutes, 350 μl of buffer N3 was 
added to neutralise the cell lysate. The cell suspension was then centrifuged for 
10 minutes at 13,500 x g to pellet the precipitated proteins and chromosomal 
DNA, and the supernatant containing plasmid DNA was applied to a QIAprep® 
spin column. DNA was adsorbed to the silica column by centrifugation at 
13,500 x g for 30 seconds, discarding the flow-through after spinning. Salts 
were removed by washing with 750 μl buffer PE and centrifugation as before. 
The flow-through was discarded and any residual buffer was removed by an 
additional 1 minute centrifugation. The DNA was finally eluted in a clean tube 
by adding 50 μl of buffer EB to the column, followed by 1 minute standing and 
1 minute centrifugation.  
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For Midiprep, essentially the same procedure was followed by inoculating the 
single bacterial colonies in 250 ml of LB medium and using the equivalent 
buffer volumes suggested in the manufacturer’s instructions. Finally, DNA was 
precipitated using 0.7 volumes of room temperature isopropanol and 
centrifuging at 2,500 x g for 60 minutes. The supernatant was carefully 
decanted and the pellet was washed with 70% ethanol to remove precipitated 
salts. The DNA pellet was allowed to air-dry for 5-10 minutes and finally 
dissolved in 200 μl of RNAse-free water.  
 
Sequencing  
Upon plasmid isolation and concentration determination using NanoDrop 
ND1000® spectrophotometer (Thermo Scientific, Wilmington, USA), 500 ng of 
each plasmid was used to check the integrity of its start and stop codons using 
3.3 pM of the required primer (Supplementary Figure S2.1). Samples were sent 
to the Genomics Laboratory (MRC Clinical Sciences Centre) for sequencing 
using an Applied Biosystems 3730xl DNA Analyser (Applied Biosystems, 
Carlsbad, USA). The forward primer used for sequencing the two plasmids was 
5’-CGCAATGGGCGGTAGGCGTG-3’. The sequences of the reverse primers 
used for the pcDNA3.1-EP300 and pcDNA3-hE-cadherin plasmids were 5’-
CCCCACTCCAGTCCTTCCCC-3’ and 5’-TAGAAGGCACAGTCGAGG-3’, 
respectively.  
75 
 
 
Supplementary Figure S2.1: Sequence chromatograms indicating the START and 
STOP codons of the inserts. The chromatograms shown indicate the START (green arrows) 
and STOP (red boxes) codons of the pcDNA3.1-p300 (A) and hE-cadherin-pcDNA3 (B) 
recombinant plasmids.  
 
Double digestion and plasmid linearisation  
Double digests of the plasmids were performed for insert verification 
(Supplementary figure S2.2). The cloning sites used for gene insertion in the 
pcDNA3.1 vector were cut in order to liberate the DNA fragments 
corresponding to the insert and the vector. The pcDNA3.1-p300 plasmid was 
digested using HindIII and NotI whereas hE-cadherin-pcDNA3 was digested 
using HindIII and XbaI (Promega, Mannheim, Germany). Restriction reactions 
were performed in a final reaction volume of 20 μl using 250 ng of each 
plasmid and 3 units of each of the restriction enzymes by incubation at 37°C for 
1.5 hours as indicated in the manufacturer’s instructions. Digested and un-
digested samples were then run in parallel in a Tris-acetate-EDTA (TAE) 1% 
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agarose gel at 100 V for 5 hours and visualized in a Platinum HD7 
transilluminator (Uvitec, Cambridge, UK).  
 
Supplementary Figure S2.2: Agarose-GE showing double-digested recombinant 
plasmids for EP300 and CDH1. L1: Marker (1kb), L2: HindIII and NotI digested 
pcDNA3.1-EP300 recombinant plasmid, L3: undigested pcDNA3.1-EP300, L4: double-
digested pcDNA3.1-hCDH1 recombinant plasmid, L5: undigested pcDNA3.1-hCDH1, L6: 
restriction digestion (HindIII, NotI and Xba1) of pcDNA3.1 and L7: undigested pcDNA3.1. 
 
Upon insert verification, linearisation of 100 μg of each plasmid was performed 
using 160 units of PvuI (Promega, Mannheim, Germany) in a final reaction 
volume of 200 μl and incubation at 37°C for 4 hours according to the 
manufacturer’s instructions. Digested and un-digested samples were then run in 
a Tris-Acetate-EDTA (TAE) 1% agarose gel to confirm linearization 
(Supplementary Figure S2.3).  
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Supplementary Figure S2.3: Plasmid linearization by PvuI digestion. Linearisation of 
100 μg of each plasmid was performed using 160 units of PvuI and incubation at 37°C for 4 
hours. Digested and un-digested samples were then analysed by agarose gel electrophoresis. 
Lane 1: Marker (1 Kb DNA ladder). Lane 2: PvuI digestion of pcDNA3.1-p300 recombinant 
plasmid. Lane 3: Un-digested pcDNA3.1-p300 recombinant plasmid. Lane 4: PvuI digestion 
of hE-cadherin-pcDNA3 recombinant plasmid. Lane 5: Un-digested hE-cadherin-pcDNA3 
recombinant plasmid. Lane 6: PvuI digestion of pcDNA3.1 plasmid. Lane 7: Un-digested 
pcDNA3.1 plasmid. 
 
Linearised DNA was then purified by phenol-chloroform extraction by mixing 
equal volumes of DNA and phenol-chloroform solution (Sigma Aldrich, St 
Louis, USA). After brief vortexing, samples were centrifuged for 2 min at 
14,000 x g allowing DNA to separate in the aqueous phase while retaining 
proteins and carbohydrates in the lower organic phase. Following extraction 
from the upper aqueous phase, DNA was precipitated by adding 3 volumes of 
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ice cold 100% ethanol and 1/10 volume of 3M sodium acetate. The DNA pellet 
was finally re-suspended in sterile water, its concentration determined in 
NanoDrop ND1000® spectrophotometer (Thermo Scientific, Wilmington, USA) 
and kept at -20°C for use in the transfection experiments.  
 
Geneticin kill curve construction  
The kill curves were used to determine geneticin concentration in order to select 
CAL-51 and MDA-MB-231 cells expressing the vectors. For this, CAL-51 and 
MDA-MB-231 cells were seeded in 6-well plates and treated with increasing 
geneticin (G418, Gibco) concentrations once 60-70% confluence was reached. 
After treatment of CAL-51 and MDA-MB-231 for 5 and 10 days, respectively, 
cells were washed twice with 1X PBS and fixed with 100% methanol for 10 
minutes, keeping plates on ice. Methanol was then aspirated and cells were 
stained using 0.5% crystal violet solution (in 25% methanol) for a 10 minute 
period. The crystal violet solution was then rinsed using ddH2O and plates were 
allowed to dry overnight. Crystal violet was then solubilised by shaking in 33% 
acetic acid for 30 minutes at room temperature and absorbance was read at 490 
nm in a Sunrise microplate reader (Tecan, Männedorf, Switzerland). Plotting 
the respective absorbance [OD490 (a.u.)] values against the corresponding 
geneticin concentrations [G418 (mg/ml)] for each of the cells (CAL-51 and 
MDA-MB-231) yielded the kill curves, as shown in Supplementary Figure S2.4. 
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Geneticin concentration used for selection of both Cal-51 and MDA-MB-231 
cells post-transfection for the maintenance of the cells expressing the vectors 
was 1 mg/ml. 
 
Supplementary Figure S2.4: Geneticin (G418) kill curves for CAL-51 and MDA-MB231 
cells. CAL-51 and MDA-MB-231 cells were seeded in 6-well plates and treated with 
increasing geneticin (G418) concentrations once 60-70% confluence was reached. After 
treatment of CAL-51 and MDA-MB-231 for 5 and 10 days, respectively, surviving cells were 
fixed and stained with 0.5% crystal violet solution. Subsequent solubilisation with 33% acetic 
acid solution was performed and absorbance was read at 490 nm to determine the surviving 
cell densities at each G418 concentration. Kill curves for CAL-51 (A) and MDA-MB-231 (B) 
were subsequently drawn to determine the geneticin concentration required for selection of 
successful transfectants. Data represent a single experiment. 
80 
 
Chapter 3: Nicastrin as a Drug Resistance Marker in Breast Cancer  
 
3.1 Introduction 
3.1.1 Notch signaling and role of nicastrin  
The core Notch pathway comprises ligands (Dll1, Dll3 and Dll4 and Jag1 and 
Jag2), receptors (Notch1-4), transcription factors (CSL)  and downstream target 
genes (Hes and Hey families) (Hu, Zheng et al. 2012). Notch signalling is 
initiated after ligand-receptor interaction, which triggers three sequential 
proteolytic cleavages. First, S1 cleavage of precursor of the Notch receptor at a 
site S1 in the Golgi network by a furin-like convertase forms a non-covalently 
joined heterodimeric form (comprising an extracellular subunit, a 
transmembrane subunit and a cytoplasmic subunit) at the cell surface 
(Blaumueller, Qi et al. 1997).  Next, S2 cleavage is activated in response to 
ligand binding whereby the Notch transmembrane subunit is cleaved by 
ADAM/TACE metalloprotease family of enzymes. This releases the Notch 
extracellular domain (NECD) and creates a membrane-spanned Notch 
extracellular truncation (NEXT), which gives rise to Notch intracellular domain 
(NICD) by γ-secretase (GS)-mediated S3 cleavage on the plasma membrane. As 
an integral part of the GS system, nicastrin play the most important role by 
catalysing the cleavage reaction (Filipovic, Gronau et al. 2011). NICD 
eventually enters the nucleus where it interacts with members of the DNA-
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binding protein, viz., RBP-Jk or CBF1/Su(H)/Lag-2 (CSL) family of 
transcription factors and forms the Notch transcriptional activation complex or 
enhanceosome (Borggrefe and Oswald 2009). This results in transcription of a 
variety of downstream Notch target genes.  
 
3.1.2 Role of γ-secretase (GS) in invasive breast cancer 
A functionally active GS complex is an atypical transmembrane aspartyl 
protease (Watanabe, Tomita et al. 2005) and consists of nicastrin (NCT), 
anterior pharynx defective 1 homolog (Aph1), presenilin enhancer-2 (Pen-2), 
and presenilin (PS1/PS2) (Dries and Yu 2008, Filipovic, Gronau et al. 2011). 
NCT is an essential component of the GS enzyme complex, required for its 
synthesis and recognition of substrates. Presenilin 1 (PS1) forms the catalytic 
centre of the GS complex (Wolfe, Xia et al. 1999, Koo and Kopan 2004, 
Filipovic, Gronau et al. 2011). Aph-1, a multi-transmembrane domain protein, 
together with NCT, acts as a scaffold to facilitate the assembly and trafficking 
of GS (Niimura, Isoo et al. 2005). Pen-2 is incorporated into the Aph-1-NCT-PS 
trimeric intermediate, resulting in a conformational change in NCT. This leads 
to the induction of endoproteolysis catalysed by presenilin (Watanabe, Tomita 
et al. 2005).  The proteolytic targets of GS include the amyloid precursor 
protein (Filipovic, Gronau et al. 2011) and a variety of proteins (that facilitate 
tumour cell proliferation, adhesion, and migration) including: Notch 1–4, 
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ErbB4, CD44, E-cadherin, and EpCAM (Kopan and Ilagan 2004, Maetzel, 
Denzel et al. 2009). Abnormal activation of these substrates can lead to 
tumourigenesis, metastasis, and development of resistance to existing treatment 
regimens in oncology (Dontu, Jackson et al. 2004, Liu, Dontu et al. 2005). 
 
3.1.3 Nicastrin: Biological roles 
Nicastrin (NCT), a 709-amino acid (AA) long protein is the largest subunit of 
the GS complex. It contains an amino-terminal signal peptide (AA 1-33), a large 
ectodomain (AA 34-669) containing a conserved pentapeptide DYIGS motif 
and multiple glycosylation sites, a single transmembrane domain (TMD) (AA 
670-690), and a 20-residue cytoplasmic domain (AA 691-709) (Yu, Nishimura 
et al. 2000). The cytoplasmic domain of NCT is not necessary for GS complex 
formation, however, the TMD is required for assembly of an active GS complex 
(Capell, Kaether et al. 2003), and the large ectodomain functions as a receptor 
which recognizes and captures the N-termini of substrates to facilitate regulated 
intramembrane proteolysis (RIP) by GS (De Strooper 2005). 
NCT is synthesized in the endoplasmic reticulum (ER) as an endoglycosidase 
H-sensitive glycosylated precursor, imNCT (immature NCT) with a molecular 
mass of 110-120 kDa, which then undergoes post-translational N-glycosylation 
to generate a 130-140 kDa mature form (mNCT) during intracellular trafficking 
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from the ER to the Golgi apparatus (Yu, Nishimura et al. 2000). This mature, 
extensively glycosylated form mNCT (Figure 3.1) becomes part of the complex  
 
Figure 3.1: Maturation and intracellular trafficking of nicastrin. The individual 
components of the gamma secretase (GS) complex is formed within the endoplasmic 
reticulum and are assembled together. The immature nicastrin (imNCT) is transported by a 
vesicular transport along with other three components, namely Aph1, presenilin enhancer-2 
(Pen-2) and presenilin (PS) of the GS system, to Golgi apparatus. By N-glycosylation, the 
imNCT is converted to the active, mature nicastrin (mNCT) that stays incorporated to the GS 
complex.    
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GS system and is required for its acitivity (Yang, Tandon et al. 2002). A recent 
study demonstrated that SGK1, a serum and glucocorticoid regulated kinase can 
modulate the expression of NCT and thus can inhibit the functioning of GS. By 
co-transfecting HEK293 cells with NCT and SGK1 and in the presence of 
lysosomal and proteasomal inhibitors, they showed that SGK1 downregulates 
the expression of NCT by way of proteasomal and lysosomal degradation in a 
dose-dependent manner (Mo, Yoon et al. 2012). 
 
3.1.4 Nicastrin as a therapeutic target 
Nicastrin (NCT), the only GS component with a single pass transmembrane 
domain and a large extracellular domain (ECD), is potentially targetable with an 
antagonistic antibody. The DYIGS region is mainly responsible for the GS 
substrate binding to NCT ECD (De Strooper 2005). NCT overexpression is 
shown to induce GS activity and substrate cleavage (Filipovic, Gronau et al. 
2011) whereas its stable knockdown is able to render the basal like BC sensitive 
to anti-proliferative effects of EGFR inhibition (Dong, Li et al. 2010). NCT 
levels are elevated in response to chemotherapy in colon cancer, indicating its 
involvement in development of chemo-resistance. Moreover, NCT is thought to 
possess a GS independent function involving p53 signalling and also PI-3 
Kinase regulation of cell death (Filipovic, Gronau et al. 2011).  
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GS inhibitors (GSIs) targeting the entire GS system are being developed by 
Roche and Pfizer. Orally administered GSIs targeting the catalytic function of 
PS are in Phase I and II clinical trials for advanced cancers. They demonstrate 
different efficacies but they have adverse effects, particularly goblet cell 
hyperplasia, that limits their administration as such. In breast cancer, rare cell 
lines and tumours with Notch gene rearrangement, resulting in constitutively 
active NICD, are most susceptible to single agent GSI growth inhibition 
(Robinson, Kalyana-Sundaram et al. 2011, Zhang, Pavlicek et al. 2012), while 
others are insensitive. GSIs, via down-regulation of Bcl-2, Bax and Bcl-XL, 
have been shown to induce G2/M arrest resulting in apoptosis (Rasul, 
Balasubramanian et al. 2009). Furthermore, treatment with a GSI induces NCT 
gene up-regulation in tumour tissue (Robinson, Kalyana-Sundaram et al. 2011). 
These indicate a need for an additional/alternate strategy to target GS, 
potentially through targeting NCT (Filipovic, Gronau et al. 2011, Hayashi, 
Takatori et al. 2012, Lombardo, Filipovic et al. 2012). 
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3.2 Hypotheses and aims of the project 
It has been shown by our group that compared to normal breast, NCT is 
overexpressed in 47.5% of patients’ (n = 1050) as confirmed by BC tissue 
microarray (TMA). High NCT levels has been shown to confer worse overall 
survival in ER-negative patients, whose tumours were more aggressive 
(Filipovic, Gronau et al. 2011). NCT amplification occurs in 7% of breast 
cancers, almost entirely restricted to basal type breast cancers. Also, nicastrin 
overexpression has been linked to the worse overall survival among the patients, 
particularly in case of the triple-negative sub-type. Thus, it has been 
hypothesized that this protein can be a good target for treating invasive, 
metastatic breast cancers. Furthermore, stable NCT knockdown in TNBC HCC-
1806 cells showed that NCT shRNA: i) inhibits growth in vitro and in vivo and 
ii) inhibits invasion via down-regulation of vimentin, Snail, Twist, MMP-2/7/9 
(Lombardo, Filipovic et al. 2012). Moreover, nicastrin  overexpression has been 
found to confer tamoxifen resistance linked to acquisition of EMT phenotype in 
estrogen-positive MCF-7 cells (Lombardo, Faronato et al. 2014). In this study I 
aimed to explore the effect of nicastrin on drug sensitivity pattern using short-
term SRB assays and long-term clonogenic assays. I also attempted to 
investigate whether there is any effect of combining the conventional 
chemotherapeutic agents with the investigational GSI agents (developed by 
Roche). For this, I used nicastrin overexpressed MCF-7 cells and nicastrin 
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down-regulated HCC-1806  cells along with corresponding empty vector 
control for each set of cells. At the end, I studied the effects of the drugs on the 
expression of nicastrin in wild type MCF-7 cells. 
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3.3 Materials and methods 
3.3.1 Nicastrin knocked-down and overexpressed cell lines and cell culture 
HCC-1806  shLUC and HCC-1806  shNCT cells were a kind gift of M. Loren 
(Department of Cell Biology and Physiology, Washington University School of 
Medicine, St. Louis, MO) and were established as previously reported (Kenny, 
Lee et al. 2007) Infected cells were maintained in medium containing 2 μg/mL 
puromycin (Invitrogen®). 
 
3.3.2 Overexpression of nicastrin and transfection 
Nicastrin stably overexpressing MCF-7 cell line (MCF-7-NCT) was generated 
by using the cDNA encoding full-length human nicastrin that was subcloned 
into a retroviral expression vector pMXs-puro. The construct was kindly 
provided by Prof. Gopal Thinakaran, (University of Chicago, USA). MCF-7 
cells were infected by the pMXs-puro-nicastrin retroviral vector. Control cells 
(MCF-7-Ctrl) were generated by retroviral transduction of the empty vector 
pMXs-puro (Cambridge Bioscience, Cambridge, UK). Stable, polyclonal cell 
populations were established after puromycin selection (0.5 μg/ml). 
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3.3.3 Cell-cycle analysis by cell synchronization, thymidine and double-
thymidine block followed by Western blotting 
MCF-7 cells were synchronized by inducing G1/S arrest using double-
thymidine blockade. In brief, 500,000 MCF-7 cells were seeded in six 6 cm 
dishes. The day after, 2 mM thymidine was added in DMEM (with 10% fetal 
calf serum, FCS + 1% Penicillin-Streptomycin + 1% Glutamine) for 16 hours. 
Cells were washed with 1xPBS and released in DMEM (10%FCS, 1% 
Penicillin-Streptomycin, 1% Glutamine) for 8 hours. This was followed by a 
second thymidine block in the same way for 16 hours. Finally, cells were 
washed with 1xPBS and released for 12 hours in DMEM every 3 hours. Since 
the level of cyclin B1 is increased as the cell-cycle progresses to the S-phase, 
accumulation of cyclin B1 over time was assessed by Western blotting to 
evaluate the double-thymidine block.  
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3.4 Results 
3.4.1 Nicastrin expression in breast cancer cell lines 
Western blotting (Figure 3.2) confirmed the expression of nicastrin in all these 
cells at variable amount. According to the western blot, ZR-75 had the highest 
amount of nicastrin expressed and MCF-7 had the least. However, the  
 
 
 
   
 
Figure 3.2: Western blot analysis showing expression of nicastrin in different breast 
cancer cell lines. Expression of nicastrin is demonstrated by the presence of the mature 
form (140 kDa), along with a smaller immature form (120 kDa) as the lower bands. β-Actin 
was used as the loading control. Migration of molecular mass markers (in kDa) is indicated 
in the left. It is worth mentioning that a post-translational maturation of nicastrin by N-
glycosylation gives rise to the mature form from the immature nicastrin (Chen, Yu et al. 
2001). 
 
expression of nicastrin in the cell lines was found to vary from one passage to 
the next and the blots from different passage were observed to contain different 
levels of the protein in the same cell type. This might be due to technical error 
of reproducibility of the blots or may be due to change of nicastrin expression 
over time as the cell cycle is progressed.  
In order to correlate the nicastrin protein with its mRNA, RT-qPCR was 
performed. The highest nicastrin mRNA expression level was found in T-47D 
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cells, with an almost 6-fold increase in comparison to the expression found in 
the other 3 cell lines (Figure 3.3). Although nicastrin protein levels varied, the 
mRNA levels were found pretty consistent irrespective of the different 
passages.  
 
 
 
 
 
 
 
 
Figure 3.3: Relative nicastrin mRNA expression in breast cancer cell lines. Real-time 
RT-qPCR analysis of nicastrin in breast cancer cells. The data was normalized to the 
expression of GAPDH mRNA. Relative values were compared to those of MDA-MB-231 
cells that were arbitrarily set to 1. The values are representative of the average of five 
biological replicates ± SD (*P<0.05). 
 
3.4.2 Regulation of nicastrin expression during cell cycle 
It was assumed that the variation found in nicastrin protein levels in different 
cells might be the result of analysing asynchronous cultures and the protein 
expression being regulated at the cell cycle level. In addition, as many 
chemotherapeutic drugs affect the cell cycle, to ascertain whether nicastrin is 
cell cycle regulated will be important to understand its biological effects on 
cancers. In order to examine the cell-cycle regulated expression of nicastrin, 
MCF-7 cells were synchronized at G1/S stage by inducing double-thymidine 
* 
* 
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block and released for 12 hours to reach a peak at mitosis. The levels of cyclin 
B1 remained unchanged (Figure 3.4) and this indicates that the double 
thymidine block did not work as there is no gradual increase of its level as it 
was expected. However, other cell synchronization methods, such as, 
nocodazole block at pro-metaphase should be used before drawing any 
conclusion. 
 
 
 
 
 
 
 
 
Figure 3.4: Expression of nicastrin is not regulated by cell-cycle. Western blot showing 
expression of nicastrin in MCF-7 synchronized with a double-thymidine block. The blot was 
probed with anti-nicastrin, anti-cyclin B1 and anti-actin antibodies. Migration of molecular 
mass markers (in kDa) is indicated in the left. 
 
3.4.3 Possible regulation of nicastrin by SGK1 
An initial hypothesis of the project, which has been later abandoned, was 
whether the variable levels of nicastrin expression might arise due to its post-
translational modifications, one of which includes phosphorylation by SGK1, as 
found in HEK-293 cells by Mo et al. (Mo, Yoon et al. 2012). We asked whether 
this is the case also in the breast cancer cell lines. However, the result shows 
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that induction of the SGK1 expression by dexamethasone (Mo, Yoon et al. 
2012) did not reduce the nicastrin levels (Figure 3.5).  
 
 
 
 
 
 
Figure 3.5: Nicastrin expression is not regulated by SGK1 at the post-transcriptional 
level. Western blot showing expression of nicastrin (NCT) and SGK1 (50-85 kDa or ~68 
kDa) in two breast cancer cell lines in presence or absence of dexamethasone treatment for 
24 hours. β-actin was used as protein normalizer. The immunoblot shown here is a 
representative example of at least 3 independent experiments.   
 
3.4.4 Effect of nicastrin modulation on drug sensitivity 
In order to determine the drug sensitivity curves of cells treated with 
conventional chemotherapeutic agents (etoposide, doxorubicin and paclitaxel), 
nicastrin down-regulated HCC-1806 cells and nicastrin overexpressed MCF-7 
cells were used along with the corresponding control lines with empty vector. 
The drug sensitivity pattern was investigated by sulphorhodamine B staining. It 
was anticipated that when nicastrin is either down- or up-regulated, the cells’ 
response toward the chemotherapeutic agents changes accordingly. i.e., the cells 
devoid of nicastrin become more resistant and cells overexpressing it become 
more sensitive toward the drug treatment. Paclitaxel sensitivity was found to be 
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altered in both nicastrin overexpressed (Figure 3.6 C) and down-regulated 
(Figure 3.6 F) lines. However, there appeared to be no significant differences in 
short-term drug sensitivity against etoposide (Figure 3.6 A and D) and the short-
term doxorubicin sensitivity was modified only slightly in case of the nicastrin 
knocked-down and overexpressed lines (Figure 3.6 E). 
 
 
Figure 3.6: Experimental modulation of nicastrin does not alter short-term drug 
sensitivity. Drug sensitivity assay showing cell viability against drug concentration (in log 
scale) in nicastrin overexpressed (A-C) MCF-7 and knock-down (D-F) HCC-1806 cells. Cells 
were seeded in 96-well plates at a density of 5000 cells/well and were exposed to the drugs 
for 3 days. After sulforhodamine B staining, the optical density was measured at 492 nm. 
Data represent the average ± SD of 3 independent experiments. IC50 values were determined 
by using Graph Pad Prism Software based on data obtained from drug sensitivity curves. 
Statistical analyses were done by performing paired t-tests comparing the mean for each data 
points between the control and the overexpressed or knock-down lines and the levels of 
significance are indicated by the P values in each graph. Statistical analyses were performed 
comparing IC50 values (paired t-tests). Statistical significance is indicated in each graph. 
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Table 3.1: IC50 values of drugs in nicastrin down-regulated and overexpressing cells 
Drug IC50 value (μM) 
HCC-1806   MCF-7  
shLUC shNCT NCT Ctrl 
Doxorubicin 0.22 0.13 0.083 0.05 
Etoposide 1.03 0.93 0.78 0.66 
Paclitaxel 0.29 0.18 0.85 0.51 
 
 
The IC50 values (Table 3.1 and Figure 3.6) showed that there was very little 
difference when nicastrin is either overexpressed or down-regulated on short-
term drug sensitivity in vitro, although in some cases this difference was 
statistically significant. However, none of these differences reached 2-fold and 
it is difficult to ascertain their biological significance, as it was not consistent 
across drugs. Thus, a long-term clonogenic assay was adopted to test the effect 
of nicastrin modulation on chemoresistance (Section 3.4.6). 
 
3.4.5 Effect on combining drugs (etoposide, doxorubicin and paclitaxel 
combined with GSI) 
Although there were slight variations in the IC50 values of etoposide, 
doxorubicin and paclitaxel (taxol) in nicastrin overexpressing or down-regulated 
cells, this was considered to be of little, if any, biological significance. 
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However, an attempt was made to explore whether combination of those drugs 
(at their IC50 concentration) can achieve any better efficacy along with an 
investigational gamma secretase inhibitor (GSI) developed by Roche. This GSI 
(effective concentration 10 μM) has been previously shown to reduce tumour 
growth and invasion by our group. Again, no significant differences were 
observed in terms of cell survival as they were treated with the drugs combined 
with GSIs in presence (Figure 3.7 A-C) or absence (Figure 3.8) of nicastrin. 
However, the effect of combination was higher in the basal type, triple-negative 
HCC-1806 cells (Figure 3.8) as compared to the ER/PR/HER-positive MCF-7 
cells (Figure 3.7 A-C). In addition, there were comparatively more decrease in 
the cell survival when the cells were exposed to both the drugs and the GSI as 
compared to that in the GSI treated cells. 
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Figure 3.7: Nicastrin over-expression does not affect the cell survival on combining 
drugs with GSI. Drug sensitivity pattern in nicastrin overexpressing MCF-7 cells (A-C) 
showing the effect of combining drugs (etoposide, doxorubicin and paclitaxel) with GSI in 
the presence of nicastrin. The cells were seeded in 96-well plates at a density of 5000 
cells/well. All 3 drugs were added at their IC50 concentration alone and with 3 concentrations 
of GSI (effective concentration = 10 μM) and the % cell viability were determined by SRB 
assay. The results show that GSI works better when combined with conventional 
chemotherapeutic agents. However, no synergistic or additive effects were observed. Data 
represents the average ± SD of 3 different experiments. 
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Figure 3.8: Nicastrin down-regulation does not affect the cell survival on combining 
paclitaxel with GSI. Drug sensitivity pattern in nicastrin down-regulated HCC-1806 cells 
showing the effect of combining paclitaxel with GSI in the absence of nicastrin. The cells 
were seeded in 96-well plates at a density of 5000 cells/well. All 3 drugs were added at their 
IC50 concentration alone and with 3 concentrations of GSI (effective concentration = 10 μM) 
and the % cell viability were determined by SRB assay. The results show that GSI works 
better when combined with conventional chemotherapeutic agents. However, no synergistic 
or additive effects were observed. Data represents the average ± SD of 3 different 
experiments. 
 
3.4.6 Effect on long-term drug resistance 
In order to explore the effect of nicastrin on the generation of drug resistance, 
the long-term clonogenic assays (Figure 3.9) were performed in both nicastrin 
overexpressing (MCF-7) and knocked-down (HCC-1806) cells. As the overall 
survival of TN BC patients is shorter in those overexpressing nicastrin 
(Filipovic, Gronau et al. 2011), we have hypothesized that an overexpression of 
the protein should confer cells an increase in drug resistance whereas a down-
regulation in nicastrin should render cells more sensitive. However, in the cell 
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models described above, nicastrin overexpression (Figure 3.9 A-C) showed a 
slight decrease and nicastrin knock-down (Figure 3.9 D-F) a slight increase in 
the number of the resistant clones generated. Nevertheless, it is difficult to infer 
any biological significance to these small differences. 
 
 
Figure 3.9: Modulation of nicastrin expression affects the long-term doxorubicin 
sensitivity. Long-term clonogenic assay followed by crystal violet staining in MCF-7 and 
HCC-1806 cells with nicastrin overexpressed (A-C) and down-regulated (D-F), respectively. 
In all cases (Ma, Young et al.), cells were treated for 24 hr with 50 ng/ml doxorubicin and 
drug-resistant clones were stained after 3 weeks with crystal violet (left panels, A and D) and 
counted (middle panels, B and E) and then solubilized with 33% acetic acid to measure 
relative optical density (OD) at 490 nm (right panels, C and F). Numerical data represent the 
average ± SD of at least 3 different experiments (* P<0.05). Pictorial data show the 
representative picture of plates repeated in triplicate for each cells.  
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3.4.7 Effect on drug-induced senescence  
The senescence associated (SA) - β-gal assay was performed to investigate 
whether nicastrin overexpression can lead to the appearance of more senescence 
and hence more resistant to death as observed by the β-galactosidase enzymatic 
activity in response to doxorubicin treatment. Doxorubicin has been found to 
increase SA-β-gal activity as a consequent increase in the number of senescent 
cells which can express relatively more β-galactosidase enzyme as compared to 
the normal non-senescent cells. Here, a slight increase in the β-galactosidase 
positive cells was observed (Figure 3.10) and the differences in terms of 
senescence, although minimal, may indicate a possible involvement of nicastrin 
in drug-induced senescence. 
 
 
 
 
 
Figure 3.10: Overexpression of nicastrin changes the drug-induced senescence after 
doxorubicin treatment. Cells were treated 3 days with 25 ng/ml doxorubicin and cells were 
stained for SA-β-galactosidase after 5 days. The plates were incubated at 37°C overnight after 
staining and pictures were taken 1 week after drug treatment. MCF-7-NCT, cell 
overexpressing nicastrin; MCF-7-Ctrl, cells expressing empty vector. Percentage of senescent 
cells is indicated after monitoring at least six fields of view (typical variation approximately 
10%) from 3 independent experiments. For clarity, only one picture is shown. 
 
+ Doxorubicin 
MCF-7-NCT MCF-7-Ctrl 
+ Doxorubicin 
93±8% 83±10% 
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3.4.8 Short-term nicastrin expression response to drug treatment 
In order to study whether there is any short-term expression response of 
nicastrin to chemotherapeutic agents, wild-type MCF-7 cells were treated by 
different concentrations of doxorubicin and paclitaxel. The cells were exposed 
to 3 different concentrations of both of the drugs, one at the corresponding IC50 
values, another 10-fold higher and the other 10-fold lower than the IC50 values. 
The cells were treated in this way and harvested at 4 different time points to 
extract RNA. The RT-qPCR was performed to find the fold changes in the 
nicastrin mRNA levels (Figure 3.11). It has been observed that upon short-term 
exposure to drugs (3 hours, in this case), nicastrin expression was slightly 
increased (Figure 3.11 A) up to 2-fold. However, the effect did not persist as the 
drug exposure was prolonged further (Figure 3.11 B-D). Overall, the changes of 
nicastrin mRNA levels with time exposure were very minimal and non-
consistent, despite having some significance (Figure 3.11 B-D). Thus, it was 
very difficult to associate these changes with any biological effect. 
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Figure 3.11: Variation in nicastrin expression after short-term exposure to doxorubicin 
and paclitaxel. RT-qPCR showing short-term expression response of nicastrin in MCF-7 
WT cells treated with Doxorubicin (0.0013, 0.013 and 0.13 μM) and Paclitaxel (0.015, 0.15 
and 1.5 μM) for 0-3 days. RNA extractions were performed after 3 (A), 24 (B), 48 (C) and 72 
(D) hour following respective drug treatments. ND = no drug control. RPS6 and RPS14 were 
used as normalizers for expression data. Data represents the average ± SD of 3 different 
experiments. Statistical analyses were done by performing 2-way ANOVA comparing means 
to the ND control and the P-values are indicated (*P<0.05, **P<0.01 and ***P<0.001). 
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3.5 Brief discussion  
In a previous study, Filipovic et al. (Filipovic, Gronau et al. 2011) demonstrated 
a marked upregulation of nicastrin protein levels in four BC cell lines (MCF-7, 
MDA-MB-231, BT-474, and SKBR-3) as compared to non-tumourigenic breast 
cell line (184A1). They also reported that high nicastrin expression is positively 
correlated with hormonal (HER2) receptors and estrogen (ERα) and 
progesterone (PR) receptors. In the present study, 3 of the 4 cell lines (except 
MDA-MB-231) belonged to the luminal subtypes that express ER and/or PR. 
Among these, ZR-75 and T-47D was found to contain more protein as 
compared to the other 2 cells (Figure 3.1). The relatively higher amount of 
nicastrin in ZR-75 and T-47D might be explained in terms of their luminal 
phenotype, i.e., presence of ER. However, the results of the western blot in the 
present study were not consistent and needs further confirmation. Flow 
cytometry based (FACS) detection of nicastrin expression using appropriate 
nicastrin antibody might be an alternative approach for investigating nicastrin 
expression in breast cancer cell lines and for comparing the result with that of 
western blot. 
The mRNA levels in the cell lines were consistent in 5 experiments with 
different biological replicates (Figure 3.2). However, in case of T-47D, there 
was a variable level of nicastrin mRNA in cells representing different passage. 
SNP array based LOH (loss of heterozygosity) and copy number analysis in T-
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47D shows that the long arm of chromosome 1 of this cell is almost 4-fold 
amplified as compared to that of MCF-7 or MDA-MB-231. This might be the 
reason of high fold change of mRNA in T-47D.  
The double thymidine block could not induce cell-cycle arrest at G1/S phase in 
MCF-7 cells (Figure 3.3). Further modification of the experiment and 
optimization of the method is required. In particular, we will re-initiate our 
studies using MDA-MB-231 cells, and, if necessary HeLa cells (from which the 
thymidine block protocol was obtained).  
The aim of this part of the thesis was to investigate any potential association of 
nicastrin with drug resistance in breast cancer. This was based on the previous 
findings that nicastrin, as an integral component of gamma-secretase (GS) 
enzyme system, renders the cells more invasive and helps acquire an EMT 
phenotype (Lombardo, Filipovic et al. 2012) and that nicastrin regulates cell 
death via phosphoinositide 3-kinase/Akt and p53-dependent pathways 
(Pardossi-Piquard, Dunys et al. 2009). Based on those findings, I characterized 
the drug sensitivity pattern in the presence or absence of nicastrin. Both the 
short-term (Table 3.1 and Figure 3.5 3.6 and 3.7) and long-term (Figure 3.8) 
assay could not delineate any variability in the sensitivity pattern to paclitaxel 
and doxorubicin in the cells overexpressed or down-regulated for nicastrin. 
Furthermore, the senescence associated-β-gal test also did not show any 
differences in the appearance of β-gal positive cells when nicastrin level was 
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high (Figure 3.9). Such findings led to test whether there was any likely impact 
of the drugs in altering the expression pattern of nicastrin which might be the 
reason of finding no difference in drug sensitivity. Although nicastrin 
expression goes up following short-exposure (3 hours) to drugs (Figure 3.10 A), 
there is no significant changes after 1, 2 or 3 days of drug treatment (Figure 
3.10 B-D). It has been found recently that Nicastrin overexpression per se can 
induce tamoxifen resistance that is associated with the acquisition of EMT 
phenotype (Lombardo, Faronato et al. 2014). Although nicastrin has been 
shown to regulate breast cancer stem cell (CSC) properties and tumour growth 
in vitro and in vivo (Lombardo, Filipovic et al. 2012), its direct association with 
drug resistance has not been studied in detail. Nicastrin has been shown to 
switch on EMT via up-regulation of the EMT signature genes like VIM, Twist, 
Snail, MMP2 and MMP9 and thus promoting cell invasiveness. Moreover, 
nicastrin up-regulation was also found to be associated with the appearance of 
CSC phenotype as demonstrated by high proportion of CD44+/CD24- and 
higher ALDH1 (Lombardo, Filipovic et al. 2012). Recently it has been found 
that EMT and CSC may contribute to drug resistance (Singh and Settleman 
2010). However, all the effects of nicastrin expression on EMT and CSC have 
been observed in MCF10A cells overexpressing nicastrin. As I have used two 
different cell models to study the effects of overexpressing and down-regulating 
nicastrin, it is now clear that it is difficult to generalize and ascribe a particular 
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function to nicastrin using just one cell system. As no correlation between 
nicastrin and doxorubicin or paclitaxel resistance was found, further work with 
nicastrin was abandoned. 
However, EMT, CSC and drug resistance has also been studied by our group 
working with a transcriptional co-activator, EP300, which has been shown to 
regulate the EMT axis via down-regulation of E-cadherin. This prompted us to 
further study the role of EP300 as a marker of drug resistance. 
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Chapter 4: EP300 as a Marker of Drug Resistance/Chemosensitivity, EMT and 
Stemness in Breast Cancer 
 
4.1  Introduction 
4.1.1 Transcription factors and cancer drug resistance 
Eukaryotic cells respond to various stimuli via modulation of specific gene 
expression programmes that elicits biological response by evoking the 
production of specific effector proteins and transcripts (Johnston and Carroll 
2015). Various upstream cellular pathways trigger the activation of transcription 
factors (TFs), which are the proteins that initiate and regulate the transcription 
of genes. They have DNA-binding domains that endow them with the ability to 
bind to specific sequences of DNA called enhancer or promoter sequences. 
These regulatory sequences (i.e, enhancers and promoters) are usually located 
thousands of base pairs upstream or downstream of the particular gene being 
transcribed. Mechanistically, there are some transcription factors that bind to a 
DNA promoter sequence near the transcription start site and help form the 
transcription initiation complex. There are yet some other transcription factors 
that bind to regulatory sequences, such as enhancer sequences, and can either 
stimulate or repress transcription of the related gene (Figure 4.1). Regulation of 
gene transcription by the TFs is the most common form of gene control. 
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Figure 4.1: Mechanism of action of transcription factors (TFs). (A) TFs (blue ovals) bind 
to core promoter regions via recognition of common elements such as TATA box elements 
and initiators (INR). (B) Promoter activity can be increased (represented by +) by site-
specific DNA-binding factors (red trapezoid) interacting with cis elements (dark blue box) in 
the proximal promoter region; this stabilizes the recruitment of the transcriptional machinery 
via direct interaction of the site-specific factor and the general factors. (C) Promoter activity 
can be further stimulated to higher levels by site-specific factors (orange octagon) binding to 
enhancers. The enhancer factors can stimulate transcription by - (D) recruiting a histone-
modifying enzyme, for example, a histone acetyltransferase (HAT) i.e. histone acetylation 
(Ac) or by (E) recruiting a kinase that can stimulate elongation by phosphorylating the C-
terminal domain of RNA polymerase II. Figure adapted from Farnham (Farnham 2009). 
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Briefly, activated transcription factors function in concert with multi-protein 
complexes and along with cofactors, and bind directly to specific sites on 
accessible DNA to regulate gene expression via recruitment of the RNA 
polymerase II machinery (Carrera and Treisman 2008). In cancer, impaired 
gene expression regulation can occur at multiple levels viz. - i. alterations of the 
upstream signalling components or ii. changes in the downstream signals 
mediated by the transcription factor itself, or by both i. and ii. Such impairments 
of gene expression regulation are envisioned as cardinal features observed in 
acquired drug resistance secondary to cancer chemotherapy. This is also 
supported by the fact that various transcription factors and cofactors regulate 
oncogenic cell signalling pathways that influence the development of many 
hallmarks of cancer progression (Hanahan and Weinberg 2000). Therefore, 
targeting transcription factors and cofactors can be of prudent choice for 
addressing as well as tackling the problem of drug resistance in cancers. 
 
4.1.2 EP300 as a transcriptional co-activator 
EP300 or p300 together with its family member CBP (cAMP-response-element-
binding Protein, abbreviated for CREB), were originally discovered as 
transcriptional co-activators that play pivotal and crucial roles in integrating and 
mediating multiple signal-dependant transcription events in vivo (Goodman and 
Smolik 2000). It is the adenovirus E1A-associated cellular p300 transcriptional 
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co-activator protein that serves as a histone acetyltransferase (HAT) or lysine 
(K) - acetyltransferase (KAT3B) enzyme in regulating transcription via 
chromatin remodeling. The protein has its direct involvement in cellular 
proliferation, differentiation and apoptosis (Chan and La Thangue 2001). 
Histone acetyltransferases (HATs) are enzymes that acetylate conserved lysine  
 
Figure 4.2: Biological effects of histone acetylation by histone acetyltransferases 
(HATs). (A) Flow diagram showing effect of HATs on transcription. (B) Schematic 
representation depicting the function of HATs and histone deacetylases (HDACs).  
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amino acids on histone proteins by transferring an acetyl group from acetyl CoA 
to form ε-N-acetyl lysine. DNA is wrapped around histones, and, by transferring 
an acetyl group to the histones, genes can be turned on and off (Figure 4.2). In 
general, histone acetylation increases gene expression culminating into a diverse 
biological effects involving cell growth and proliferation, migration and 
regulation of cell cycle and cell death via apoptosis. Like other HATs, EP300 
also play crucial roles in modulating gene expression. Understanding the role of 
EP300 in this context therefore necessitates the brief discourse on its basic 
structure and functions. 
 
4.1.3 Structural aspects of EP300 
EP300 Gene 
Human EP300 gene (ENTREZ Gene ID 2033) is a 88,293 bp long gene 
(Whyte, Williamson et al. 1989, Eckner, Arany et al. 1994) encoding the p300 
transcriptional co-activator protein containing 31 exons. Chromosomally, it is 
located in the long (q) arm of chromosome 22 at the locus 13.2 (22q13.2). 
EP300 has a single splice variant with an mRNA of 9585 bp that includes a 5'-
untranslated region (UTR) of 1219 bp and a 3'-UTR of 1121 bp (Atlas of 
Genetics and Cytogenetics in Oncology and Haematology, 
http://atlasgeneticsoncology.org/Genes/P300ID97.html). Figure 4.3 depicts the 
cytogenetic location and structure of EP300 gene. This gene is conserved in a 
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spectrum of multicellular organisms from worms to humans (Chan and 
Thangue, 2001) and no pseudogenes has been reported as yet. 
 
 
Figure 4.3: Chromosomal location and structure of EP300 gene. (A.) Cytogenetic band 
showing the location of EP300 gene (Human Gene Database, GeneCards). (B.) Schematic 
representation of EP300 gene. Exons are represented by black boxes while the 5’- and 3’- 
UTRs are denoted by the grey boxes. Adapted from: Atlas of Genetics and Cytogenetics in 
Oncology and Haematology (http://atlasgeneticsoncology.org/Genes/P300ID97.html). 
 
EP300 Protein 
EP300 (also known as KAT3B) is a large (2414 amino acid, 264 kDa) multi-
domain protein that belongs to the HAT (histone acetyl transferase) or KAT3 
(lysine or K-acetyltransferase) family (Valor, Viosca et al. 2013) family of 
enzymes (EC 2.3.1.48). Molecular functions of EP300 are related to its 
structural and functional domains (illustrated in Figure 4.4).  
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Figure 4.4: Domain architecture of EP300 core protein. A model showing all the domains: 
NRID (nuclear receptor interaction domain), CH1 (cysteine/histidine-rich region 1, also 
known as transcriptional-adaptor zinc-finger domain 1 or TAZ1), KIX (kinase inducible 
domain of CREB interacting domain), BROMO (bromodomain), PHD (plant homeodomain 
finger), HAT (histone acetyltransferase domain), AIL (auto-inhibitory loop), ZZ (ZZ-type 
zinc finger domain), TAZ2 (transcriptional-adaptor zinc-finger domain 2; ZZ and TAZ2 
together are sometimes referred to as CH3 or cysteine/histidine-rich region 3), and IBiD 
(IRF3-binding domain). The amino acid positions are from UniGene NP_001420.2.  
 
The protein EP300 consists of several conserved domains (Bedford and Brindle 
2012, Wang, Marshall et al. 2013) including a central chromatin association and 
modification region. This region includes the bromodomain/PHD finger module 
and the HAT or KAT11 domain (Rack, Lutter et al. 2014) which is flanked by 4 
transactivation domains (TADs). They are:  
i) the CH1 that encompasses the TAZ1 domain 
ii) the KIX (Kinase-inducible domain of CREB-interacting) domain 
iii)  another CH3 containing the TAZ2 domain and a ZZ domain and 
iv)  the IBiD (IRF3 binding domain), also known as nuclear coactivator- 
binding domain (NCBD). 
The bromodomain mediates binding of EP300 to acetylated histones, 
nucleosomes and transcriptional factors and play a crucial role in attaching 
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EP300 to specific chromosomal sites (Kalkhoven 2004, Rack, Lutter et al. 
2014). This domain, in addition to the HAT domain, is required for effective 
substrate acetylation. The loss of the bromodomain impairs substrate specificity 
and transcriptional activity of EP300 (Delvecchio, Gaucher et al. 2013). 
The PHD finger, which is associated with the bromodomain, is an integral part 
of the catalytic core of the protein facilitating recognition and acetylation of 
both itself (auto-acetylation) as well as of histones and non-histone substrates 
(Kalkhoven 2004, Wang, Marshall et al. 2013, Rack, Lutter et al. 2014). The 
KAT11 or HAT catalytic domain can acetylate EP300 itself and a variety of 
proteins (both histones and non-histones) and the 3 cysteine/histidine-rich 
regions (CH1, CH2 and CH3) are able to bind zinc and are involved in protein-
protein interaction (Valor, Viosca et al. 2013, Wang, Marshall et al. 2013). 
The RING (Really Interesting New Gene) domain is endowed with the E3 
ligase activity that binds E2 ubiquitin-conjugating enzymes to mediate transfer 
of ubiquitin to substrates. The HAT domain consists of a central β-sheet 
comprising seven β-strands surrounded by nine α-helices and several loops, 
with the last three α -helices and the last β -strand coming from the C 
subdomain (Liu, Wang et al. 2008). The HAT domain of EP300 key to the 
acetylation of promoter-bound histones, resulting in modulation of transcription 
(Ito, Ikehara et al. 2000). The bromodomain, PHD, RING and HAT domains 
form a compact bromodomain-RING-PHD (BRP) module. This module closely 
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associates with the HAT domain and the RING domain is juxtaposed with the 
HAT substrate-binding site (Delvecchio, Gaucher et al. 2013). 
EP300, through its well-defined domains including the CH1 (TAZ1), KIX, CH3 
(ZZ-TAZ2) and NCBD domains, interact with various transcription factors and 
the basal transcription machinery as well as with other transcriptional co-
activators (Goodman and Smolik 2000). The functional domains of EP300 
enables this protein to play vital roles in mediating epigenetic and 
transcriptional regulations of numerous genes as outlined in the following 
section (4.1.4). 
The EP300 protein is regulated at the post-translational level by various 
mechanisms, viz., acetylation and deacetylation (Delvecchio, Gaucher et al. 
2013), methylation (Lee, Coonrod et al. 2005), sumoylation (Girdwood, 
Bumpass et al. 2003), ubiquitination (Shima, Shima et al. 2008) and 
phosphorylation (Yang, Hong et al. 2001).  
EP300 is highly homologous to the cyclic AMP response element-binding 
(CREB) binding protein, known as CBP, with 63% identity and 75% similarity 
at amino-acid level (Wang, Marshall et al. 2013). Due to the similarity in 
functional parts and for having an extensive sequence homology, EP300 and 
CBP shares common functions and mechanism with respect to transcriptional 
regulation of their target proteins. 
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4.1.4 Biological functions of EP300 
As a histone acetyltransferase (Ogryzko, Schiltz et al. 1996), EP300 regulates 
transcription via chromatin remodelling (Grunstein 1997) and is important in 
the processes of cell proliferation and differentiation (Yao, Oh et al. 1998, 
Gayther, Batley et al. 2000). Despite sharing extensive sequence homology and 
functional similarity with CBP, genetic and molecular pathway analyses suggest 
that EP300 has also some unique functions (Chan and La Thangue 2001). 
EP300, by way of its intrinsic lysine acetyltransferase activity, regulates 
transcriptions and expression of its target proteins including a wide variety of 
histones and non-histone substrates (Lee and Workman 2007, Wang, Marshall 
et al. 2013).  
The intrinsic acetyltransferase activity of EP300 and therefore, the biological 
functions of EP300 can be discussed under 2 categories as follows: 
 
i. Histone modification and chromatin remodelling 
As a "writer" of the epigenetic code (Berdasco and Esteller 2013), EP300 can 
modify chromatin structure (from hetero- to eu-chromatin state) by acetylating 
all 4 core histones (H2A, H2B, H3 and H4). Through the catalytic activity of its 
HAT domain, EP300 can acetylate the N-terminal tails of the nucleosomal 
histones resulting in chromatin remodelling and relaxation (Berdasco and 
Esteller 2013, Wang, Marshall et al. 2013). This renders an enhanced 
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accessibility of the DNA to other regulators that are essential for gene 
expression (Wang, Marshall et al. 2013). 
ii. Acetylation of non-histone transcription factors leading to transcriptional 
regulation 
Through its four conserved transactivation domains (TADs), EP300 can interact 
with the TADs of numerous other transcription factors (Figure 4.5). These 
transcription factors, using their intrinsically disordered regions (IDRs) or 
TADs, recruits EP300 in response to various stimuli and undergo post- 
translational modification by acetylation (Wang, Marshall et al. 2013). This 
 
Figure 4.5: The functional domains interaction partners of EP300. The regions of EP300 
that are reported to bind various target proteins, together with the interacting proteins, are 
shown. The figure taken from (Wang, Marshall et al. 2013). 
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eventually leads to activation of the transcription factors for regulating 
expression of their target genes. 
In general, acetylation of non-histone substrates by EP300 can result in either 
positive or negative effects on transcription by mechanisms involving: 
i) protein-protein interactions (e.g., activator of thyroid and retinoid  
receptors, ACTR) 
ii) protein-DNA interactions (e.g. the high mobility group protein, HMGI) 
iii)  nuclear retention (e.g., the hepatocyte nuclear factor, HNF4) and 
iv) protein half-life (e.g., E2F). 
EP300 can interact with more than 400 partner proteins (Bedford and Brindle 
2012). Notably, the large EP300 interactome (Wang, Marshall et al. 2013) 
includes: 
a. various pro-proliferative proteins and oncoproteins, viz., c-Myc, c-Myb, 
CREB, c-Jun and c-Fos. 
b. transforming viral proteins, such as, E1A, and E6 
c. tumour suppressors and pro-apoptotic proteins: Forkhead box class O 
(FoxO) transcription factors, e.g., FoxO1, FoxO3a, and FoxO4, signal 
transducers and activators of transcription (STAT) 1 and STAT 2, 
Hypoxia-inducible factor 1α (HIF-1α), breast cancer 1 (BRCA1), 
SMA/MAD homology (Smad) proteins, the Runt-related transcription 
factor-1 (RUNX1) and E2 Transcription Factor (E2F). 
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Table 4.1: EP300 substrates and their cellular effects  
EP300 
Substrates 
Category Key Effect Reference(s) 
E1A, TFIIB General Transcription Factors DNA Binding (Felzien, Farrell et al. 1999) 
TBP General Transcription Factor DNA Binding (Swope, Mueller et al. 1996) 
TFIIEβ, TFIIF General Transcription Factors DNA Binding (Dietschy, Shevelev et al. 2009) 
E2F General Transcription Factor Cell Cycle 
Regulation 
(Dietschy, Shevelev et al. 2009) 
Rb General Transcription Factor Cell Cycle 
Regulation 
(Wang, Elder et al. 2005) 
CREB  Transcription Factor DNA Binding (Sugase, Dyson et al. 2007) 
TP53 Transcription Factor DNA Binding (Ferreon, Lee et al. 2009) 
FOXO1, 
FOXO3a, 
FOXO4  
Transcription Factors DNA Binding (Wang, Marshall et al. 2012, Wang, 
Marshall et al. 2013) 
RUNX1 Transcription Factor DNA Binding (Wang, Marshall et al. 2013) 
HIF-1a  Transcription Factor DNA Binding (Ruas, Poellinger et al. 2005) 
BRCA1 Transcription Factor DNA Binding (Lee, Bedford et al. 2011) 
E2A Transcription Factor DNA Binding (Hyndman, Thompson et al. 2012) 
CITED1  Transcription Factor DNA Binding (Yahata, de Caestecker et al. 2000) 
CITED2  Transcription Factor DNA Binding (Yin, Haynie et al. 2002) 
c-Myb,  
c-Myc 
Transcription Factors DNA Binding (Zor, De Guzman et al. 2004, Wang, 
Marshall et al. 2013) 
GATA1 Transcription Factor DNA Binding (Dietschy, Shevelev et al. 2009) 
STAT1, 
STAT2 
Transcription Factors DNA Binding (Wojciak, Martinez-Yamout et al. 
2009) 
c-Jun Transcription Factor DNA Binding (Campbell and Lumb 2002) 
c-Fos Transcription Factor DNA Binding (Wang, Marshall et al. 2013) 
MEF2 Transcription Factor DNA Binding (He, Ye et al. 2011) 
MLL Transcription Factor DNA Binding (De Guzman, Goto et al. 2006) 
LEF1 Transcription Factor DNA Binding (Hecht and Stemmler 2003) 
IRF2 Transcription Factor DNA Binding (Masumi and Ozato 2001) 
IRF3 Transcription Factor DNA Binding (Qin, Liu et al. 2005) 
DDX5 Transcription Factor DNA Binding (Rossow and Janknecht 2003) 
ESR1 Transcription Factor DNA Binding (Kang, Guermah et al. 2002) 
Mdm2 Transcription Factor DNA Binding (Grossman, Perez et al. 1998) 
PPARA Transcription Factor DNA Binding (Dowell, Ishmael et al. 1997) 
PPARG Transcription Factor DNA Binding (Kodera, Takeyama et al. 2000) 
SMAD1 Transcription Factor DNA Binding (Pearson, Hunter et al. 1999) 
SMAD2 Transcription Factor DNA Binding (Pessah, Prunier et al. 2001) 
SMAD7 Transcription Factor DNA Binding (Gronroos, Hellman et al. 2002) 
TCF3 Transcription Factor DNA Binding (Bradney, Hjelmeland et al. 2003) 
TWIST1 Transcription Factor DNA Binding (Hamamori, Sartorelli et al. 1999) 
RXR Nuclear Receptor DNA Binding (Chakravarti, LaMorte et al. 1996) 
ER Nuclear Receptor DNA Binding (Fronsdal, Engedal et al. 1998) 
AR Nuclear Receptor DNA Binding (Hanstein, Eckner et al. 1996) 
PCAF Co-activator DNA Binding (Yang, Ogryzko et al. 1996) 
ACTR Co-activator DNA Binding (Dietschy, Shevelev et al. 2009) 
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EP300 binding with its partner proteins (e.g. those mentioned in Table 4.1) 
modulates their activity either positively (up-regulation) or negatively (down- 
regulation). For instance, some acetylated EP300 targets regulate the expression 
of histone methyltransferase leading to chromatin condensation and gene 
silencing. E300, as a "molecular bridge", links the DNA-bound transcription 
factors (activators) to the basal transcription machinery through direct 
interaction with TFIID, including TATA-binding protein (TBP) and 13 TBP-
associated factors (TAFs) and TFIIB promoting the pre-initiation complex 
(PIC) assembly (Wang, Marshall et al. 2013). 
Some of the indirect chromatin-related functions of EP300 include the 
following: 
a. Regulation of p53 activity: EP300, via MDM2 (murine double minute-2), 
is involved in p53 degradation. It forms a ternary complex with p53 and 
MDM2 that mediates the ubiquitination and subsequent degradation of 
p53 in the cycling cells. Also, the poly-ubiquitin ligase activity of the 
CH1-region of EP300 helps regulate the cellular turnover of p53 (Wang, 
Marshall et al. 2013). On the contrary, EP300 acetylation of p53 
promotes its tumour suppressor activity (Lunning and Green 2015). 
b. Regulation of cell-cycle: EP300, by associating with the cyclin E-cdk2 
(cyclin-dependent kinase-2), regulates the propagation of cell cycle 
(Wang, Marshall et al. 2013). 
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c. Regulation of DNA repair: EP300 is also involved in DNA repair 
mechanism by interactions with various DNA repair enzymes, e.g., DNA 
polymerase b, Flap endonuclease-1 (Fen1), Recql4 (RecQ protein-like-4) 
helicase and thymine DNA glycosylase (Dietschy, Shevelev et al. 2009). 
d. Regulation of nuclear import: The two proteins involved in regulating 
nuclear import, the importin-α1 isoform Rch1 and importin-α7, are 
acetylated by EP300. 
 
4.1.5 EP300 mutation in cancers  
Overall, the frequency of EP300 mutation in cancer is reported to be low. There 
are, however, some evidence confirming EP300 mutations in breast, colon and 
ovarian cancers. EP300, which is a tumor suppressor gene, is located on 
chromosome 22q13. This is a region where loss of heterozygosity (LOH) is 
very common, as reported in the primary tumours including breast (36%), colon 
(38%) and ovarian (49%) cancers (Bryan et al., 2002). LOH on chromosome 
22q, accompanied by missense mutations of EP300, has been also reported in 
colorectal and gastric carcinomas (Muraoka, Konishi et al. 1996).  
Genomic deletions and or somatic mutations removing or inactivating the HAT 
domain of EP300 and CBP genes have also been recently documented in diffuse 
large B-cell lymphoma (~39%) and follicular lymphoma (41%) cases (Gayther, 
Batley et al. 2000, Pasqualucci, Dominguez-Sola et al. 2011). 
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EP300 truncating mutations, involving an inactivation of the second allele, have 
been detected in two primary tumours (one colorectal, the other breast) and four 
cancer cell lines (including the colon cancer line HCT-116). Three of these 
mutations resulted in functionally null EP300 protein, truncated upstream of the 
HAT domain. The identification of these truncating mutations of EP300 
provides the first evidence for a role of EP300 as a classical tumour suppressor 
gene in a variety of epithelial malignancies (Gayther, Batley et al. 2000). 
 
4.1.6 EP300 and drug resistance 
Experimental down-regulation of EP300 has been previously reported to be 
associated with doxorubicin and cisplatin resistance in bladder cancer cells 
(Shiota, Yokomizo et al. 2010, Takeuchi, Shiota et al. 2012). Recently, it has 
been demonstrated by our lab that experimental down-regulation of EP300 in 
breast cancer cells leads to resistance against doxorubicin and paclitaxel by 
overcoming drug-induced senescence (Zhou, Hu et al. 2014) and evading 
apoptosis (Hu, Li et al. 2015), respectively.  
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4.2 Hypotheses and aims of the project 
Our group has recently described a novel EMT regulatory axis controlled by the 
miR-106b~25 cluster down-regulating the E-cadherin transcriptional activator 
EP300. We confirmed previously that cells over-expressing the miR-106b~25 
cluster, or in which either EP300 or E-cadherin has been down-regulated not 
only increase their motility and invasive properties, but also leads to the 
generation of doxorubicin and radiation resistant derivatives (Zhou, Hu et al. 
2014).  
Therefore, we hypothesised that - 
1. Stable KD of EP300 leads to paclitaxel resistant cancer cells with 
mesenchymal (EMT) and CSC phenotype.  
2. Overexpression of EP300 re-sensitises cancer cells to paclitaxel, reverses 
EMT and reduces CSC characteristics. 
The aims of this part of the project were - 
i. To demonstrate correlation between EP300 and E-cadherin expression. 
ii. To evaluate the effects of EP300 KD or OE on drug resistance, EMT and 
CSC phenotype.   
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4.3 Materials and methods 
4.3.1 Cell lines and cell culture 
In order to validate our hypothesis, we used two MCF-7 derivatives (Figure 
4.6), designated shEP1 and shEP2, which were stably knocked down using 2 
different hairpins (in order to eliminate any possible off-target effects). These 
two lines were generated previously in the lab by using a lentivirus expressing 
hairpins targeting EP300 (Raguz, Adams et al. 2013). Hairpins for targeting 
EP300 (TGTGCACAACTGTTTGCCG and TAATCTATCTTCAGTAGCT) 
were cloned in pGIPZ and obtained from the Broad Institute (Cambridge, MA, 
USA). MCF-7 cells with pGIPZ (MCF-7 shev) were used as the negative 
control line to compare the effects of EP300 knock down. We also used 
corresponding paclitaxel resistant (resistant against 20 nM paclitaxel) version of 
the MCF-7 shEPs generated for this study. As positive controls, we used two E-
cadherin (CDH1) knocked-down MCF-7 lines (designated shCDH1s) 
containing hairpins targeting this epithelial marker protein. MCF-7-shev, MCF-
7-shEP1 and MCF-7-shEP2 cells were cultured in DMEM (Dulbecco's 
Modified Eagle Medium) supplemented with 10% FCS, 10 mL of PSG 
(Invitrogen) and 1 μg/mL puromycin (Sigma-Aldrich) to maintain pGIPZ 
selection (Kochneva, Babkina et al. 2013, Sippl, Zeilbeck et al. 2014). 
We also used HCT-116 cells and their EP300-null-derivatives (Figure 4.6), 
designated as HCT KOEP (knocked-out EP300) cells. This genetically 
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knocked-out HCT-116, together with the wild type HCT-116, were purchased 
from Cancer Research Technology. HCT-116 cells were chosen since they are 
hemizygous for the EP300 locus and amenable to homologous gene 
recombination, thus a genetic EP300 knock-out is available (Krubasik, Iyer et 
al. 2006). For clarity, EP300 knocked-out HCT-116 cells and MCF-7-shEP300 
cells used in the study are described as EP300
-
 cells. All the HCT-116 and HCT 
KOEP cells were cultured in McCoy’s 5A medium supplemented with 10% 
FCS and 10 mL of PSG (Invitrogen) (a mixture containing 200 nM L-
glutamine, 10,000 U of penicillin and 10mg streptomycin per mL). 
In addition to the EP300- MCF-7 and HCT-116, we also used minimally 
transformed mammary epithelial cells (MTMECs) which was transfected 
previously with the constructs pLKO containing a short-hairpin RNA (shRNA) 
targeting EP300 (hereinafter MTMEC-shEP300) allowing stable knockdown of 
EP300 (Hu, Li et al. 2015) and the corresponding empty vector (hereinafter 
MTMEC-pLKO). MTMEC cells were a gift from W. Hahn (Dana Farber, 
Boston, MA, USA) and expressed TERT, SV40 large antigen, a constitutively 
active form of PI3K, p110α and oncogenic RAS (Zhao et al., 2003). These cells 
were cultured in a mixture of 50% HuMEC Serum-free Medium (Life 
Technologies, Paisley, UK) supplemented with 1% (v/v) of a mixture 
containing epidermal growth factor, hydrocortisone, isoproterenol, transferrin 
and insulin (Life Technologies), 0,5% (w/v) bovine pituitary extract (Life 
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Technologies) and 1% antibiotic-antimycotic (Sigma-Aldrich, St Louis, MO, 
USA); and 50% Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-
Aldrich) supplemented with 10% (v/v) fetal calf serum (FirstLink, 
Wolverhampton, UK), 2 mM L-glutamine, 50 units/ml penicillin and 50 μg/ml 
streptomycin (Sigma-Aldrich) in an humidified atmosphere at 37°C and 5% 
CO2. 
We wanted to investigate further whether the phenotypic changes brought about 
upon EP300 deletion (in epithelial MCF-7) can be rescued by overexpressing 
the protein in cell lines. For this, we used CAL-51 and MDA-MB-231, two 
well-characterised triple negative and mesenchymal breast cancer lines, in 
which we overexpressed EP300 by stable transfection (shown in Figure 4.6 and 
described in section 4.3.2). The wild type version of these two lines was 
originally obtained from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures (CAL-51) and the European Collection of 
Cell Cultures (ECACC). We used pcDNA3.1 and E-cadherin (CDH1) 
transfected derivatives from each of the two mesenchymal lines as the negative 
and positive controls, respectively. All these cells were cultured in low glucose 
(1 g/L) Dulbecco’s modified Eagle’s medium (DMEM) (Sigma Aldrich, St 
Louis, USA) supplemented with 10% (v/v) foetal calf serum (FCS) and 10,000 
units/ml penicillin, 10 mg/ml streptomycin and 200 mM L- glutamine (Sigma 
Aldrich, St Louis, USA). Cells were grown at 37°C in a humidified 5% CO2 
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atmosphere and maintained by serial passaging using 25 g/L trypsin solution 
(Sigma Aldrich, St Louis, USA) in 0.02% ethylenediaminetetraacetic acid 
(EDTA) (Sigma Aldrich, St Louis, USA) when 70-80% confluence was 
reached. 
All cell culture procedures were carried out in a Class II laminar flow hood 
(BioMAT 2,MAT, Derby, U.K.), and cells were grown in a Galaxy 170R 
incubator at 37°C with 5% CO2 (RS Biotech, Ayrshire, U.K.). 
 
 Figure 4.6: Schematic representation of the cell lines used.  (A) MCF-7 cells were 
obtained by a stable transfection using two hairpins targeting EP300 (shEP1 and shEP2) and 
E-cadherin, CDH1 (shCDH1 A and shCDH1 H). (B) HCT-116 cells were subjected to 
homologous recombination by targeting the single expressed EP300 allelle resulting in cells 
null for any expressed EP300 protein (Krubasik, Iyer et al. 2006). (C) CAL-51 and (D) 
MDA-MB-231 cells expressing E-cadherin, EP300 or the empty pcDNA3.1 vector (negative 
control) were generated by stable transfection. 
 
128 
 
All the resistant lines were derived by following a “pulse” methodology as 
described before (Raguz and Yagüe 2010) as this regimen gives a better 
approximation to the chemotherapy regimens received by cancer patients  
 
Figure 4.7: Generation of paclitaxel resistant derivatives by pulse method. For each cell 
type, the three small arrows indicate each pulse of the three when Paclitaxel was added to 
the culture medium at a concentration of 40 nM. The gaps in between arrows indicate the 
passages when the cells were cultured and allowed to grow in drug-free medium. After 
completion of the 3-pulses, the cells were allowed to grow for several passages until stable 
resistant derivatives were obtained as confirmed by drug sensitivity assay by SRB staining. 
 
(Agarwal and Kaye 2003) . In short, EP300- were treated cells with paclitaxel 
(20 nM for MCF-7 and 30 and 40 nM for HCT-116 derivatives) for 3 days, after 
which the media were changed (to make drug-free) and kept the cells growing 
for 2 passages containing their normal growth medium (without paclitaxel). 
Then the same process were repeated twice more and finally the stable 
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paclitaxel resistant derivatives were derived. The entire process (as shown in the 
following schema) took a few months (Figure 4.7). The paclitaxel sensitivity of 
the resistant lines was verified by drug sensitivity assay described before. 
 
4.3.2 Cell transfection  
CAL-51 and MDA-MB-231 cells expressing E-cadherin (CDH1), EP300 or the 
empty pcDNA3.1 vector (negative control) were generated by stable 
transfection. The procedural details of the transfection methods are described 
briefly as follows: 
 
FuGENE® Transfection 
FuGENE6® transfection reagent (Promega UK, catalog no. E2693) was used for 
empty vector (pcDNA 3.1) and E-cadherin (CDH1) transfection. In brief, CAL-
51 and MDA-MB-231 cells were seeded in 75 cm2 flasks to reach to ~50-60% 
confluence on the day of transfection.  Before transfecting, the medium was 
replaced by antibiotic-free medium and 2.2 ml of pre-warmed opti-MEM was 
used to dilute 75 μl of the FuGENE6 transfection reagent. After a 5-minute 
incubation at room-temperature, the volume corresponding to 25 μg of 
linearised plasmid was added to the opti-MEM/FuGENE6 mix for a 3:1 ratio of 
transfection reagent: DNA. Complex formation was allowed for 15 minutes at 
room temperature and finally the mixture was added to the 75 cm2 flasks. Two 
days post-transfection the medium was changed to contain penicillin and 
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streptomycin and G418 was added at a final concentration of 1 mg/ml to select 
for the transfected cells (Supplementary Figure S2.4). 
 
GenJet® Transfection 
Ectopic over-expression of EP300 in CAL-51 and MDA-MB-231 cells was 
performed using GenJet® In Vitro DNA Transfection Reagent (SignaGen 
Laboratories, catalog no. SL100488). For this, cells were grown to ~90% 
confluence in 25 cm2 flasks on the day of transfection. For formation of optimal 
size of complex particles, serum-free DMEM with high glucose (4.5 g 
glucose/L) was used to dilute the DNA and GenJet reagent. Α volume of 250 μl 
of medium was used to dilute 5 μg of DNA and 20 μl of GenJet reagent in two 
separate tubes for a 4:1 ratio of transfection reagent:DNA. The diluted GenJet 
reagent was then added to the diluted DNA solution, the mixture was vortexed 
and complex formation was allowed by incubation at room temperature for 15 
minutes. Cells were then trypsinised, counted and the volume corresponding to 
2.7x106 cells was centrifuged for 10 minutes at 150 x g at room temperature. 
The supernatant was aspirated and the cell pellet was completely re-suspended 
in the 500 μl transfection complex and subsequently incubated at 37°C for 20 
minutes. At the end of the incubation, 5 ml of pre-warmed fresh complete 
growth medium was added to the cells and these were plated in 25 cm2 flasks. 
Antibiotic selection was added two days post-transfection, as before. 
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For this, cells were grown to ~90% confluence in 25 cm2 flasks and transfection 
was performed using a 4:1 transfection reagent:DNA ratio with 5 μg of the 
linearised plasmid. The DNA and transfection reagent were diluted in serum-
free DMEM with 4.5 g glucose/L (Sigma-Aldrich, St Louis, USA) as described 
in the manufacturer’s instructions. Selection of transfected cells was performed 
by addition of 1 mg/ml geneticin (G418®, Gibco) (Supplementary Figure S2.4) 
two days post-transfection and maintained for 4 weeks. Pools of resistant clones 
were trypsinised and propagated in new flasks for subsequent protein and RNA 
extractions, as well as for drug sensitivity and soft agar assays. 
 
4.3.3 Cell cycle profile analysis  
Analysis of cell cycle profile was performed by following the protocol 
described elsewhere (Rasul, Balasubramanian et al. 2009, Raguz, Adams et al. 
2013). Briefly, MTMEC cells (3X105) containing the vectors pLKO (empty 
vector control, designated herein as MTMEC-shev) and shEP300 (MTMEC-
shEP300) were seeded in respective culture plates containing HuMEC complete 
medium. After 24 h, the medium was changed with fresh HuMEC containing 20 
nM paclitaxel (Tocris®). As controls, and in order to compare the effects of 
paclitaxel on the alteration of cell cycle, untreated cells were used along with 
the paclitaxel treated cells. Forty-eight hours post-treatment, both adherent as 
well as floating cells were harvested, fixed with ice-cold 70% methanol, washed 
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twice with 5ml PBS, treated with 10 mg RNAse, and stained with 50 mg 
propidium iodide, and their DNA content was estimated by flow cytometry 
using a Beckton Dickinson FacsCanto® flow cytometer (Beckton Dickinson, 
Franklin Lakes, NJ, USA) to determine the proportion of cells at each stage of 
the cell cycle. 
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4.4 Results 
4.4.1 Correlation between FOXA1, RUNX1, EP300 and E-cadherin 
(CDH1) expression in the selected panel of breast cancer cell lines 
FOXA1, RUNX1, EP300 are three well-known transcriptional activators of the 
epithelial protein E-cadherin (CDH1) (Liu, Lee et al. 2005, Lombaerts, van 
Wezel et al. 2006). In a panel of four selected breast cancer cell lines (two 
epithelial and two mesenchymal), the mRNA expression levels of the E-
cadherin (CDH1) and its transcriptional co-activators FOXA1, RUNX1 and 
EP300 were assessed by qRT-PCR. The levels of these transcription factors 
varied in the four lines with FOXA1 mostly correlating with E-cadherin 
expression (Figure 4.8 A and B). As expected, in the 2 mesenchymal lines, 
CAL-51 and MDA-MB-231, the level of E-cadherin was practically absent as 
compared to the epithelial lines. The endogenous level of EP300 varied in the 
lines although not much remarkably and the endogenous EP300 levels did not 
correlate with E-cadherin levels (Figure 4.8 C and D). This highlights the co-
factor role of EP300 for the transcriptional activation of E-cadherin. 
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Figure 4.8: Expression of FOXA1, RUNX1, EP300 and E-cadherin (CDH1) in the 
selected panel of breast cancer cell lines. Western blot and quantitative PCR (qPCR) 
analyses were performed on a panel of four breast cancer cell lines, with CAL-51  and MDA-
MB-231 representing our mesenchymal models and MCF-7 and T-47D representing the 
epithelial ones in order to assess FOXA1 (A), RUNX1 (B), EP300 (C) and E-cadherin (D) 
expression in these. Data presented for the western blots are representative of three 
independent biological repeats of each cell line (n=3). EP300 blots were performed 
throughout this thesis with nuclear extracts because of the poor detection of the protein in 
total cellular extracts. For qPCR analysis, relative mRNA levels were calculated by 
normalisation to the ribosomal protein S14 (RPS14) and RPLO housekeeping genes. Fold-
changes in the cell lines were calculated relative to CAL-51. The bars presented show mean ± 
standard deviation of the three biological repeats. Statistical analysis was performed using the 
one-way ANOVA test and performing multiple comparisons and results were considered 
significant when P<0.05 (*). Increasing statistical significance is indicated with more 
asterisks (**P≤0.01, ***P≤0.001). 
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4.4.2 EP300 positively regulates E-cadherin expression 
Loss of E-cadherin leads to an EMT phenotype associated with increased 
migration and invasiveness (Peinado, Olmeda et al. 2007). Since EP300 has 
been shown to be a transcriptional co-activator of E-cadherin (Liu, Lee et al. 
2005), the effects of EP300 modulation on E-cadherin expression, and hence on 
the phenotypical change (from epithelial to mesenchymal characteristics), were 
investigated first. 
In the EP300 down-regulated MCF-7 and HCT-116 cells (Figure 4.9 A and B, 
respectively), E-cadherin levels decreased significantly, both at the mRNA and 
protein levels and with respect to the respective empty vector controls. 
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Figure 4.9: Absence of EP300 causes the down-regulation of E-cadherin. Western blots 
for nuclear and total proteins (left panel) in MCF-7 (A) and HCT-116 (B) derivatives are 
shown. Samples were loaded in two adjacent wells for all cells. Molecular mass is indicated 
on the right. Note that EP300 is truncated in HCT-116 cells (Gayther et al., 2000). Lamin B 
and β-actin were used as loading control for nuclear and total proteins, respectively. 
Immunoblots show a representative of 3 replicates. E-cadherin and EP300 mRNA levels 
(right panel) in MCF-7 (A) and HCT-116 (B) derivatives were determined by RT-qPCR. WT 
represents wild type, naïve cells, used as control and KOEP denotes EP300 knocked-out 
HCT-116 cell. Numerical data represent the average ± SD of 6 replicates. Statistical tests 
(Student’s t test or ANOVA) were performed and significance was considered when *P<0.05 
(*). Increasing statistical significance is indicated with more asterisks (**P≤0.01, 
***P≤0.001). 
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Figure 4.10: Overexpression of EP300 induces expression of E-cadherin. CAL-51 and 
MDA-MB-231 cells were either transfected with the empty pcDNA3 vector or the one 
encoding for EP300. Following geneticin selection, total RNA and protein extracts were 
obtained from the cells in order to assess EP300 and E-cadherin levels in these and their 
respective non-transfected controls. The protein (left panel) and mRNA levels of EP300 (mid 
panel) and E-cadherin (right panel) in CAL-51 (A) and MDA-MB-231 (B) were assessed by 
Western blots and qRT-PCR, respectively. Lamin B and β-actin were used as loading 
controls for EP300 and E-cadherin detection, respectively. For qPCR analyses, bars represent 
the mean ± SD of three independent experiments, with gene expression levels represented 
relative to the respective control (empty vector) transfected cells. Gene expression was 
normalised to the RPS14 and RPLO housekeeping genes, as before. EP300 appears to be up-
regulated 2- and 3- fold in CAL-51 and MDA-MB-231 cells, respectively. Ectopic expression 
of EP300 appears to cause a 20-fold or a 2-fold increase in E-cadherin expression in CAL-51 
and MDA-MB-231 cells, respectively.  
 
It was further demonstrated that overexpressing EP300 can re-activate E-
cadherin expression in mesenchymal cells. In CAL-51, a 2-fold up-regulation of 
EP300 resulted 20-fold up-regulation of E-cadherin mRNA (Figure 4.10 A, 
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right panel). In MDA-MB-231, however, a 3-fold induction of EP300 led to a 
modest, 2-fold up-regulation of E-cadherin mRNA (Figure 4.10 B, right panel).  
Interestingly, in both of these two mesenchymal and triple negative breast 
cancer cell lines (CAL-51 and MDA-MB-231), EP300 overexpression led to re-
expression of E-cadherin (Figure 4.10 A and B, left panels). This further 
supports the activity of EP300 as a transcriptional co-activator of E-cadherin, 
although some additional level of control appears to regulate EP300 activity or 
E-cadherin expression to different extents in the two cell lines. 
 
4.4.3 EP300 modulation alters paclitaxel sensitivity 
In order to evaluate the effects of EP300 down- or up-regulation on drug 
resistance, the IC50 values (median inhibitory concentration) of paclitaxel were 
determined in the EP300 down-regulated MCF-7 and HCT-116 lines (Figure 
4.11 A and B, respectively) by the SRB assay following a 48-h paclitaxel 
treatment (using a range of paclitaxel concentration, 0.1-80 nM and 0.1-60 nM, 
respectively).  
In both cells, down-regulation of EP300 led to remarkable increases in the 
paclitaxel IC50 values, indicating the potential role of EP300 in altering the 
short-term drug sensitivity. Interestingly, EP300 knock-down in the MTMEC 
series also led to a significant increase in the paclitaxel resistance (Figure 4.12). 
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Figure 4.11: Down-regulating EP300 increases paclitaxel resistance.  Increased cell 
survival and paclitaxel IC50 in EP300
- MCF-7 cells (A) and HCT-116 cells (B). All cells were 
seeded in 96-well plates and treated with paclitaxel at a range of concentration from 0.1 to 80 
nM for MCF-7 and from 0.1 to 60 nM for HCT-116 cells. Forty-eight hours after treatment, 
cells were fixed and stained with the protein-binding dye SRB. Values obtained where 
normalised against the corresponding untreated controls and presented as percentages (The 
cell survival value was set up at 100% for both untreated cells). Values were adjusted to a 
three parameters curve log (dose) vs. response and the median inhibitory concentrations, IC50 
(nM) determined using Graph Pad Prism (ver. 5) software. Statistical analysis was performed 
using a one-way ANOVA test and comparing control (shev empty vector) transfected cells 
(for MCF-7) or the WT (for HCT-116) to shEP- and shEP Tx transfected or KOEP and 
KOEP 30/40- cells, respectively (*P<0.05, **P<0.001, ***P<0.0001). Histograms represent 
data (mean ± SD) obtained from at least nine independent replicates.  
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Figure 4.12: EP300 knockdown in MTMEC increases short-term cell survival upon 
paclitaxel treatment. A. EP300 knockdown assessment. Total RNA was extracted and qPCR 
performed. Values were normalised against the housekeeping genes RPS6 and RPS14. B. 
Increased cell survival of MTMEC-shEP300 and MTMEC-shEP300Tx cells upon paclitaxel 
treatment. MTMEC-pLKO, MTMEC-shEP300 and MTMEC-shEP300 Tx were seeded in 96-
well plates and treated with paclitaxel at a range of concentration from 0.1 to 50 nM. Forty-
eight h after treatment, cells were fixed and stained with the protein-binding dye SRB. Values 
obtained where normalised against the corresponding untreated control and presented as 
percentages (The cell survival value was set up at 100% for both untreated cells). Values 
were adjusted to a three parameters curve log (dose) vs. response and inhibitory 
concentrations 50 (IC50) determined for MTMEC-pLKO: 7.04 nM, MTMEC-shEP300: 11.28 
and MTMEC-shEP300 Tx: 22.43 nM. Data indicated mean ± SD from three independent 
repeats, and was statistically analysed by one way ANOVA test comparing MTMEC-
shEP300 with the MTMEC-pLKO control (*P<0.05). 
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Similarly, over-expression of EP300 results in elevated drug response and thus 
reduced cell viability upon paclitaxel treatment in both CAL-51 and MDA-MB-
231 cells (Figure 4.13). 
 
Figure 4.13: EP300 over-expression increases short-term drug sensitivity to paclitaxel. 
CAL-51 and MDA-MB-231 cells were seeded 3,000 cells per well in 96-well plates and 
treated with different paclitaxel concentrations ranging from 0 to 40 or 160 nM, respectively. 
Cells were fixed and stained with SRB 72 hours post-treatment. The stain was finally 
solubilised and absorbance measurements at 492 nm were obtained. Values obtained were 
converted to percentage viability, with the untreated cells set to 100% viability. Paclitaxel 
concentrations were converted to log values in order to plot the data in a three parameters 
curve of log (dose) vs. response, and IC50 values were determined. Statistical analysis was 
performed using a one-way ANOVA test and comparing control (empty vector) transfected 
cells to EP300- or CDH1- transfected ones (*P<0.05, **P<0.01, ***P<0.001). Data are 
representative of three independent experiments (n=3).  
 
4.4.4 Experimental modulation of EP300 modifies long-term paclitaxel 
resistance 
As short-term exposures to paclitaxel in the EP300 down-regulated cells led to 
significant increase in the IC50 values, and a decreased sensitivity toward the 
drug in the EP300 overexpressed lines, the long-term drug sensitivity of these 
cells were determined by a clonogenicity assay. The survival rate and clone 
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forming ability in paclitaxel is increased in both MCF-7 (Figure 4.14 B) and 
HCT-116 (Figure 4.15 B) EP300- cells. This indicates that absence of EP300 
increases drug resistance in cancer cells. As shown previously, EP300 knock- 
down in MTMEC cells also gave rise to long-term paclitaxel resistance (Hu, Li 
et al. 2015).   
 
Figure 4.14: Down-regulating EP300 increases long-term drug resistance in MCF-7 
cells. (A) Paclitaxel resistant clones under microscope. (B) Number of resistant clones (upper 
panel) and absolute absorbance values at 490 nm (lower panel). Clones were allowed to grow 
35 days when they appeared following a 3-day pulse with paclitaxel at 5, 10 and 15 nM). 
Statistical analysis was performed using a two-way ANOVA test and comparing control 
(shev empty vector) transfected cells to shEP-transfected ones (**P<0.01, ***P<0.001). Data 
represent average number of resistant clones ± SD from three independent experiments (n = 
3). 
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A phenotypic observation shows loss of EP300 changes the appearance of drug 
resistant clones and slows down the rate at which the cells grow. Due to a 
disrupting of cell-cell adhesion and loss of E-cadherin caused by down-
regulating EP300, clones in MCF-7-shev (Figure 4.14 A) and HCT-116 (Figure 
4.15 A) appeared round and big compared to scattered and small clones in their 
EP300- derivatives. Drug resistant clones were defined as clones containing at 
least 50 cells. The numbers of clones were recognized and counted manually 
(and verified later by using Image-Pro Plus 6.0 software) and compared to the 
absolute absorbance values at 490 nm, of solubilized clones as described 
(Figure 4.13 B). 
 
 
Figure 4.15: Down-regulating EP300 increases long-term drug resistance in HCT-116 
cells. (A) Paclitaxel resistant clones under microscope. (B) Absolute absorbance values at 
490nm. Clones were allowed to grow 28 days when they appeared following a 3-day pulse 
with paclitaxel (15 and 20 nM). Statistical analysis was performed using a one-way ANOVA 
test and comparing control (wild type) cells to KOEP and KOEP 30/40 cells (*P≤0.05, 
**P≤0.01). Data represent average number of resistant clones ± SD from three independent 
experiments (n = 3). 
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CAL-51 cells transfected with an EP300 overexpressing plasmid showed a 
significant (p<0.001) level of resistance with less than 50% of resistant clones 
as compared to the empty vector (Figure 4.16 B). The E-cadherin (CDH1) 
overexpressing CAL-51  derivative also gave rise to ~30% more resistant clones 
(Figure 4.16 B) as compared to the empty vector control (P<0.05). Analysis of 
paclitaxel resistance in MDA-MB-231 cells using the same method, however, 
did not show any consistent pattern (not shown). 
 
Figure 4.16: Overexpressing EP300 reduces long-term drug resistance in CAL-51 cells. 
(A) Paclitaxel resistant clones under microscope. (B) Absolute absorbance values at 490 nm. 
As they formed following a 3-day paclitaxel (5 nM) treatment, the clones were allowed to 
grow 28 days. Statistical analysis was performed using a one-way ANOVA test and 
comparing control (empty vector) transfected cells to EP300- or CDH1- transfected ones 
(***P<0.0001). Data represent average number of resistant clones ± SD from three 
independent experiments (n = 3). 
 
145 
 
4.4.5 EP300 regulates stem cell phenotype of cancer cells 
One of the well-established mechanisms of drug resistance in cancer is the 
acquisition of a stem cell-like phenotype (Voulgari and Pintzas 2009, Sharma, 
Lee et al. 2010). The cancer stem cell (CSC)-like populations can display drug 
resistance by various mechanisms (Singh and Settleman 2010). Considering 
this, and in order to explore if the resistance to paclitaxel in EP300
-
 cells is 
imparted by the CSC-like populations, the sphere formation assay was 
conducted. 
For this assay, EP300 down-regulated MCF-7 cells (shEPs) and their 
corresponding paclitaxel resistant derivatives (shEP Txs), were used along with 
the empty vector negative control (shev), and the E-cadherin (CDH1) down-
regulated (shCDH1s) as the positive controls. All the cells were grown in low 
attachment plates and in a media favouring the growth of stem cells 
(DMEM/F12 supplemented with 20 ng/ml EGF, 20 ng/ml bFGF and 1X B27). 
The cells were grown for the sphere to appear and the plating efficiency was 
measured as the percentage of sphere forming efficiency (%SFE). 
As expected, all the EP300 down-regulated and the resistant derivatives, like the 
E-cadherin knocked-down cells, showed a remarkable increase (P<0.0001) in 
the sphere formation capacity (%SFE) as compared to the control cell (Figure 
4.17 B). Also, the loss of EP300 was associated with a phenotypic change 
involving appearance of scattered and smaller spheres as compared to the more 
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regular, spherical and bigger spheres formed in the empty vector control (Figure 
4.17 A). 
 
Figure 4.17: EP300
- 
MCF-7 cells acquire enhanced mammosphere forming capacity. (A) 
MCF-7 mammospheres were grown in the stem cell media (DMEM:F12 = 1:1) in the 
presence of growth factors (EGF, bFGF and B27). (B) Average mammosphere formation 
rates (%SFE) of all types of MCF-7 cells; shev, empty vector control; shEP1 and shEP2, 
EP300 down-regulated cells; and shEP1 Tx and shEP2 Tx, corresponding paclitaxel resistant 
derivatives of shEP1 and shEP2, respectively. Statistical analysis was done using one-way 
ANOVA with Dunnett’s multiple comparison test (***P<0.0001). For clarity, representative 
sample images are shown (A). Histograms represent data (average ± SD) were obtained from 
3 independent replicates. Size bars in the images represent 400 μm. 
 
The same sphere formation assay was carried out in the EP300- HCT-116 colon 
cells and their corresponding resistant line with the similar findings as described 
above for the MCF-7 cells. Here also, loss of EP300 was associated with a 
dramatic increase in the sphere forming ability (Figure 4.18 A and B). 
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Figure 4.18: EP300
- 
HCT-116 cells acquire enhanced sphere forming capacity. (A) 
Spheres in HCT-116 cells were grown in the stem cell media (DMEM:F12 = 1:1) in the 
presence of growth factors (EGF, bFGF and B27). Note that mammospheres in this cell line 
trend to conglomerate. (B) Average sphere formation rates (% SFE) and (C) Average no. of 
clones per well of all types of HCT-116 cells. Statistical analysis was performed using one-
way ANOVA with Dunnett’s multiple comparison test (**P<0.01, ***P<0.001). For clarity 
representative sample images are shown (A). Histograms represent data (average ± SD) 
obtained from 3 independent replicates, comparing with respect to the wild type HCT-116. 
 
After confirming that EP300 loss results in the enhanced sphere formation 
capacity in cancer cells (both colon and breast), the similar sphere formation  
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Figure 4.19: Ectopic expression of EP300 in CAL-51 cells reduces mammosphere 
forming capacity. (A) CAL-51 mammospheres grown in stem cell media (DMEM:F12 = 
1:1) in the presence of growth factors (EGF, bFGF and B27). Cells stably transfected with 
EP300 expression construct was used along with the empty vector controls. For clarity 
representative sample images are shown. (B) Average sphere formation rate (%SFE) formed 
by all types of CAL-51 cells are shown. Histograms represent data (mean ± SD) were 
obtained from 3 independent replicates. Size bars in the images represent 400 μm. Statistical 
analysis was done by a two-way ANOVA following a Bonferroni post-test (*P<0.05, 
***P<0.001). 
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assay was carried out using the EP300 and E-cadherin overexpressed CAL-51 
cells. As anticipated, the ectopic expression of EP300 in CAL-51 significantly 
(P< 0.0001) diminished the sphere formation ability of the cells (Figure 4.19).  
 
4.4.6 EP300 and anchorage independence 
Anchorage-independent growth is one of the hallmarks of tumourigenesis, 
invasion and metastasis (Robbins et al., 1984) and the in vitro soft agar clone 
formation assay (Freedman and Shin, 1974) is adopted as a well-established 
method for characterising this capacity (Schwartz 1997).  
 
Figure 4.20: EP300
- 
MCF-7 cells exhibit enhanced potential in vitro tumourigenesis. (A) 
MCF-7 clones anchored in agar. (B) Average clone rates of all types of MCF-7 cells: shev, 
control; shEP1 and shEP2, EP300 KD cells; shEP1 Tx and shEP2 Tx, paclitaxel resistant 
derivatives of shEP1 and shEP2, respectively; and shCDH1A and B, CDH1 KD cells. 
Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple 
comparison test (***P<0.001). For clarity representative sample images are shown (A). Note 
that MCF-7 shEP2 Tx clones are smaller than those obtained with the other cells. Histograms 
represent data (mean ± SD) were obtained from at least 5 independent replicates. Size bars in 
the images represent 400 μm.  
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In order to further elucidate the role of EP300 in stemness as well as in CSC-
mediated drug resistance, the soft agar clone formation assay was performed to 
measure the anchorage-independent growth. In MCF-7 cells (Figure 4.20), loss 
of EP300 and E-cadherin was accounted for a tremendous (P<0.0001) increase 
in the clone formation efficiency as indicated by the no. of clones (Figure 4.20 
B, left panel) and percentage (Figure 4.20 B, right panel) of the plating 
efficiency (%PE). Similar results were obtained in EP300- HCT-116 cells 
(Figure 4.21). 
 
 
Figure 4.21: EP300
- 
HCT-116 cells exhibit enhanced potential in vitro tumourigenesis. 
(A) HCT-116 clones anchored in agar. (B) Average clone rates of all types of HCT-116 cells 
including - KOEP, i.e., the EP300 knocked-out cells; and KOEP 30 and KOEP 40, i.e., the 
KOEP cells resistant to 30 nM and 40 nM of paclitaxel, respectively. For clarity 
representative sample images are shown (A). Histograms represent data (mean ± SD) were 
obtained from at least 6 independent replicates. Size bars in the images represent 400 μm. 
Statistical analysis was performed using one-way ANOVA with Bonferroni’s multiple 
comparison test (*P<0.05 and ***P<0.001). 
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Figure 4.22: EP300 over-expression reduces anchorage-independence in breast cancer 
cells. In order to assess the role of EP300 in stemness, CAL-51  cells expressing the empty 
vector (ev) or over-expressing EP300 or E-cadherin (CDH1) were seeded 30,000 cells per 
well in 0.3% soft agar. Colony formation by CAL-51 cells was allowed for 10 days. At the 
end of this period, the colonies with diameter equal to or bigger than 50 μm were counted in 
6 separate fields of each well. The absolute number of colonies and plating efficiencies (B) 
were calculated for each well and images at 4X and 10X magnifications were taken (A). 
EP300- and CDH1- overexpressing cells exhibit a 3-fold lower plating efficiency when 
compared to control transfected cells, thus indicating their reduced ability to form colonies in 
an anchorage-independent manner. The images and numerical data presented are illustrative 
of three biological repeats (n=3), with the bars showing the mean ± SD. Size bars in the 
images represent 1000 and 400 μm at 4x and 10x magnifications, respectively. Statistical 
analysis was performed using one-way ANOVA test and comparing control (empty vector) 
transfected cells to EP300- or CDH1-transfected ones (**P<0.01). 
 
In both MCF-7 and HCT-116 models, down-regulating EP300 caused 
phenotypic changes of clones that exhibit properties with loss of cell-cell 
adhesion. The phenotype observed in EP300- MCF-7 and HCT-116 cells were 
reversed in EP300 and E-cadherin overexpressing CAL-51  cells, where the 
aggressive nature of the wild type CAL-51  was significantly (P<0.01) 
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attenuated as reflected by the diminished soft agar clone formation or plating 
efficiency (Figure 4.22).   
 
4.4.7 EP300 deficient cells are enriched in CD44high/CD24low population  
As EP300 loss favors the growth of cancer stem cell (CSC)-like cells, the 
expression of CSC markers was further investigated in these cells. Among the 
well-studied CSC markers in breast cancer cells are CD44 and CD24 (Al-Hajj, 
Wicha et al. 2003). It is well-documented (Sheridan, Kishimoto et al. 2006, 
Jaggupilli and Elkord 2012) that CSC-like populations in breast cancers express 
a CD44high/CD24low sub-population. Therefore, a flow-cytometry based analysis 
was performed to characterise the EP300- cells in terms of CD44 and CD24. 
Notably, down-regulation of EP300 resulted in a significant enrichment of the 
CD44high/CD24low sub-population (Figure 4.23). However, the E-cadherin 
knocked-down lines and one of the paclitaxel resistant derivative of the EP300- 
cells did not show any apparent increase in this CSC sub-population. 
This led to further investigation for the expression of these 2 markers in the 
EP300- colon cancer lines where loss of EP300 accounted for a significant 
(P<0.0001) enrichment of the CSC population with high CD44 and low CD24 
(CD44high/CD24low) in all lines including the 2 paclitaxel resistant derivatives 
(Figure 4.24). 
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Figure 4.23: EP300 KD cells are enriched in CD44-positive population. (A) 
Representative flow cytometry plot for MCF-7 cells stably transfected with shEP300 or 
shCDH1. Cells were assessed for CD44 and CD24 expression by flow cytometry using 
allophycocyanin (APC) - and phycoerytrin (PE) -conjugated specific antibodies respectively. 
The figure shows quadrants defining populations, positioned by placing ≈100% of unstained 
cells in Q4 (CD44-, CD24-). B. A bar chart presenting the mean ± standard deviation of the 
% of CD44-positive populations (CD24 staining did not work for MCF-7 cells), obtained 
from 3 independent biological replicates. Statistical analysis was performed using one-way 
ANOVA following Dunnett’s multiple comparison test and comparing control (shev empty 
vector) transfected cells to shEP300 (shEP1, shEP2) - or shCDH1 (shCDH1 A and shCDH1 
H) - transfected cells and the paclitaxel resistant shEP300 cells, i.e., shEP1 Tx and shEP2 Tx 
(*** P<0.001).  
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Figure 4.24: EP300 KO cells are enriched in CD44high/CD24low population. (A) 
Representative flow cytometry plot for HCT-116 cells with knock-out EP300 (KOEP) and 
their two paclitaxel resistant derivatives (KOEP 30nM and KOEP 40 nM) of KOEP. Cells 
were assessed for CD44 and CD24 expression by flow cytometry using fluorescein 
isothiocyanate (FITC) - and phycoerytrin (PE) - conjugated specific antibodies respectively. 
The figure shows quadrants defining populations, positioned by placing ~100% of unstained 
cells in Q4 (CD44-, CD24-). (B) A bar chart presenting the mean ± standard deviation of the 
% of CD44high/CD24low populations, obtained from 3 independent biological replicates. 
Statistical analysis was performed using one-way ANOVA following Dunnett’s multiple 
comparison test and comparing control (wild type) cells to knock-out EP300 (KOEP) and the 
two paclitaxel resistant derivatives of the KOEP cells, i.e. KOEP 30nM and KOEP 40nM 
(**P<0.01 and *** P<0.001). 
 
 
4.4.8 EP300 overexpression reduces cancer stem cell-like subpopulation 
Epithelial breast cancer cell lines show a high proportion of CD24+ and low 
CD44+ cells, whereas, cell lines with a mesenchymal phenotype, demonstrate an 
opposite phenotype (Sheridan, Kishimoto et al. 2006). As loss EP300 has been 
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shown to increase the CD44high/CD24low population, it was asked whether its 
overexpression can decrease the same stem cell population. With this end, the 
percentage population of MDA-MB-231 cells with this phenotype (i.e., 
CD44high/CD24low) was assessed by flow cytometry. The result showed that the 
 
Figure 4.25: EP300 and CDH1 overexpression reduce the CSC like populations in 
MDA-MB-231 cells. (A) Representative flow cytometry plot for MDA-MB-231 cells stably 
transfected with either EP300 or CDH1. Cells were assessed for CD24 and CD44 expression 
by flow cytometry using phycoerytrin (PE)-, and Fluorescein isothiocyanate (FITC)-
conjugated specific antibodies respectively. The figure shows quadrants defining populations, 
positioned by placing ≈100% of unstained cells in Q4 (CD44-, CD24-). (B) The bar chart 
presented shows the mean ± standard deviation of the % of CD44high/CD24low populations, 
obtained from 3 independent biological replicates. Statistical analysis was performed using 
one-way ANOVA following Dunnett’s multiple comparison test and comparing control (wild 
type) cells to knock-out EP300 (KOEP) and their corresponding paclitaxel resistant cells (*** 
P < 0.0005). 
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overexpression of EP300 resulted in a significant decrease in the 
CD44high/CD24low population in EP300-transfected cells of around 50% 
(P<0.005). Cells overexpressing E-cadherin (CDH1), however, did not show 
any prominent changes in CD44high/CD24low population (Figure 4.25). Thus, 
overexpression of EP300 or CDH1, in MDA-MB-231 cells, reduced the CSC 
population.  
CAL-51 cells assessed using the same method did not show any notable 
reactivity with the CD44 and CD24 antibodies. In fact, no CD44+ population 
was detected in these cells, suggesting that either further optimisation of the 
assay may be necessary in order to detect a CSC population in this cell line or 
that this particular set of markers is not suitable for this cell line.  
The decrease in the stem cell like population between the empty vector 
transfected MDA-MB-231 cells and those overexpressing CDH1 lends further 
support to the function of E-cadherin in suppressing stemness, and consequently 
the emergence of drug resistance. Interestingly the decrease in the CSC 
population in cells overexpressing EP300 was even greater. This lends further 
support to the role of EP300 in the maintenance of a differentiated phenotype, 
preventing the acquisition of stemness and its related drug resistance, and also 
suggests that functions of EP300, beyond that of a positive regulator of CDH1, 
play a significant part in EP300’s ability to influence tumour progression and 
drug resistance. 
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4.4.9 EP300 down-regulated cells acquire EMT markers characteristic of  
cancer stem cell-like (CSC) cells  
In epithelial cells, transcription factors like Twist and Snail can trigger the 
epithelial-to-mesenchymal transition (EMT) by repressing E-cadherin 
expression and hence these are characterised as the EMT markers (Mani, Guo et 
al. 2008). Most of the mesenchymal-like or CSC-like cells that have undergone 
EMT has been reported to acquire a CD44high/CD24low antigenic phenotype 
(Liao, Zhang et al. 2007, Mani, Guo et al. 2008). Since EP300 loss results in 
high proportion of the CD44high/CD24low population in MCF-7, the expression 
of some EMT markers was assessed. 
Thus, in order to further characterize the CSC-like population up-regulated in 
absence of EP300, and to elucidate the role of EP300 in EMT and drug 
resistance, the expression levels of some key markers of EMT were assessed by 
Western blot and qRT-PCR in the EP300- lines.  
Notably, the loss of EP300 was found to significantly up-regulate mRNA of 
Snail, Zeb2, vimentin and Twist, in EP300- MCF-7 (P<0.05) and vimentin and 
Twist in the HCT-116 cells (P<0.0001) (Figure 4.26 C). At the protein level, 
expressions of N-cadherin, Zeb1, β-catenin, vimentin and Snail were prominent 
in MCF-7 (Figure 4.26 A). In the HCT-116 model, β-catenin and vimentin were 
among the notably expressed EMT markers (Figure 4.26 B). 
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Figure 4.26: EP300 down-regulated MCF-7 and HCT-116 cells acquire EMT markers. 
The protein levels of some EMT markers were assessed by western blots in MCF-7 (A) and 
HCT-116 (B) derivatives. Lamin B and β-actin were used as loading controls. The figures are 
representative of experiments using at least 3 biological replicates. (C) The mRNA levels of 
some of the EMT markers were detected in MCF-7 (left) and HCT-116 (right) derivatives by 
RT-qPCR. The bars represent the mean ± SD of three independent experiments, with gene 
expression levels represented relative to the respective controls (wild type and empty vector 
transfected cells). Gene expression was normalised to the RPS14 and RPLO housekeeping 
genes. Statistical analysis was performed using one-way ANOVA following Dunnett’s 
multiple comparison test and comparing control (empty vector transfected MCF7 and wild 
type HCT-116) cells to knocked-down EP300 cells (shEPs) and their corresponding 
paclitaxel derivatives and to knock-out EP300 (KOEP) and their corresponding paclitaxel 
resistant cells. P-values were calculated with respect to the corresponding controls and 
marked with asterisks (*P<0.05, **P<0.01 and *** P<0.001). 
 
 
 
159 
 
4.4.10 EP300 over-expression partially reverses EMT potentially by 
decreasing the expression of EMT-inducing factors 
Since EP300-transfected mesenchymal cells induced expression of the epithelial 
marker E-cadherin, the EMT phenotype of these cells was characterised. Since 
EP300 loss resulted up-regulation of the EMT marker protein Snail, Zeb2 and 
vimentin (encoded by SNAI1, ZEB2, and VIM, respectively), the gene 
expressions of these mesenchymal markers were assessed in CAL-51 and 
MDA-MB-231 cells ectopically expressing EP300 or CDH1. Although not very 
prominent, there was a significant reduction in the mRNA levels of the two 
EMT-inducing transcription factors, SNAI1 and ZEB2, in cells over-expressing 
EP300 or E-cadherin (Figure 4.27 A and B). However, decreases in these 
transcription factors were not sufficient to weaken expression of the 
mesenchymal cytoskeletal filament, vimentin, in these mesenchymal breast 
cancer lines. This suggests that EP300 acts to oppose the repressor activity of 
SNAI1 and ZEB2, but additional transcriptional co-factors are required to fully 
reverse EMT and its associated expression of mesenchymal markers like 
vimentin. 
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Figure 4.27: EP300 over-expression reduces the expression of the EMT-inducing 
factors, SNAI1 and ZEB2. Quantitative PCR (qPCR) analysis was performed on EP300- or 
CDH1-transfected CAL-51 (A) and MDA-MB-231 (B) cells in order to assess SNAI1, ZEB2 
and vimentin expression. SNAI1 and ZEB2 expression appears to decrease in the transfected 
cells when compared to control (empty vector, ev) transfected cells. On the contrary, the 
mesenchymal cytoskeletal filament, vimentin, doesn’t exhibit a significant change in cells 
that are ectopically expressing EP300 or CDH1. Relative mRNA levels were calculated by 
normalisation to the ribosomal protein S14 (RPS14) and RPLO housekeeping genes. Fold 
changes in the cell lines were calculated relative to the respective control (empty vector) 
transfected cells. The bars presented show mean ± standard deviation of three independent 
biological repeats (n=3). Statistical analysis was performed using the one-way ANOVA test 
and comparing to the empty vector transfected cells (*P<0.05, **P<0.001, ***P<0.0001). 
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4.4.11 EP300- cells up-regulate anti-apoptotic protein Bcl-2 
Mesenchymal-like cancers, in particular, basal subtypes of breast cancers are 
reported to be highly chemotherapy resistant (Neve, Chin et al. 2006). Thus, 
cancer cells that have undergone EMT are likely to become drug resistant. 
Cancer cells become resistant to chemotherapy by various mechanisms and one 
way is upregulation of anti-apoptotic proteins (Wilson, Johnston et al. 2009, 
Vinogradov and Wei 2012). Since EP300- cells up-regulated EMT markers, this 
prompted to investigate if there is any connection between EP300 and drug 
resistance in this regard. As EP300 down regulation led to increased expression 
of the EMT markers, which are characteristics of the drug-resistant CSC-like 
cells, the expression of one of the anti-apoptotic protein Bcl-2 was checked in 
the MCF-7 and HCT-116 models by Western blot and qRT-PCR. Notably, the 
expression of Bcl-2 was significantly up-regulated at both protein and mRNA 
levels in EP300- MCF-7 (Figure 4.28 A) and HCT-116 (Figure 4.28 B) cells.  
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Figure 4.28: EP300 down-regulated cells up-regulate anti-apoptotic Bcl-2. The mRNA 
levels of Bcl-2 were detected in MCF-7 (left) and HCT-116 (right) derivatives by RT-qPCR. 
The bars represent the mean ± SD of three independent experiments, with gene expression 
levels represented relative to the respective controls (wild type and empty vector transfected 
cells). Gene expression was normalised to the RPS14 and RPLO housekeeping genes. 
Statistical analysis was performed using one-way ANOVA following Dunnett’s multiple 
comparison test and comparing control (wild type and empty vector transfected) cells to 
knocked-down EP300 cells (shEPs) and their corresponding paclitaxel derivatives and to 
knock-out EP300 (KOEP) and their corresponding paclitaxel resistant cells. 
 
4.4.12 EP300 down-regulated cells acquire paclitaxel resistance via evasion 
of apoptosis as revealed by less caspase-8 and -9 activation 
Apoptosis occurs by either death receptor (the extrinsic mechanism) - or 
mitochondria (the intrinsic mechanism) - mediated pathway. Caspase-8 is 
activated by the death receptor signaling, while caspase-9 by the mitochondrial 
pathway (Adams 2003). The anti-apoptotic protein Bcl-2 is well-documented to 
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regulate both apoptotic pathway by blocking the action of caspase-8 and -9 via 
reduction of cytochrome c release (by decreasing mitochondrial permeability) 
from mitochondria (Li, Nijhawan et al. 1997). Based on the finding that Bcl-2 is 
up-regulated in EP300- (MCF-7 and HCT-116) cells, it was asked whether 
absence of EP300 can play any role in regulating the initiator caspases (caspase 
-8 and -9). As depicted in figure 4.29, down-regulating EP300 in MCF-7 led to 
less activation of both caspase-8 (Figure 4.29 A) and caspase-9 (Figure 4.29 B) 
in presence of paclitaxel. For both caspase-8 and caspase-9, EP300- cells 
showed as low as 3-fold less activation irrespective of the paclitaxel 
concentration. 
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Figure 4.29: EP300 down-regulated cells acquire paclitaxel resistance via evasion of 
apoptosis as revealed by less caspase-8 and -9 activation. EP300 and E-cadherin (CDH1) 
down-regulated (shEPs and shCDH1 A and H) and corresponding paclitaxel resistant 
derivatives of EP300 knocked-down (shEP Tx) MCF-7 cells were seeded at a density of 
10,000 cells/well in white 96-well plates and treated for 24 hours with paclitaxel (0, 10, 20 
and 50 nM) after which they were treated and incubated for 45 min to an hour with Caspase-
Glo® -8 and -9 (Promega) reagents and the luminescent signals were read using a 
luminometer. The values obtained were normalized from the SRB controls and the fold 
changes were compared with respect to the empty vector respective controls. Statistical 
analyses were performed by one way ANOVA following Dunnett’s multiple comparison test 
and comparing all the values for each type of cells with respect to that of the control line 
(shev). All values were found to be significantly different (*P< 0.05, **P < 0.01, ***P < 
0.001) from the means. 
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In MTMEC cells, silencing EP300 led to enhanced cell viability and higher IC50 
values against paclitaxel (Figure 4.12). As evident from our previous study, 
paclitaxel resistance and hence multi-drug resistance (MDR) in EP300- 
MTMEC cells is not mediated by ABC (ATP-binding cassettes) transporters 
(Hu, Li et al. 2015). In the same study, we showed that paclitaxel treatment in 
naive MTMEC cells leads to a dose-dependent increase in annexin V staining 
and activation of caspase-9 (Hu, Li et al. 2015). Since apoptosis evasion is 
adopted as one the mechanisms for acquiring drug resistant phenotype in breast 
cancers (Friedrich, Wieder et al. 2001), we asked if this was so in case of 
MTMEC-shEP300 cells and if apoptosis and caspases are involved here. 
Thus, in order to further explore whether the changes in paclitaxel sensitivity 
were due to evasion of apoptosis in the EP300- MTMEC cells, caspase-9 
activity was evaluated also in these cells. As paclitaxel was found to trigger 
activation of caspase-9 in MTMECs (Hu et al., 2015), we asked whether 
paclitaxel treatment in the MTMEC-shEP300 cells had any effect on caspase-9, 
an initiator caspase involved in the intrinsic apoptotic pathway. Notably, 
caspase-9 activation following treatment with paclitaxel (20 and 40 nM for 72 
h) was lower in the MTMEC-shEP300 cells as compared to the MTMEC-shev 
control cells (Figure 4.30). Thus, absence of EP300 led to a significant 
reduction (P<0.05) of the Caspase-9 activity suggesting paclitaxel resistance. 
166 
 
 
Figure 4.30: Silencing EP300 in MTMEC leads to reduction in caspase-9 activity. 
Caspase-9 activity was measured using the Caspase-Glo®-9 assay. MTMEC-pLKO and 
MTMEC-shEP300 cells were seeded at a density of 8,000 cells/well in 96-well white plates 
and treated with 40 and 80 nM of paclitaxel. Seventy-two hour later, caspase-9 activity was 
measured by incubating with the Caspase-Glo®-9 reagent and data was then normalised to the 
cell density against the untreated control by sulphorhodamine B assay. Data presented were 
representative of four independent repeats (n=4). Statistical analysis was performed using a 
two-tailed Student’s t-test comparing each value to the shev empty vector control (*P<0.05). 
As shown, EP300 loss resulted a minimal reduction in the caspase-9 activity. 
 
 
4.4.13 EP300 knockdown impairs the initiation of apoptosis triggered by 
paclitaxel in MTMEC cells 
Annexin V has been developed as a protein-dye conjugated for apoptotic assays, 
staining early apoptotic cells (Lizarbe, Barrasa et al. 2013). This is a protein 
capable of binding specifically to the negatively charged surface protein 
phosphatidylserine (PS) on the inner leaflet of the cell membrane in presence of 
Ca+2. Phosphatidylserine (PS) is a phospholipid normally located in the inner 
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part of the membrane and its exposure on the outer leaflet of the membrane is 
the first detectable change in cells activating the apoptotic programme. This 
forms the basis of the annexin V binding affinity assay that uses a conjugate of 
annexin V and a fluorescent or enzymatic label, biotin or other tags, or a 
radioelement, in a suitable buffer, i.e., annexin V binding buffer (since annexin 
V binding to the PS occurs in a Ca2+ dependent manner). The assay combines 
annexin V staining of PS as a membrane event coupled with the staining of 
DNA in the cell nucleus with propidium iodide (PI) which is detected by flow 
cytometry. PI, a fluorescent dye is used to stain and label DNA. Staining with 
PI in the assay design helps in distinguishing viable cells from the late apoptotic 
and necrotic cells (where plasma membrane disruption or extensive cell 
permeability causes increased penetration of this dye to the cell). 
In MTMEC cells, silencing EP300 led to increased cell survival and paclitaxel 
resistance, which has been observed so far due to reduction of caspase-9 
activity. Thus, in order to further assess that the augmented paclitaxel resistance 
in these EP300- cells are due to alteration in the apoptosis process, an annexin V 
binding assay was performed. Specifically, the percentage of dead cells after 
paclitaxel treatment (20 and 40 nM for 48 h) was determined by flow cytometry 
after staining with Annexin V and propidium iodide. As expected, a dose-
dependent effect on cell death was observed in the MTMEC-shev control cells 
(25% at 20 nM and 45% at 40 nM). However, the MTMEC-shEP300 cells 
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showed only 10% and 15% cell death after treatment with 20 and 40 nM 
paclitaxel, respectively (Figure 4.31 A and B). This, together with the caspase-9 
assay, suggests the apoptosis evasion mechanism in the EP300- breast cancer 
(MTMEC) cells. 
 
 
Figure 4.31: Silencing EP300 in MTMEC leads to reduction in apoptotic activity. (A) 
Detection of apoptotic cells by Annexin V/PI staining. Cells were treated with paclitaxel at 0, 
20 and 40 nM for 48 h with a corresponding untreated control. Cell suspensions were stained 
with annexin V-FITC and propidium iodide for apoptosis detection and analysed by flow 
cytometry. Overlap between the two dyes fluorescence spectrum was properly compensated 
with single-stained controls. Number of apoptotic cells (Annexin V-positive cells, both in 
early apoptosis, lower right quadrant, and late apoptosis, upper right quadrant) was decreased 
in MTMEC-shEP300 cells. (B) A representative dot plot is shown. Data presented were 
representative of four independent repeats (n=4). Statistical analysis was performed using a 
two-tailed Student’s t-test comparing each value to the shev control (*P<0.05). 
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4.4.14 Paclitaxel alterations in the cell cycle are abolished in MTMEC-
shEP300 cells  
Paclitaxel acts by arresting the G2/M phase in the cell cycle, primarily by 
interfering with spindle microtubule dynamics. This eventually leads to cell 
cycle arrest and apoptosis (McGrogan, Gilmartin et al. 2008). Therefore, I 
explored further the effect of EP300 down-regulation on the cell cycle profiles.  
 
 
Figure 4.32: G2/M cell cycle arrest induced by paclitaxel is abolished in MTMEC-
shEP300 cells. A. Cell cycle analysis of MTMECs treated with paclitaxel for 48 h. Cells 
were stained with propidium iodide and gated according to their fluorescence to differentiate 
cell cycle phases (from left to right: G1, S, G2/M). B. Histogram data represent the 
percentage of cells at different stages of cell cycle obtained in absence or presence of 
paclitaxel (20 nM) treatment. Experiments were performed in triplicate and a representative 
plot is shown as the average of three independent experiments. For clarity, error bars have 
been omitted (typical variation between experiments: ±10%) (Hu, Li et al. 2015). 
 
Briefly, EP300 down-regulated MTMEC cells along with the empty vector 
control, MTMEC-shev, were treated with 20 nM paclitaxel for 48 h. Following 
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this, all the cells were stained (with propidium iodide) and fixed (with ice-cold 
70% methanol) and the DNA content of the cells were estimated by a flow-
cytometry assay as described before (Raguz, Adams et al. 2013). MTMEC-shev 
control cells showed, as expected, a decrease in the percentage of cells at the G1 
phase of the cell cycle and an increase in G2/M (from 67 to 52% in G1 and 
from 13 to 29% in G2/M). The percentage of cells in S was practically the same 
(Figure 4.32). However, the percentage of cells in G2/M after paclitaxel 
treatment increased only by 1% only in MTMEC-shEP300 cells (from 14 to 
15%). Thus, the cell cycle effects of paclitaxel are abolished in EP300- 
MTMEC cells. This provides another line of evidence for the role of EP300 in 
mediating breast cancer drug resistance. 
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4.5 Brief discussion 
The present study is based on a previous finding that EP300, as a transcriptional 
activator of E-cadherin (CDH1), is down-regulated by a micro-RNA cluster 
(miR-106b~25) and is associated with increased resistance, and an EMT-like 
phenotype including increased cell motility, invasion and proliferation capacity 
following doxorubicin treatment (Zhou, Hu et al. 2014). Since it was shown that 
EP300 increased resistance to doxorubicin, we hypothesised that this could be 
extended to other chemotherapeutic drugs and tested the hypothesis using 
paclitaxel. 
In order to study the role of the transcriptional co-activator EP300 in mediating 
drug resistance, EMT and stemness in breast cancer, in vitro models were 
generated (as described in section 4.3.1) by manipulating expression of EP300 
(by shRNA silencing and transducing EP300 gene). Along with the EP300 
down-regulated and overexpressed models, E-cadherin (CDH1) knocked-down 
and overexpressed lines were used as positive controls to compare the 
phenotypic changes in the EP300 manipulated lines. Also, in the EP300 
knocked down models, the corresponding paclitaxel resistant derivatives were 
obtained by employing a pulse method described elsewhere (Raguz and Yagüe 
2010). All the lines generated by stable knock-down or overexpression, 
presented robust cellular models for the present study as confirmed by 
validating the expression level for EP300 and CDH1. The colon (HCT-116) and 
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the mammary epithelial (MTMEC) lines were included along with the epithelial 
and mesenchymal breast cancer lines down- and up-regulating EP300 and 
CDH1. 
 
4.5.1 EP300 regulates E-cadherin levels in breast cancer cells in vitro 
In the present study, down-regulation of EP300 in MCF-7 led to concomitant 
decrease in E-cadherin expression, both at the mRNA and protein levels. 
Moreover, experimental over-expression of EP300 led to E-cadherin up-
regulation in both CAL-51 and MDA-MB-231 cell, thus validating the role of 
EP300 as a positive regulator of E-cadherin (Liu, Lee et al. 2005, Lombaerts, 
van Wezel et al. 2006). In both CAL-51 and MDA-MB-231, a 2-fold up-
regulation of EP300 resulted 20-fold and 2-fold increase of E-cadherin mRNA, 
respectively. The effect of EP300 overexpression was smaller in MDA-MB-231 
as compared to CAL-51. This suggests an additional level of control on E-
cadherin expression other than EP300-mediated regulation in the two cell lines. 
The defect in E-cadherin expression is attributed to epigenetic mechanisms, viz., 
transcriptional silencing and promoter hyper-methylation (Vesuna, van Diest et 
al. 2008). Such epigenetic regulations coupled with genetic mutation of E-
cadherin drives the progression of cancer. Thus, our findings here suggest that 
in addition to the transcriptional regulation of E-cadherin by EP300, other 
factors might come into play. 
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The variable level of E-cadherin expression upon experimental modulation of 
EP300 indicates that regulation of E-cadherin takes place in a cell-type specific 
manner. As a whole, the findings confirm the role of EP300 in regulating E-
cadherin expression. Silencing E-cadherin by RNA interference was found to be 
associated with bypass of doxorubicin-induced senescence and to the 
emergence of drug-resistant cells with increased motility and invasion (Zhou, 
Hu et al. 2014). Therefore, the findings here forms the basis for exploring the 
role of EP300 in maintaining drug resistance, stemness and the EMT phenotype. 
 
4.5.2 Silencing EP300 increases in vitro tumourigenicity and cancer stem 
cell-like properties 
Chemotherapy resistance in cancer is also attributed to the presence of a small 
population of cells that are known as the cancer stem cell-like (CSC-like) cells 
(Singh and Settleman 2010). These cells, like the normal stem cells, are 
endowed with endless potential for self-renewal as well as for differentiating 
into a heterogeneous lineages of cancer cells (Regenbrecht, Lehrach et al. 2008, 
Zhang, Tong et al. 2015). These tumour-initiating cells, in turn, drives EMT, 
invasion and metastasis, and eventually, death. The CSC-like metastatic breast 
cancer cells are endowed with an enhanced ability to form mammospheres 
(Grimshaw, Cooper et al. 2008) and an increased capacity of growing in an 
anchorage-independent fashion in serum-free conditions (Gupta, Onder et al. 
2009, de la Mare, Sterrenberg et al. 2013) at the functional levels. 
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Phenotypically, such CSC-like cells are characterised by their expression of 
high CD44 and low CD24 as identified as a small sub-population of cells (de la 
Mare, Sterrenberg et al. 2013, Ghebeh, Sleiman et al. 2013).  
In the EP300- MCF-7 and HCT-116 cells, the significant increase in the sphere 
formation and anchorage-independence confirms the role of EP300 in stemness. 
This is further evident from the findings that re-expression of EP300 and E-
cadherin (CDH1) in the aggressive, triple-negative breast lines MDA-MB-231 
and CAL-51 decreased the sphere (in MDA-MB-231) - and soft agar clone (in 
CAL-51) -formation capacity. In both cases, the proportional decrease in CSCs 
as a result of CDH1 expression is in concordance with data showing an inverse 
correlation between CDH1 and CD44 (Xu and Yu 2003, Ye, Wu et al. 2012). 
The increased effect of EP300 on reducing the CD44+, CD24- population is, 
again, possibly due to the other interactions of EP300 in the context of CSCs. 
For example, EP300 has been implicated as a vital regulator of Wnt signalling 
(Li, Sutter et al. 2007). While CDH1 is also implicated in this pathway, data 
suggest EP300 may exert some influence over it, independently of CDH1, and it 
may be that a number of EP300 interactions of this nature each contribute a part 
to the effect of EP300 in reduction of CSCs. 
Here, in the EP300-deleted MCF-7 and HCT-116 cells, the significant 
enrichment of the CD44high/CD24low sub-population characterizes the CSC-like 
breast cells. In the triple-negative MDA-MB-231 cells, which represent an 
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aggressive breast cancer line, EP300 re-introduction was accompanied by 
reduced stemness as evidenced by reduced anchorage-independence and 
decreased percentage of the CD44high/CD24low sub-population, from functional 
and phenotypic points of view, respectively. Interestingly, and unlike MDA-
MB-231, in CAL-51, EP300 overexpression did not produce similar changes in 
expression of cells with the CD44high/CD24low phenotype. This may be 
explained by the fact that both CD44 and CD24 are expressed usually at very 
low levels in CAL-51 (Kao, Salari et al. 2009), despite its aggressive nature and 
triple-negative phenotype. Thus CD44 and CD24 seem to be poor markers for 
characterising the CSC-like species in the CAL-51 model. 
 
4.5.3 Experimental modulation of EP300 alters paclitaxel sensitivity via 
regulation of EMT markers, apoptosis and expression of Bcl-2 
The classical tumour suppressor role of EP300 indicates that this protein has a 
definite role in mediating drug resistance. In the current study, modulation of 
EP300 led to remarkable changes in paclitaxel sensitivity. This has been 
confirmed in both EP300 down- and up-regulated cells. This is consistent with 
previous finding that demonstrated that EP300 loss is responsible for 
augmenting doxorubicin resistance (Zhou, Hu et al. 2014). Furthermore, the 
changes in paclitaxel sensitivity, as confirmed by both short-term and long-term 
drug sensitivity screening, occurs in a  cell type independent manner.  
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The positive regulation of E-cadherin by EP300 led to investigate its potential 
role on EMT. Thus, expression of EMT inducers were analysed in EP300 
modulated cells. Loss of EP300 led to increased expression of the classical 
EMT inducers like Snail, Zeb2, vimentin and Twist, whereas, a significantly 
low levels of these proteins (except vimentin) were observed in EP300 
overexpressed lines. E-cadherin expression is found to be repressed by Snail, 
Zeb1 and Twist in invasive ductal carcinoma (IDC) of breast (Montserrat, 
Gallardo et al. 2011). This indicates that in addition to regulation of E-cadherin 
transcriptionally, EP300 also controls EMT via the classical EMT inducers as 
evidenced by the alterations in the levels of the EMT markers expressed in the 
EP300 modulated cells.  
One of the mechanisms of chemotherapy resistance is evasion of apoptosis 
(Friedrich, Wieder et al. 2001). Cancer cells, by supressing the apoptosis can 
overcome the chemotherapy (Hu, Guo et al. 2015). It has been recently reported 
(and published by our group) that paclitaxel treatment in MTMECs leads to an 
increase in early apoptotic cells (Annexin V-positive), activation of caspase-9 
and increase in the proportion of cells at the G2/M phase of the cell cycle in a 
dose-dependent manner (Hu, Li et al. 2015). Also, in the same study, the 
apoptotic activity was found to be reduced in EP300 silenced MTMECs, as 
evident from the reduction in the annexin V positive cells (Hu, Li et al. 2015). 
The two principle apoptotic pathways involves the activation of initiator 
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caspases, i.e., caspase-8 (extrinsic pathway) and caspase-9 (intrinsic pathway). 
It was observed that EP300 deletion leads to reduced activity of both caspase-8 
(in MCF-7) and caspase-9 (in both MTMEC and MCF-7 models) in presence of 
paclitaxel which is dependent on the dose of the drug. This confirms the role of 
EP300 in mediating chemotherapy resistance via evasion of apoptosis. 
Furthermore, the level of the anti-apoptotic protein Bcl-2 is also elevated 
remarkably in EP300 knocked-down cells and their corresponding paclitaxel 
resistant derivatives. This provides another line of evidence and an additional 
mechanism of drug resistance acquired by the EP300- cells in addition to the 
alteration in the G2/M phase of the cell cycle. 
 
In the present study, by using the EP300- breast and colon cancer models, it has 
been observed that the EP300 deletion renders the cells to acquire the ability to 
generate more spheres that exhibit CSC-like features including anchorage-
independent growth and expressing cells bearing a CD44high/CD24low 
phenotype. These has been also confirmed in the paclitaxel resistant versions of 
the EP300-deleted cells. Altogether, the data provides a strong evidence for the 
role of EP300 in stemness and that the drug resistance mediated by EP300 
might be due to the presence of the CSC-like populations and evasion of 
apoptosis. 
178 
 
Chapter 5: Transcriptome profiling identifies potential EP300-regulated genes 
involved in drug resistance, EMT and stemness 
5.1  Introduction Background and aim 
It has been already confirmed in the previous chapter that EP300 mediates 
paclitaxel resistance partly by inactivating apoptosis, up-regulating EMT-
associated genes and favouring growth of chemo resistant breast cancer stem-
like cells. This led to follow-up with the apoptosis and related pathways with a 
view to elucidate further the paclitaxel resistance mechanism by identification 
of potential down-stream targets. 
First, a PCR-based and pathway-specific RT2 profiler array (Qiagen, 
Manchester, UK) was performed to identify apoptosis-related genes altered in 
EP300- MTMEC cells. Next, using EP300- MCF-7 cells and their 
corresponding paclitaxel resistant derivatives, sixteen whole transcriptome 
arrays were carried out. The later involved an extensive transcriptome based 
search for target genes down-stream of EP300. For this, GeneChip® Whole 
Transcript (WT) Expression Array (Affymetrix, High Wycombe, UK) was 
performed. This chapter elaborates the procedural details of the above methods 
and the findings obtained herein suggesting potential mechanisms of EP300-
mediated drug resistance in breast cancer. In short, the principle aims of the 
study was to identify potential targets down-stream of EP300 and thus to 
explore further EP300-mediated drug resistance via EMT and CSC. 
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5.1.2 Whole transcriptome expression analysis and profiling 
Microarray based whole transcriptome expression profiling is one of the most 
reliable tools for elucidating spatio-temporal patterns of mRNA transcripts 
within a particular set of genomes or organism. It is one of the best methods of 
choice for gene expression analysis after next generation sequencing (NGS) in 
terms of both sensitivity and specificity. Whole transcript expression array 
enables molecular biologists to perform the analysis and profiling of the 
transcriptome of a particular genome within an organism. The key applications 
of transcriptome analysis include analysis of differential gene expression pattern 
within selected organisms and gene signature and pathway discovery. These in 
turn, help elucidate a particular genome for further research, such as, finding out 
target genes to manipulate their expression, elaborating mechanisms of 
signalling and drug resistance and pathway and drug discovery. Currently, 
various state-of-the-art techniques and array applications are available that are 
routinely used for transcriptome analysis and profiling. Among these include 
GeneChip® Whole Transcript (WT) Expression Arrays developed by 
Affymetrix (High Wycombe, UK). 
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5.1.3 GeneChip® whole transcript (WT) expression array 
Gene transcripts profiling using Affymetrix® WT arrays is a well-proven and 
high-throughput technique for expression analysis as well as biomarker 
discovery. These array techniques uses GeneChip® WT PLUS Reagent Kit (WT 
PLUS Kit, catalog no. 902280), which, with its high sensitivity and specificity, 
offers a robust WT assay to unravel the transcription and gene signatures within 
a set of samples at both gene and transcript or exon levels. 
In principle, WT PLUS Kit uses a reverse transcription priming method in order 
to prime the entire length of each RNA transcript. The RNA transcript includes 
both poly-A and non-poly-A mRNA covering the complete transcriptome in an 
unbiased way. The kit is capable of generating amplified and biotinylated sense-
stranded DNA targets, avoiding loss of specificity due to antisense strand 
interference. 
(http://www.affymetrix.com/catalog/prod770005/AFFY/WT+PLUS+Reagent+Kit#1_1)  
The kit includes:  
i) the amplification module coupled with  
ii) GeneChip® WT Terminal Labeling Kit and  
iii) GeneChip® WT Controls Kit (more details in Table 5.1).  
These kits allow for preparing ‘hybridization-ready’ targets from as small as 50 
ng to 500 ng of total RNA. The key features and benefits of the kit include: 
 A complete target prep kit with proven sensitivity and specificity. 
 A low sample input requirement of as small as 50 ng of RNA.  
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 A variety of sample types, including fresh-frozen tissues, cell lines, and 
whole blood (no requirement for ribosomal RNA depletion or a globin 
reduction step when applied for blood samples). 
 Efficient workflow. 
In the present study, we performed 16 arrays using GeneChip® Whole 
Transcript (WT) Expression Array in order to find out putative target genes that 
are differentially regulated in EP300 down-regulated and corresponding 
paclitaxel resistant derivatives of MCF-7. 
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5.2 Materials and methods 
5.2.1 Gene expression profiling using quantitative PCR arrays  
MTMEC-shev and MTMEC-shEP300 cells were cultured in 10 cm dishes until 
80-90% confluence was reached. RNA from three independent repeats was 
extracted using the miRCURYTM RNA isolation kit - Biofluids (Exiqon, 
Vedbaek, Denmark). RNA was quantified using a Nanodrop ND1000 
spectrophotometer (Labtech International, East Sussex, UK) and 0.5 μg of each 
biological repeat pooled in a single sample to average internal variations. 
Expression of a total of 84 key apoptosis-related genes was measured using the 
Human Apoptosis RT2 Profiler PCR Array® (Qiagen, Manchester, UK) specific 
for apoptotic signalling according to manufacturer instructions. In order to 
identify the differentially expressed genes regulated by EP300, two arrays were 
performed, one for the MTMEC empty vector (shev) control and the other for 
the MTMEC cell containing shEP300 vector. CT values corresponding to the 84 
genes evaluated were analysed using the software provided by the manufacturer 
(www.SABiosciences.com/pcrarraydataanalysis.php). Very low expressed 
genes with CT values above 35 in both samples were directly removed from the 
analysis as classified as random hits. Amongst the 5 housekeeping genes 
provided within the array, GAPDH and HPRT1 presented less variability and 
were thus used for normalisation purposes. Comparison was carried out 
between the control, MTMEC-pLKO (MTMEC-shev) and MTMEC-shEP300 
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for each individual gene and the fold-up and down-regulation values for genes 
significantly changing were presented. 
 
5.2.2 GeneChip® whole transcript (WT) expression array in EP300- MCF-
7 cells 
In total, sixteen GeneChip® WT PLUS Reagent Kits (WT PLUS Kit, catalog no. 
902280) purchased from Affymetrix (High Wycombe, UK) were used for 
transcriptome profiling in EP300- MCF-7 cells. Among the 16 arrays, 4 was 
used for the empty vector control MCF-7-shev, and 3 for each of the EP300- 
lines (MCF-7-shEP1 and MCF-7-shEP2) and 3 for each of the corresponding 
paclitaxel-resistant lines (MCF-7-shEP1 Tx and MCF-7-shEP2 Tx). 
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The complete assay protocol can be outlined as follows (Figure 5.1): 
Figure 5.1: WT Plus Amplification and Labeling Processes. Schematic representation 
of the GeneChip® WT Plus showing the step-wise processes from the first-strand cDNA 
synthesis through amplification and labeling to hybridization (taken from UserGuide on 
GeneChip® WT PLUS Reagent Kit. Manual Target Preparation for GeneChip®, Whole 
Transcript (WT) Expression Arrays, Affymetrix). 
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The reagents used were purchased from Affymetrix and the complete kit (Table 
5.1) contained essential reagents are described in the following table: 
 
Table 5.1: GeneChip® WT PLUS reagent kit contents and storage 
Component 
10-Reaction Kit for  
manual use (P/N 902280) 
 Storage 
WT Amplification Kit Module 1   
First-Strand Enzyme 11 μL –20°C 
First-Strand Buffer  44 μL –20°C 
Second-Strand Enzyme  22 μL –20°C 
Second-Strand Buffer  198 μL –20°C 
IVT Enzyme  66 μL –20°C 
IVT Buffer 264 μL –20°C 
Control RNA (1 mg/mL HeLa total RNA) 5 μL –20°C 
2nd-Cycle Primers  44 μL –20°C 
2nd-Cycle ss-cDNA Enzyme 44 μL –20°C 
2nd-Cycle ss-cDNA Buffer 88 μL –20°C 
RNase H 44 μL –20°C 
Nuclease-free Water 2 x 1.0 mL any temp 
WT Amplification Kit Module 2   
Purification Beads  2.2 mL 4°C * 
GeneChip® Poly-A RNA Control Kit   
Poly-A Control Stock 16 μL –20°C 
Poly-A Control Dil Buffer 3.8 mL –20°C 
GeneChip® WT Terminal Labeling Kit  
10X cDNA Fragmentation Buffer 48 μL –20°C 
UDG, 10 U/μL 10 μL –20°C 
APE 1, 1,000 U/μL 10 μL –20°C 
5X TdT Buffer 120 μL –20°C 
TdT, 30 U/μL 20 μL –20°C 
DNA Labeling Reagent, 5 mM 10 μL –20°C 
RNase-free Water 825 μL any temp * 
GeneChip® Hybridization Control Kit   
20X Hybridization Controls 450 μL –20°C 
3 nM Control Oligo B2 150 μL –20°C 
*NO freezing. 
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5.2.3 RNA extraction from EP300 KD lines and their corresponding 
paclitaxel resistant derivatives 
All the EP300 knocked-down and their corresponding paclitaxel resistant 
derivatives MCF-7 cells were grown in a medium (DMEM) containing FCS and 
glutamine and without any antibiotics or paclitaxel. RNA extractions were 
performed using RNeasy Mini Kit® from QIAGEN (Manchester, UK). 
Following assessment of RNA integrity (as measured from the RNA integrity 
number, RIN), three independent biological replicates (four replicates for the 
control group) for each cell type were used for microarray analysis. 
 
5.2.4 Preparation of control RNA 
To verify that the reagents are working as expected, a Control RNA sample (1 
mg/mL total RNA from HeLa cells) is included with the kit. The Control RNA 
(for positive control reaction) was prepared as follows: 
1. On ice, 2 μL of the Control RNA was dispensed in 78 μL of Nuclease-free 
Water for a total volume of 80 μL (25 ng/μL). 
2. 2 μL of this diluted Control RNA (50 ng) was used in the control reaction to 
prepare the Total RNA/Poly-A RNA Control Mixture as outlined below (in 
section 5.2.4). 
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5.2.5 Preparation of poly-A RNA control 
Poly-A RNA Controls were prepared for 100 ng of total RNA by following the 
protocol outlined in the UserGuide on GeneChip® WT PLUS Reagent Kit 
provided by Affymetrix. 
 
5.2.6 Preparation of total RNA 
Following extraction of RNA (as described in section 5.2.1), and as an initial 
check, the quality of all 16 samples were determined by measuring the A260/A280 
ratio (RNA of acceptable quality was considered in the range of 1.7 to 2.1). The 
integrity of the RNA sample, or the proportion that is full length, is an important 
component of RNA quality. Therefore, RNA integrity was evaluated by 
microfluidic analysis using the Agilent 2100 Bioanalyzer (DE24802458, ver. 
2.6) with an RNA LabChip® Kit or equivalent instrument. As a measure of 
biological quality control, the levels of EP300 and CDH1 mRNAs were 
determined in all RNA samples before proceeding with further steps. 
Reassuringly, both transcripts were confirmed to be down-regulated in all 
samples when compared to empty vector cells (data not shown). 
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5.2.7 Preparation of total RNA/Poly-A RNA control mixture 
Total RNA/Poly-A RNA Control Mixture were prepared (see Table 5.2 below) 
for 100 ng of total RNA by following the protocol outlined in the UserGuide on 
GeneChip® WT PLUS Reagent Kit provided by Affymetrix. 
 
Table 5.2: Total RNA/Poly-A RNA control mixture 
Component 
 Volume for One 
Reaction 
Total RNA Sample (50-500 ng)  Variable 
Diluted Poly-A RNA Controls (4th Dilution)  2 μL 
Nuclease-free Water  variable 
Total Volume  5 μL 
 
5.2.8 Synthesis of first-strand cDNA 
In this reverse transcription procedure, total RNA (100 ng), for each sample, 
was primed with primers containing a T7 promoter sequence. The reaction 
synthesizes single-stranded cDNA with T7 promoter sequence at the 5' end. 
First-strand cDNAs were prepared (as shown in Table 5.3 below for preparation 
of the master mix) by following the protocol outlined in the UserGuide on 
GeneChip® WT PLUS Reagent Kit provided by Affymetrix. 
 
Table 5.3: Preparation of first-strand master mix 
Component Vol./Reaction (μL) 
First-strand Buffer 4 
First-Strand Enzyme 1 
Total Volume 5 
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In each 0.2 µL tube, 5 µL of the first-strand master mix was added to 5 µL total 
RNA (i.e., total RNA/Poly-A RNA control mixture, as prepared in section 
5.2.5). 
 
5.2.9 Synthesis of second-strand cDNA 
In this procedure, single-stranded cDNA is converted to double-stranded cDNA, 
which acts as a template for in vitro transcription. The reaction uses DNA 
polymerase and RNase H to simultaneously degrade the RNA and synthesize 
second-strand cDNA. Second-strand cDNAs were prepared by following the 
protocol outlined in the UserGuide on GeneChip® WT PLUS Reagent Kit 
provided by Affymetrix. The second-strand master mix was prepared as follows 
(Table 5.4): 
 
Table 5.4: Preparation of second-strand master mix 
Component Vol./Reaction (μL) 
Second-Strand Buffer 18 
Second-Strand Enzyme 2 
Total Volume 20 
 
In each 0.2 µL tube, 20 µL of the second-strand master mix was added to 10 
µL of the first-strand cDNA (as prepared in section 5.2.6). 
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5.2.10 Synthesis and purification of cRNA by in vitro transcription 
In this procedure, antisense RNA (complimentary RNA or cRNA) is 
synthesized and amplified by in vitro transcription (IVT) of the second-stranded 
cDNA template using T7 RNA polymerase. This method of RNA sample 
preparation is based on the original T7 in vitro transcription technology known 
as the Eberwine or RT-IVT method (Van Gelder et al., 1990). In this step, all 
the cRNAs were prepared by following the step-wise protocol as outlined in the 
UserGuide on GeneChip® WT PLUS Reagent Kit provided by Affymetrix. All 
the reactions for cRNA preparation, including the preparation of the IVT master 
mix (Table 5.5), were carried out at room temperature.  
 
Table 5.5: Preparation of IVT master mix 
Component Vol./Reaction (μL) 
IVT Buffer 24 
IVT Enzyme 6 
Total Volume 30 
 
In each 0.2 µL tube, 30 µL of the IVT master mix was added to 30 µL of the 
second-strand cDNA (as prepared in section 5.2.7). 
Following synthesis, cRNAs were purified using the beads supplied with the 
purification kit and as per the protocol provided. The purification step was also 
performed at room temperature.  
Finally, the concentration of a cRNA solutions were determined by measuring 
its absorbance at 260 nm using 1.5 µL of the cRNA sample (directly) and 
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nuclease-free water (as blank) and with a NanoDrop Spectrophotometer. The 
concentrations of the cRNA were calculated in μg/mL using the equation 
shown below: 
1 A260 = 40 µg RNA/mL 
The expected yield for 100 ng of input total RNA was considered to be >20 µg 
of cRNA. 
 
5.2.11 Synthesis of 2nd-cycle single-stranded cDNA 
In this procedure, sense-strand cDNA is synthesized by the reverse transcription 
of cRNA (anti-sense strand) using 2nd-Cycle Primers. The sense-strand cDNA 
contains dUTP at a fixed ratio relative to dTTP. 15 µg of cRNA is required for 
2nd-cycle single-stranded cDNA synthesis. All the steps were carried out as 
described in the protocol provided by the Affymetrix Inc. as a user manual. In 
brief, 24 µL of 15 µg cRNA was prepared by adjusting the volume with 
nuclease-free water and combined (in ice) with 4 µL of the 2nd-cycle primers 
(Table 5.6). 
 
Table 5.6: Preparation of the cRNA/2nd-cycle primers mix 
Component Vol./Reaction (μL) 
cRNA Sample (15 µg) 24 
2nd-Cycle Primers 4 
Total Volume 28 
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Next, the 2nd-Cycle ss-cDNA master mix was prepared (on ice) in a nuclease-
free tube by adding the components in the sequence shown in the table below 
(Table 5.7).  
 
Table 5.7: Preparation of 2nd-Cycle ss-cDNA master mix 
Component Vol./Reaction (μL) 
2nd-Cycle ss-cDNA Buffer 8 
2nd-Cycle ss-cDNA Enzyme 4 
Total Volume 12 
 
Finally, in each 0.2 µL tube, 12 µL 2nd-Cycle ss-cDNA master mix was added 
to 28 µL cRNA/2nd-Cycle primers samples, mixed thoroughly by gently 
vortexing the tube and incubated in a thermal cycler setting the program as 
delineated in the protocol. 
  
5.2.12 Hydrolysis of RNA using RNase 
In this step, RNase H was added to each 2nd-cycle ss-cDNA sample for 
hydrolysing the cRNA template in order to obtain single-stranded cDNA. In 
short, 4 µL of the supplied RNase H was added to 40 µL of the 2nd-Cycle ss-
cDNA and the mixture was incubated in a thermal cycler by following the 
program as mentioned in the protocol. Finally, 11 µL of nuclease-free water was 
added to the hydrolysed samples which were processed immediately for the 
next step. 
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5.2.13 Purification of 2nd-cycle single-stranded cDNA 
After hydrolysis, the 2nd-cycle single-stranded cDNAs were purified to remove 
enzymes, salts, and unincorporated dNTPs and to prepare the cDNA for 
fragmentation and labeling. The entire purification process was done following 
the step-wise protocol as explained in the protocol of the array manual.  
The yield of the purified 2nd-cycle single-stranded cDNAs (expected yield >5.5 
µg for a 15 µg of input cRNAs) was determined by measuring the absorbance of 
the ss-cDNA solutions (1.5 µL) at 260 nm. The concentrations (in µg/mL) were 
calculated using the equation below: 
1 A260 = 33 µg DNA/mL 
 
Since the expected cDNA profile (the median cDNA size being ~ 400 nt) does 
not resemble that of the cRNA, the cDNA size distributions were analysed 
using an Agilent 2100 Bioanalyzer, a RNA 6000 Nano Kit (PN5067-1511), and 
mRNA Nano Series II assay. 
 
 
5.2.14 Fragmentation and labeling of single-stranded cDNA  
In this procedure, the purified, sense-strand cDNA is fragmented by uracil-DNA 
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1) at the 
unnatural dUTP residues and breaks the DNA strand. The fragmented cDNA is 
labeled by terminal deoxynucleotidyl transferase (TdT) using the Affymetrix 
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proprietary DNA Labeling Reagent that is covalently linked to biotin. 5.5 μg of 
single-stranded cDNA is required for fragmentation and labeling. 
First, 5.5 μg of ss-cDNA was prepared for each sample in a volume of 31.2 μL 
(the volume was adjusted with nuclease-free water). Next, the fragmentation 
master mix was prepared by combining the components in a sequence as 
mentioned in the following table (Table 5.8): 
 
Table 5.8: Preparation of the fragmentation master mix 
Component Vol./Reaction (μL) 
Nuclease-free Water 10 
10X cDNA Fragmentation Buffer 4.8 
UDG, 10 U/μL 1 
APE 1, 1,000 U/μL  1 
Total Volume 16.8 
 
Both of the (sample and master mix) preparations were done on ice. 
The fragmentation master mix (16.8 μL) was transferred to each (31.2 μL) of 
purified ss-cDNA sample for a final reaction volume of 48 μL, which was then 
incubated in a thermal cycler by following the program as prescribed in the 
protocol. 
A post-fragmentation analysis was then performed to confirm the size 
distribution of the fragmented ss-cDNA samples by using a Bioanalyzer. The 
range in the peak size of the fragmented samples are ~40-70 nt. 
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After confirming the ss-cDNA integrity, the labeling master mix was prepared 
on ice by combining the components in a sequence as shown below (Table 5.9): 
 
Table 5.9: Preparation of the labeling master mix 
Component Vol./Reaction (μL) 
5X TdT Buffer 12 μL 12 
DNA Labeling Reagent, 5 mM 1 μL 1 
TdT, 30 U/μL 2 μL 2 
Total Volume 15 
 
The labelling master mix (15 μL) thus prepared was transferred on ice to each 
(45 μL) fragmented ss-cDNA sample for a final reaction volume of 60 μL. The 
resulting mixture was then mixed thoroughly by gentle vortex and incubated in 
a thermal cycler as per the program set in the protocol. The fragmented and 
labeled ss-cDNAs were then processed for WT array hybridization in the final 
step. 
 
5.2.15 Cartridge array hybridization, washing, staining and scanning 
For array hybridization, GeneChip® Cartridge Array (Figure 5.2) was used. 
After preparing the hybridization master mix (Table 5.10) and hybridization 
cocktail (Table 5.11), the hybridization was performed following the prescribed 
protocol.  
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    Figure 5.2: GeneChip® Cartridge Array 
 
All the sample and array informations were registered into AGCC as suggested 
in the Affymetrix® GeneChip® Fluidics Station 450 User Guide AGCC (P/N 
08-0295). 
 
Table 5.10: Hybridization master mix for a single reaction 
Component 100 or 81/4-Format Final Concentration 
Fragmented and Labeled ss-DNA  3.5 μg 23 ng/μL 
Control Oligo B2 (3 nM) 2.5 μL 50 pM 
20X Hybridization Controls  7.5 μL 1.5, 5, 25, and 100 pM 
respectively (bioB, bioC, bioD, cre) 
2X Hybridization Mix 75 μL 1X 
DMSO 10.5 μL 7% 
Nuclease-free Water 13.5 μL  
Total Volume 109 μL   
 
All the reactions for hybridizations were carried out by Dr Nathalie Lambie, 
using appropriate instruments as suggested in the protocol and using the 
facilities provided by the Genomics Core Lab of MRC Clinical Sciences Centre 
at Imperial Centre for Translational & Experimental Medicine (ICTEM). 
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Table 5.11: Hybridization cocktail for a single array 
Component 100 or 81/4-Format 
Hybridization Master Mix 109 μL 
Fragmented and labeled ss-cDNA 41 μL (3.5 μg) 
Total Volume 150 μL 
 
All the subsequent washing, staining and scanning steps were performed by Dr 
Ivan Andrew by following the Affymetrix® GeneChip® Fluidics Station 450 
User Guide AGCC (P/N 08-0295), the GeneChip® Expression Wash, Stain, and 
Scan User Guide for Cartridge Arrays (PN 702731), and the Affymetrix® 
GeneChip® Command Console® User Guide (P/N 702569). 
 
5.2.16 Array strips hybridization on the GeneAtlas® instrument 
Prior to setting up the target hybridization and processing the Affymetrix Array 
Strips on the GeneAtlas® System, each array strip was registered and 
hybridizations setup completed in the GeneAtlas® Software. All the basic steps 
involved in hybridizing array strip(s) were on the GeneAtlas® System and were 
performed by following the steps described in the GeneAtlas® System User 
Guide (P/N 08-0306) by Dr Ivan Andrew. 
 
5.2.17 Sequential steps for analysis of array data  
After the completion of the hybridization for all the samples, the array data were 
analysed sequentially as follows: 
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a. First, the raw data were imported as the CEL files. 
b. The control probes that were used to measure microarray hybridization 
efficiency were obtained from the Affymetrix online database 
(https://www.affymetrix.com/estore/analysis/index.affx?category=34005&cat
egoryIdClicked=34005&rootCategoryId=34005&navMode=34005&aId=net
AffxNav#1_2). These control probes were filtered out before performing the 
actual analysis based on the probeset annotation file (HuGene-2_0-st-
v1.na35.hg19.probeset.csv) obtained from Affymetrix database. Since the 
repertoire of “control probe” in this annotation file is not complete, all the 
“control probes” were integrated in the design of the annotation system for 
both probeset and transcript annotation files. 
c. RMA background correction (using RMA algorithm and filtering out the 
control probes), quantile normalization, log2 transformation, and probeset 
summarization were followed using Affymetrix Expression Console® 
Software (ver. 1.4.0.38).  
d. All the QC/QA analyses for signal intensity histogram, log probe cell 
intensity plot, and principle component analysis (PCA) were performed by 
using Partek Genomic Suits® (Partek, USA). 
e. The microarray data were deposited with the NCBI Gene Expression 
Omnibus (GEO) (http://ncbi.nlm.nih.gov/geo/) under accession number 
GSE76200. 
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f. Pathway analyses were performed using the database for annotation, 
visualization and integrated discovery (DAVID; http://david.abcc.ncifcrf.gov) 
(Huang da, Sherman et al. 2009, Huang da, Sherman et al. 2009). 
g. Gene set enrichment analyses (GSEA) for the up- and down-regulated genes 
were also performed for top 50 gene sets (FDR q-value <5) using the 
Molecular Signatures Database (MSigDb) from Broad Institute 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp). The gene sets 
investigated include the GO gene sets and the KEGG gene sets. 
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5.3 Results 
5.3.1 Silencing EP300 decreases the expression of TNFRSF11B and 
TRAF2, two TNF-related genes 
As the results of the previous chapter strongly demonstrated that the apoptosis 
pathway (specifically the extrinsic one) is inactivated in EP300- breast cancer 
cells, I intended to further explore the pathway in terms of identifying the 
potential target genes regulated by EP300. Thus, qPCR arrays were used as an 
exploratory study to identify potential direct or indirect EP300 targets in the 
apoptotic cascade. Expression of apoptotic genes was measured using the RT2 
Profiler® PCR Array (Qiagen, Manchester, UK) specific for apoptotic signalling 
according to manufacturer instructions.  
 
Table 5.12: Apoptosis-related genes up- or down-regulated in MTMEC shEP300 
Gene Symbol 
Fold Change 
Fold Up- or Down- 
Regulation 
shEP300/pLKO shEP300/pLKO 
BCL2L10 2.91 2.91 
CASP5 2.27 2.27 
TNFRSF25 2.26 2.26 
LTA 2.09 2.09 
TRAF2 2.01 2.01 
TNFRSF11B 0.46 -2.16 
TNFRSF1B 0.36 -2.75 
BCL2A1 0.31 -3.18 
CD40 0.26 -3.79 
 
In brief, the array involved a gene expression profiling experiment evaluating 
84 apoptosis-related genes. MTMEC-shEP300 and MTMEC-pLKO (used as 
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control) were cultured, total RNA was extracted and the gene expression 
profiling experiment was performed. Amongst the 84 genes evaluated in the 
array, only 9 displayed significant variations given by a fold-change over 2 or 
below 0.5 (Table 5.12 and Figure 5.3A).  
 
 
Figure 5.3: The apoptosis-related genes TRAF2 and TNFRSF11B are down-regulated 
upon EP300 silencing. (A) MTMEC-pLKO (or MTMEC-shev) and MTMEC-shEP300 were 
cultured, RNA from 3 independent repeats extracted, equally pooled and analysed by qPCR 
using the Apoptosis RT2 Profiler PCR Array. CT values obtained were normalised against the 
housekeeping genes GAPDH and HPRT1. Values for each gene were normalised against the 
corresponding value in the pLKO control. Very low expressed genes (CT values above 35 in 
both samples) were directly removed from the analysis and hits presented here using fold up- 
and down-regulation. Data presented corresponded to a single experiment. (B) Total RNA 
was extracted and selected targets validated by qPCR using the standard curve method. 
Values were normalised using RPS6 and RPS14 as housekeeping genes. Data were 
representative of three independent experiments and statistical analysis was carried out using 
a two-tailed Student’s t-test comparing each value to the pLKO (shev) control (*P<0.05). 
 
This small subset of genes represented around the 11% of the total, and 
comprised genes encoding the anti-apoptotic protein BCL2A1, the pro-
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apoptotic BCL2L10, the inflammation-related caspase CASP5 and a set of 
tumour necrosis factor (TNF)-related proteins such as CD40 (TNFRSF5), LTA 
(TNF-β), TNFRSF11B (OPG), TNFRSF1B, TNFRSF25 and TRAF2.  
From the targets above identified just TNF receptor superfamily member 
(TNFRSF) 11B, TNFRSF25 and TNF associated factor (TRAF) 2 amplified 
between cycles 20 and 30 in one or both samples and thus were selected for 
validation by qPCR. RNA was extracted from three biological repeats 
corresponding to MTMEC-LKO and MTMEC-shEP300 and qPCR carried out.  
Neither TNFRSF25 nor TRAF2 presented the same behaviour as compared to 
the qPCR array (Fig. 5.3B). In the case of TNFRSF25 no change in mRNA 
levels was observed upon EP300 knockdown whereas TRAF2 was even 
presenting a reduction of expression, in clear contrast with the 2-fold increase 
observed in the array. These two genes were therefore described as false 
positives although TRAF2 could be selected as a target. On the other hand, 
TNFRSF11B was significantly down-regulated, validating the result obtained in 
the array. The remaining genes were considered as low expressed (CT values 
for both samples between 30 and 35) and not selected for initial validation.  
However, the qPCR array was performed only once, and this was an exploratory 
experiment. Therefore, further extensive studies would be required to ascertain 
the transcriptional profile variation in apoptotic-related genes in MTMECs. As 
in the meantime we had developed a robust system for the study of EP300-
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regulated genes in MCF-7 cells, we decided to perform whole transcriptome 
profiling in EP300- MCF-7 cells and their corresponding paclitaxel resistant 
derivatives. 
 
5.3.2 Sample description for the whole transcriptome array in EP300- 
MCF-7 cells 
Since data obtained from the above qPCR array targeting apoptosis pathway 
were rather inconclusive, more detail study was warranted. Using the EP300- 
MCF-7 model, used mostly in the previous study (chapter 4) so far, sixteen 
whole transcriptome arrays were performed. The prime objective was to 
identify pathways and target genes downstream of EP300 as mentioned before.  
 
Table 5.13: Sample description for hybridization in the GeneChip® WT Plus array 
Sample ID Sample File Name Hyb ID-Array Name Sample Name Sample Type 
1 Sample1 2015051801 GIPZ 1 Control 
2 Sample2 2015051802 GIPZ 2 
3 Sample3 2015051803 GIPZ 3 
4 Sample4 2015051804 GIPZ 4 
5 Sample5 2015051805 shEP1 1 shEP1 
6 Sample6 2015051806 shEP1 2 
7 Sample7 2015051807 shEP1 3 
8 Sample8 2015051808 shEP2 1 shEP2 
9 Sample9 2015051901 shEP2 2 
10 Sample10 2015051902 shEP2 3 
11 Sample11 2015051903 shEP1 Tx 1 shEP1 Tx 
12 Sample12 2015051904 shEP1 Tx 2 
13 Sample13 2015051905 shEP1 Tx 3 
14 Sample14 2015051906 shEP2 Tx 1 shEP2 Tx 
15 Sample15 2015051907 shEP2 Tx 2 
16 Sample16 2015051908 shEP2 Tx 3 
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Table 5.13 summarizes the Sample ID, along with their corresponding 
hybridization ID for the array. In total, 16 arrays were performed, of which, 3 
biological replicates were considered for each cell type, except the control line, 
for which, 4 replicates were used. 
 
5.3.3 Evaluation of RNA quality and integrity 
RNA quality was measured initially by NanoDrop® measurement from the 
A260/A280 ratio (Table 5.14) and then their integrity was assessed by performing 
Bioanalyzer assay (Figure 5.4) for RNA integrity number (RIN) as a 
confirmatory QC test.  
Table 5.14: Evaluation of RNA quality form NanoDrop® measurement 
Sample ID Sample Name A260/A280 ratio RIN 
1 GIPZ 1 2.13 9.8 
2 GIPZ 2 2.1 9.8 
3 GIPZ 3 2.12 9.8 
4 GIPZ 4 2.1 9.8 
5 shEP1 1 2.12 9.7 
6 shEP1 2 2.12 9.7 
7 shEP1 3 2.13 9.7 
8 shEP2 1 2.15 9.4 
9 shEP2 2 2.12 9.5 
10 shEP2 3 2.14 9.6 
11 shEP1 Tx 1 2.15 9.7 
12 shEP1 Tx 2 2.13 9.7 
13 shEP1 Tx 3 2.15 9.7 
14 shEP2 Tx 1 2.15 9.5 
15 shEP2 Tx 2 2.12 9.6 
16 shEP2 Tx 3 2.13 9.5 
RIN = RNA integrity number 
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Figure 5.4: Evaluation of RNA Integrity by Bioanalyzer assay. Gel electrophoresis (left) 
and electopherogram (right) indicating RNA quality for sample 1-12 (A) and 13-16 (B). The 
samples were run separately in two nano chips (max. capacity 12 sample wells). As shown in 
(B), all the RNA samples were pure and intact and each sample had a RIN >9 and had no 
genomic contamination. 
 
All the RNA samples of were of acceptable quality and within the range from 
1.7 to 2.1 for the A260/A280 ratio (Table 5.13) and their integrity (as measured 
from the RNA integrity number, RIN) were also within the limit (RIN >7) and 
as prescribed (Table 5.13 and Figure 5.4). 
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5.3.4 Assessment of cRNA yield 
The optimum cRNA yields (>20 μg) for an input of 100 ng total RNA (Table 
5.15) were ensured by calculating the amount (μg) of the sample cRNA and the 
cRNA obtained from the positive control (50 μg RNA from HeLa). As 
recommended, the positive control reaction gave a cRNA yield of  >15 μg. 
 
Table 5.15: Assessment of cRNA yield 
No. Sample Sample 
ID 
A260 cRNA Conc. 
(µg/mL) 
Total Amount of 
cRNA (µg) 
1 GIPZ 1 G1 25.584 1023.36 27.63072 
2 GIPZ 2 G2 19.334 773.36 20.88072 
3 GIPZ 3 G3 26.619 1064.76 28.74852 
4 GIPZ 4 G4 19.210 768.40 20.7468 
5 shEP1 1 PA1 24.779 991.16 26.76132 
6 shEP1 2 PA2 24.826 993.04 26.81208 
7 shEP1 3 PA3 33.869 1354.76 36.57852 
8 shEP1 Tx20 1 PAT 1 36.704 1468.16 39.64032 
9 shEP1 Tx20 2 PAT 2 29.544 1181.76 31.90752 
10 shEP1 Tx20 3 PAT 3 34.335 1373.40 37.0818 
11 shEP2 1 PB1 39.653 1586.12 42.82524 
12 shEP2 2 PB2 31.299 1251.96 33.80292 
13 shEP2 3 PB3 28.464 1138.56 30.74112 
14 shEP2 Tx20 1 PBT1 30.742 1229.68 33.20136 
15 shEP2 Tx20 2 PBT2 25.705 1028.20 27.7614 
16 shEP2 Tx20 3 PBT3 19.658 786.32 21.23064 
17 Control (HeLa) HLA 21.404 856.16 23.11632 
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5.3.5 Assessment of single-stranded cDNA yield and size distribution 
The optimum (>5.5 μg) cDNA yield (Table 5.16) and size distribution (Figure 
5.5 and 5.6) were determined both pre- and post-fragmentation. 
 
Table 5.16: Assessment of cDNA yield (pre-fragmentation) 
No. Sample ID A260 ss-cDNA Conc. 
(µg/mL) 
Total Amount 
of ss-cDNA (µg) 
1 GIPZ 1 G1 20.469 675.477 20.26431 
2 GIPZ 2 G2 18.509 610.797 18.32391 
3 GIPZ 3 G3 18.255 602.415 18.07245 
4 GIPZ 4 G4 13.863 457.479 13.72437 
5 shEP1 1 PA1 21.377 705.441 21.16323 
6 shEP1 2 PA2 18.233 601.689 18.05067 
7 shEP1 3 PA3 15.515 511.995 15.35985 
8 shEP1 Tx20 1 PAT 1 21.858 721.314 21.63942 
9 shEP1 Tx20 2 PAT 2 19.426 641.058 19.23174 
10 shEP1 Tx20 3 PAT 3 19.296 636.768 19.10304 
11 shEP2 1 PB1 21.416 706.728 21.20184 
12 shEP2 2 PB2 16.111 531.663 15.94989 
13 shEP2 3 PB3 15.229 502.557 15.07671 
14 shEP2 Tx20 1 PBT1 17.72 584.76 17.5428 
15 shEP2 Tx20 2 PBT2 16.141 532.653 15.97959 
16 shEP2 Tx20 3 PBT3 14.366 474.078 14.22234 
17 HeLA Ctrl 2 A2 11.213 370.029 11.10087 
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Figure 5.5: Evaluation of ss-cDNA size distribution by Bioanalyzer assay prior to 
fragmentation. Gel electrophoresis (left) and electopherogram (right) indicating RNA 
quality for all samples. As shown in the electropherogrqams, all the samples met the 
recommended cDNA size of ~400 nt. 
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Figure 5.6: Evaluation of ss-cDNA size distribution by Bioanalyzer assay post-
fragmentation. Gel electrophoresis (left) and electopherogram (right) indicating RNA 
quality for all samples. As can be seen from the electropherograms, all the fragmented 
samples were within the recommended size distribution limit of 40-70 nt. 
 
5.3.6 Post-hybridisation quality control check for all samples 
Signal intensity histogram (also known as ‘Density plots’) of log-intensity 
distribution (% frequency) of each array were almost 100% superposed on each 
other and confirmed that all the arrays had similar frequency distributions for 
the signals and that there were no weird distributions as such (Figure 5.7). 
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Figure 5.7: Signal intensity histogram. The intensity histograms were generated by using 
the Affymetrix Expression Console® software as a means of post-hybridisation quality 
control check of the data both before (A) and after (B) correcting for batch effect. The graphs 
showed here ensure that there were no outliers and all the data were of good quality. 
 
5.3.7 Correlation of expression between arrays by principal component 
analysis 
The principal component analysis (PCA) gives a view of the correlations of 
expression between arrays where the data are projected on several axes (or 
components), ordered by decreasing significance. The first principal component 
(PC1) explains most of the variations of expression. Clusters of genes on a PCA 
plot present a strong correlation of expression signals. 
A. 
B. 
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Figure 5.8: Principal component analysis (PCA). The PCA shows that there were no 
outlier array as seen from the 3D plots which were obtained before and after (right panel in 
A. and B., respectively) correcting for batch effects (left panel in both A. and B.) 
 
The PCA graphs generated (with the help of Dr Meng-Lay Lin) for the samples 
(Figure 5.8) show that all the arrays were of good quality having similar 
patterns (of gene expression) and that there were no outliers. Noticeably, and as 
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evident from the 3D plots, there is a clear segregation in gene expression 
patterns in EP300 down-regulated samples. This means that shEP300-
transfected MCF-7 cells exhibits a differential gene expression patterns as 
compared to the parent cell line.  
 
5.3.8 EP300 down-regulated cells exhibit differential gene expression 
pattern 
In order to explore how the EP300 down-regulated cells behave in terms of 
gene expression patterns, we constructed Venn diagrams to show the overlap 
between genes that are differentially expressed upon knockdown of EP300 
(Figure 5.9). The two EP300 knocked down cells as well as their corresponding 
paclitaxel resistant derivatives exhibited distinct gene expression patterns which 
varied from the control line as depicted in the Venn diagram (Figure 5.9) and 
previously in the PCA plots (Figure 5.8). However, there were 4044 genes in 
total that were found to be common in all the EP300- lines including the 
paclitaxel-resistant derivatives when compared to the control line. All these 
common genes were of our interests as we wanted to find out the putative 
targets in EP300 down-regulated and their paclitaxel resistant derivatives. 
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Figure 5.9: EP300 down-regulated cells exhibit differential gene expression patterns. 
Venn diagrams showing overlap between transcripts (A) and genes (B) upon stable knock 
down of EP300 in two of the down-regulated lines as well as their corresponding paclitaxel 
resistant derivatives. A total of 4435 transcripts and 4044 genes came out as common in all 
four groups shown. 
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Table 5.17: List of the most up-regulated genes in EP300 KD and their corresponding 
paclitaxel resistant derivatives of MCF-7 
 Probe set 
ID 
Gene Symbol 
shEP1 vs. 
Control 
shEP1Tx vs. 
Control 
shEP2 vs. 
Control 
shEP2Tx vs. 
Control 
p-value* FC** p-value* FC** p-value* FC** p-value* FC** 
16907979 ABCA12 2.51E-10 9.48 3.62E-07 5.25 4.16E-09 10.29 3.65E-08 13.23 
16977868 ABCG2 1.14E-07 7.15 4.94E-05 5.40 2.19E-06 7.72 0.00034 3.45 
16855673 BCL2 3.40E-10 11.43 1.20E-07 9.36 4.16E-09 14.36 1.68E-07 10.04 
17020258 BMP5 1.49E-08 20.30 5.01E-06 16.31 2.20E-05 5.09 0.001671 2.77 
17059804 CALCR 3.31E-12 11.33 8.95E-10 10.93 2.37E-11 19.76 1.77E-10 21.30 
16827041 CDH11 1.27E-06 4.53 0.000167 4.45 1.64E-05 5.11 9.91E-05 5.40 
17020846 COL12A1 3.18E-10 5.96 2.97E-08 8.13 1.85E-09 11.08 4.66E-09 16.60 
17106102 COL4A5 4.09E-07 4.76 1.81E-05 6.68 1.03E-05 4.67 6.84E-06 11.12 
17000168 CXCL14 5.22E-09 5.85 0.001299 1.70 8.93E-07 3.79 7.93E-05 2.50 
16869960 CYP4F11 2.37E-06 5.32 0.002662 2.86 8.55E-05 4.58 0.004168 2.60 
17093090 DDX58 1.02E-05 2.21 1.31E-05 5.05 0.000196 2.19 0.001427 2.04 
16897834 EFEMP1 1.26E-09 3.23 1.69E-08 6.00 3.89E-09 5.11 6.10E-08 4.84 
16908897 EPHA4 7.49E-10 8.65 4.18E-07 6.34 1.00E-08 10.29 3.63E-07 7.55 
17021092 FAM46A 6.15E-09 5.01 2.51E-06 4.37 2.04E-07 4.90 3.87E-05 2.69 
16719025 FGFR2 2.48E-07 3.31 9.11E-06 4.56 3.72E-07 6.33 6.00E-06 5.74 
16958403 HEG1 3.18E-10 4.07 1.20E-07 3.59 3.07E-09 5.78 1.47E-07 3.82 
16675045 HMCN1 2.23E-08 4.45 4.76E-06 4.46 5.03E-07 4.75 2.54E-06 5.99 
17010782 HTR1E 4.00E-08 7.10 7.95E-06 7.05 4.83E-07 9.38 6.84E-06 8.71 
16720085 IFITM1 3.62E-07 3.44 8.61E-06 5.34 2.28E-05 2.90 0.003014 1.80 
17114139 IGSF1 3.90E-08 2.26 6.36E-06 2.31 2.19E-07 2.83 7.85E-08 5.92 
16984689 ITGA2 2.29E-07 2.50 0.000525 1.78 2.94E-06 2.74 7.32E-06 3.60 
16835672 ITGA3 7.30E-08 2.22 1.76E-05 2.13 1.26E-06 2.34 8.63E-06 2.50 
16677451 KCNK2 1.36E-10 10.64 1.68E-08 13.26 3.89E-09 10.35 2.13E-05 2.41 
17018841 KCNK5 2.00E-08 6.83 1.94E-05 4.44 4.27E-07 7.50 2.19E-05 4.67 
17061662 LAMB1 1.98E-07 6.81 0.000615 3.14 3.74E-06 7.31 0.000189 4.28 
16767991 LIN7A 1.27E-09 8.61 1.34E-07 10.62 2.48E-08 9.54 2.54E-06 5.32 
16690019 LPPR5 7.50E-07 7.64 6.64E-05 8.94 2.58E-05 6.72 0.000158 6.97 
16702982 MALRD1 3.76E-08 9.56 3.73E-06 12.40 8.75E-07 9.99 6.98E-06 11.61 
17120346 MALRD1 8.68E-09 20.72 1.30E-06 24.73 2.04E-07 22.99 2.72E-06 21.79 
16947173 MME 1.27E-09 7.28 4.24E-07 6.30 7.12E-09 11.26 6.10E-08 15.06 
16743764 MMP13 4.37E-06 5.57 0.000134 8.25 0.000284 4.11 0.003315 3.12 
17078870 MMP16 3.31E-12 8.39 8.95E-10 9.36 4.72E-10 5.69 1.35E-07 2.83 
16981099 NPY1R 1.33E-10 5.06 7.13E-08 3.89 4.16E-09 4.35 2.93E-07 3.20 
17010760 NT5E 1.51E-07 12.42 2.61E-05 11.90 1.19E-06 20.02 4.86E-05 10.50 
17125282 PGM5 2.91E-08 5.16 2.34E-05 3.68 1.82E-07 8.14 8.72E-05 2.98 
17117463 PLXDC2 5.74E-07 5.22 3.98E-05 6.41 5.23E-06 6.74 4.44E-05 6.76 
16704977 PRKG1 4.68E-06 3.86 0.000169 4.99 2.23E-05 5.36 0.000872 3.35 
16755465 RMST 2.43E-09 7.69 3.19E-07 8.79 3.89E-09 23.09 3.65E-08 26.28 
16847095 RNF43 9.34E-09 7.83 3.09E-06 6.93 2.89E-07 7.69 2.18E-05 4.35 
17059771 SAMD9 5.51E-06 2.65 1.68E-05 5.74 0.000103 2.65 0.000777 2.49 
           *FDR-adjusted P-value, **FC = fold change > 5, in most cases, bold indicates functionally important genes 
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Table 5.17: List of the most up-regulated genes in EP300 KD and their corresponding 
paclitaxel resistant derivatives of MCF-7 (contd.) 
 Probe set 
ID 
Gene Symbol 
shEP1 vs. 
Control 
shEP1Tx vs. 
Control 
shEP2 vs. 
Control 
shEP2Tx vs. 
Control 
p-value* FC** p-value* FC** p-value* FC** p-value* FC** 
16773131 SGCG 2.38E-10 10.69 6.60E-08 9.58 4.16E-09 11.54 2.37E-07 7.16 
16880712 SLC1A4 5.46E-09 5.38 6.67E-05 2.40 1.43E-06 3.29 0.00016 2.17 
16991010 SLC26A2 4.22E-07 6.33 0.000582 3.48 4.74E-06 7.97 0.000113 5.64 
16886961 SLC4A10 8.59E-08 2.82 3.81E-05 2.43 3.85E-07 3.89 2.58E-07 7.86 
16970118 SYNPO2 1.34E-08 19.88 5.12E-06 15.13 5.43E-07 17.19 8.14E-05 5.96 
16906308 TFPI 1.74E-08 11.59 4.12E-07 29.19 1.01E-06 8.89 3.52E-05 5.91 
16677556 TGFB2 3.40E-10 6.23 1.68E-08 10.66 3.89E-09 8.69 6.20E-09 16.13 
16762759 TMTC1 4.97E-10 7.79 1.20E-07 7.40 8.20E-08 4.94 0.000428 1.74 
17080486 TNFRSF11B 2.99E-08 4.60 6.31E-05 2.85 1.13E-07 8.12 6.62E-07 10.14 
16877297 TRIB2 3.34E-06 4.96 0.000144 6.50 0.000357 3.39 0.004171 2.63 
16905238 WIPF1 5.77E-07 7.69 0.000116 6.84 2.60E-05 6.28 0.000496 4.55 
16914084 WISP2 3.19E-09 7.88 7.87E-07 7.46 1.43E-07 7.21 4.79E-05 3.02 
17112149 XIST 3.21E-09 15.82 4.99E-07 17.53 3.06E-07 10.20 5.12E-07 22.56 
          *FDR-adjusted P-value, **FC = fold change > 5, in most cases, bold indicates functionally important genes 
 
Genes significantly up- and down-regulated in all the EP300 down-regulated 
and their corresponding resistant lines are shown (Table 5.17 and 5.18, 
respectively). Almost all of these genes have relevance to the molecular 
functions exerted by EP300. Some of the genes that have been found to be of 
greater interests with respect to EP300-mediated drug resistance, EMT or 
stemness, are highlighted in the respective figures. Along with these genes, a 
number of long non-coding RNAs, microRNAs and other small non-coding 
RNAs were also found to be up- and down-regulated in EP300 knocked down 
MCF-7 cells (Table 5.19). 
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Table 5.18: List of the most down-regulated genes in EP300 KD and their corresponding 
paclitaxel resistant derivatives of MCF-7 
  
Probe set 
ID 
  
Gene Symbol 
shEP1 vs. Control shEP1Tx vs. 
Control 
shEP2 vs. Control shEP2Tx vs. 
Control 
p-value* FC** p-value* FC** p-value* FC** p-value* FC** 
17056861 AMPH 3.13E-06 -3.82 0.000113 -5.03 2.00E-05 -4.94 0.001183 -2.89 
16967513 AMTN 2.08E-06 -3.70 4.86E-05 -5.52 1.08E-05 -5.01 9.91E-05 -4.78 
16744205 ARHGAP20 1.62E-09 -17.14 1.61E-07 -23.65 2.88E-08 -20.51 2.55E-07 -23.84 
16863041 BCL3 2.41E-11 -3.32 8.32E-09 -3.06 3.07E-09 -2.61 8.60E-08 -2.24 
16793129 BMP4 3.63E-08 -3.00 1.80E-08 -3.24 1.06E-07 -2.69 8.62E-07 -2.24 
16920585 BMP7 2.41E-11 -5.89 1.68E-08 -4.61 6.26E-10 -6.22 1.21E-06 -2.31 
17070456 CA2 4.97E-10 -8.03 6.60E-08 -9.54 6.84E-09 -9.32 2.37E-07 -7.21 
16814584 CACNA1H 5.99E-09 -5.50 5.82E-06 -3.86 5.91E-07 -4.17 0.000125 -2.32 
16678651 CAPN9 1.26E-09 -5.35 3.19E-07 -5.03 1.50E-07 -3.91 1.28E-06 -4.11 
17048190 CDK14 2.14E-07 -6.26 1.41E-05 -8.33 7.62E-06 -5.61 0.000116 -4.68 
16862548 CEACAM5 7.88E-09 -32.68 2.95E-06 -25.10 5.91E-07 -20.63 0.000292 -4.60 
16862563 CEACAM6 5.17E-08 -26.74 1.08E-05 -25.57 2.13E-06 -21.60 0.000169 -8.19 
16685868 CITED4 2.71E-07 -2.79 2.51E-06 -5.11 4.53E-06 -2.97 1.19E-05 -3.84 
17100201 CLIC3 7.50E-08 -4.18 3.36E-06 -6.01 4.84E-06 -3.45 2.53E-05 -3.85 
16856350 CNN2 5.90E-09 -5.68 1.88E-06 -5.14 2.66E-07 -5.09 7.74E-06 -4.06 
17106438 DOCK11 2.76E-07 -4.41 6.38E-05 -4.03 8.84E-06 -4.11 0.000276 -3.03 
16877968 DPYSL5 3.28E-07 -5.48 7.22E-05 -4.98 7.04E-06 -5.62 5.91E-05 -5.57 
17075973 DUSP4 9.31E-08 -4.12 6.02E-06 -5.30 5.34E-06 -3.50 4.93E-05 -3.44 
17067963 EIF4EBP1 0.00781 -1.41 0.001235 -2.54 0.000343 -2.50 0.000501 -3.12 
16930534 EP300 2.46E-06 -1.90 0.00121 -1.62 0.00024 -1.65 0.00195 -1.55 
16983373 FAM105A 8.68E-09 -5.52 1.21E-05 -3.56 8.10E-07 -4.13 0.00013 -2.41 
16964027 FGFR3 2.48E-06 -3.04 0.000541 -2.66 3.61E-05 -3.21 0.000313 -3.02 
16904410 FIGN 4.13E-08 -3.42 3.56E-06 -4.09 1.61E-07 -5.37 6.93E-06 -3.90 
16851383 GATA6 1.12E-07 -2.99 8.32E-06 -3.50 1.62E-06 -3.29 3.02E-05 -2.91 
17086048 GCNT1 1.57E-07 -3.67 7.76E-06 -4.84 6.34E-06 -3.32 4.05E-05 -3.54 
16981631 GLRA3 1.29E-09 -15.64 3.19E-07 -14.60 5.38E-08 -13.53 6.32E-05 -3.37 
16734355 H19 5.39E-10 -5.20 1.12E-06 -3.25 1.28E-08 -5.16 3.42E-05 -2.05 
17012304 HEY2 2.77E-09 -6.06 1.85E-07 -8.29 1.95E-07 -4.89 9.89E-07 -6.06 
17005865 HIST1H2BM 4.37E-05 -2.45 0.000415 -3.49 8.15E-05 -3.49 4.82E-05 -6.65 
17117871 HMGA1 1.35E-06 -2.15 9.70E-05 -2.31 1.97E-06 -3.18 0.000116 -2.32 
17022887 HS3ST5 1.77E-06 -3.64 0.000153 -3.89 2.09E-05 -4.08 0.000168 -3.95 
16912362 ID1 3.26E-09 -8.11 7.11E-06 -4.36 2.04E-07 -6.55 4.85E-05 -3.08 
17005223 ID4 7.66E-07 -6.56 8.63E-05 -7.00 5.23E-06 -9.65 0.000153 -6.12 
16764817 KRT81 5.78E-07 -5.28 7.14E-05 -5.51 1.78E-05 -4.90 0.000399 -3.63 
16903186 LRP1B 1.88E-07 -3.58 2.34E-05 -3.71 5.46E-06 -3.44 0.000455 -2.25 
16704865 MSMB 8.84E-08 -5.54 6.57E-05 -3.88 1.53E-05 -3.57 0.000138 -3.42 
16720601 MUC5B 1.14E-08 -5.40 5.19E-07 -8.08 1.58E-07 -6.76 4.83E-06 -5.15 
16668997 OLFML3 7.25E-07 -4.93 0.000261 -3.85 2.18E-05 -4.59 0.000135 -4.76 
17104893 PABPC1L2B 4.84E-07 -3.70 0.000205 -2.97 4.63E-05 -2.86 0.000882 -2.33 
17070221 PKIA 1.11E-05 -2.86 0.000166 -4.12 0.000106 -3.16 0.000576 -3.16 
     *FDR-adjusted P-value, **FC = fold change < -5, in most cases, bold indicates functionally important genes 
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Table 5.18: List of the most down-regulated genes in EP300 KD and their corresponding 
paclitaxel resistant derivatives of MCF-7 (contd.) 
  
Probe set 
ID 
  
Gene Symbol 
shEP1 vs. Control shEP1Tx vs. 
Control 
shEP2 vs. Control shEP2Tx vs. 
Control 
p-value* FC** p-value* FC** p-value* FC** p-value* FC** 
16824109 PLA2G10 1.22E-05 -5.66 0.0008 -5.88 0.000258 -5.32 0.001234 -5.21 
17106357 PLS3 1.74E-08 -16.06 6.11E-06 -12.87 5.34E-07 -15.81 7.43E-06 -14.23 
16984287 PTGER4 3.69E-07 -7.45 2.69E-05 -9.51 2.44E-05 -5.56 0.001152 -3.26 
16852463 RAB27B 9.18E-11 -5.50 4.45E-08 -4.35 4.16E-09 -4.38 4.13E-06 -2.21 
16850923 RAB31 1.53E-08 -3.03 2.70E-07 -4.94 5.67E-06 -2.11 3.85E-06 -3.21 
16874339 RRAS 8.76E-06 -2.13 6.97E-05 -3.14 0.000406 -1.90 0.000297 -2.48 
17013520 SASH1 2.95E-09 -5.28 1.43E-06 -4.38 3.18E-07 -3.92 0.000179 -1.99 
17077341 SDR16C5 5.57E-05 -2.86 0.00297 -2.76 0.000796 -2.81 0.004 -2.60 
17064810 SHH 1.25E-08 -4.37 3.56E-06 -4.10 6.07E-07 -3.87 1.35E-05 -3.32 
16914469 SLC2A10 4.82E-09 -4.81 7.41E-07 -5.10 2.24E-07 -4.29 9.16E-06 -3.30 
16780133 SLITRK6 1.46E-07 -4.54 1.37E-05 -5.25 9.88E-08 -13.89 3.42E-05 -4.48 
17107420 SPANXA1 2.44E-05 -3.19 0.001839 -3.02 7.18E-05 -4.56 0.000393 -4.63 
17114718 SPANXA1 2.44E-05 -3.19 0.001839 -3.02 7.18E-05 -4.56 0.000393 -4.63 
17047560 UPK3B 7.03E-07 -3.02 1.70E-05 -4.36 3.33E-06 -4.09 3.33E-05 -4.02 
16690343 VAV3 5.64E-09 -4.39 1.59E-06 -4.13 2.83E-07 -3.90 5.20E-06 -3.58 
16981730 VEGFC 3.67E-06 -2.57 0.000481 -2.47 4.11E-05 -2.81 0.000874 -2.27 
16875108 ZNF320 8.28E-06 -7.15 0.000122 -14.68 3.10E-05 -12.44 0.00021 -12.15 
16875166 ZNF347 1.23E-05 -3.97 0.002416 -3.07 0.000364 -3.52 0.001963 -3.28 
16765542 ZNF385A 1.80E-06 -4.55 0.000133 -5.13 4.51E-05 -4.34 0.000347 -4.11 
16973296 ZNF732 1.23E-06 -4.04 0.001177 -2.60 0.000482 -2.39 0.00066 -2.97 
     *FDR-adjusted P-value, **FC = fold change < -5, in most cases, bold indicates functionally important genes 
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Table 5.19: List of long non-coding RNAs, microRNAs and other small non-coding RNAs 
up- and down-regulated in EP300 knocked down MCF-7 cells 
*FDR-adjusted P-value, **FC = fold change < -5 or > 5, in most cases 
 
 
5.3.9 Identification of signaling pathways by gene set enrichment analysis 
First, a hierarchical clustering analysis (done with the help of Dr Meng-Lay 
Lin) of the differentially-expressed genes in all the EP300 knocked-down lines 
divided them into 3 main clusters (Figure 5.9). Cluster 1 includes the genes 
  
Probe set 
ID 
  
Gene Symbol 
shEP1 vs.  
Control 
shEP1Tx vs.  
Control 
shEP2 vs.  
Control 
shEP2Tx vs.  
Control 
p-value* FC** p-value* FC** p-value* FC** p-value* FC** 
A. Genes up-regulated                 
16804449 LINC00052 1.62E-09 93.38 3.62E-07 87.35 6.51E-08 77.23 0.000104629 6.66 
17122474 LINC00152 1.59E-06 3.95 2.34E-05 6.90 1.22E-05 4.95 5.60E-05 5.75 
17122496 LINC00152 2.50E-06 3.73 4.78E-05 5.85 2.18E-05 4.46 8.14E-05 5.32 
17122500 LINC00152 2.00E-08 3.39 5.70E-07 5.10 3.09E-07 3.83 2.54E-06 4.18 
17122654 LINC00152 0.00011 3.30 0.0004733 6.44 0.000659 3.83 0.000615442 6.05 
17087109 MIR27B 1.39E-07 5.76 0.0010598 2.43 1.23E-06 7.74 9.27E-05 4.19 
17122488 MIR4435-1HG 1.02E-07 4.63 5.02E-06 6.54 1.23E-06 5.54 5.36E-06 7.33 
16699862 MIR4742 0.002592 2.01 0.0035593 3.32 0.002868 2.71 0.000838345 5.30 
17059826 MIR489 6.82E-06 3.66 0.0019357 2.78 1.21E-05 6.47 5.66E-05 7.65 
16983456 RNU6-1003P 0.000247 3.58 0.0009852 7.00 0.000809 4.78 0.000435013 10.29 
16715847 RNU6-1266P 0.004636 1.77 0.0021351 3.42 0.000546 3.49 0.000240809 6.90 
16998661 RNU6-334P 2.58E-05 10.00 0.0009751 12.39 0.000286 11.34 0.00108558 12.24 
16705448 RNU6-697P 0.005791 1.95 0.0017074 4.91 0.002444 3.17 0.00164309 5.07 
16777380 RNY3P4 3.75E-05 6.72 0.0006202 11.09 0.000222 9.12 0.00128221 8.25 
17012711 SNORA33 0.000875 1.76 0.0001585 4.42 0.00024 2.87 0.000117116 5.02 
17040798 SNORA38 0.002567 1.49 0.0014135 2.31 0.001666 1.88 0.00129299 2.37 
17057460 SNORA5A 6.04E-09 4.67 7.33E-07 5.31 1.50E-07 5.01 1.19E-05 3.19 
17021407 SNORD50A 2.69E-07 1.74 1.92E-05 1.87 4.97E-06 1.78 9.46E-05 1.65 
17090566 SNORD62A 0.001593 2.86 0.0017666 6.95 0.001965 4.39 0.000743195 10.47 
B. Genes down-regulated                 
17122114 LINC00665 7.35E-08 -5.28 1.35E-05 -5.24 1.66E-06 -5.44 3.55E-05 -4.41 
17122116 LINC00665 2.06E-07 -5.23 2.22E-05 -5.75 4.70E-06 -5.31 9.82E-05 -4.14 
17122120 LINC00665 2.86E-08 -6.75 7.67E-06 -6.22 8.05E-07 -6.73 1.73E-05 -5.40 
17122122 LINC00665 2.00E-08 -8.34 5.72E-06 -7.58 6.11E-07 -8.09 1.02E-05 -7.09 
17119208 LINC01293 2.38E-10 -14.63 4.78E-08 -14.03 6.10E-09 -13.00 8.60E-08 -12.88 
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which are significantly down-regulated in the EP300 knocked-down lines, 
including BMP4, BMP7, CAPN9, CEACAM5, DUSP4, EP300 and SASH1. 
Cluster 2 and 3 are comprised of the up-regulated genes in the EP300 knocked-
down lines. These include – ABCG2, BCL2, ITGA1, ITGA3, TGFB2, 
TNFRSF11B in the cluster 2 and NPY1R in the cluster 3. Next, the up- and 
down-regulated genes were subject to the GSEA (Gene Set Enrichment 
Analysis) using the MSigDb (Molecular Signatures Database, Broad Institute) 
from Broad Institute (www.broadinstitute.org/gsea/msigdb/index.jsp)  for 
computing overlaps for the selected genes with those existing in the entire 
database. Individual genes that are found to be overlapping with those in the 
MSigDb are shown in (Table 5.19 and 5.20) along with their functions and 
related pathway (only 8 out of 10 top pathways that are most relevant, are 
shown). Of particular interests, the genes that came out after hierarchical 
clustering analysis (Figure 5.10) also appeared to be enriched for multiple 
pathways (Table 5.20 and 5.21). This indicates their involvement in EP300-
mediated functions. 
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Figure 5.10: Hierarchical clustering of differentially-expressed genes in EP300 knocked-
down (KD) cells (shEP300 and shEP300 Tx). Differentially up-regulated expression values 
are shown in red, down-regulated in green; and no change in black for shev (control) vs. 
shEP300 and shEP300 Tx cells. Scale represents colour values corresponding to log2 
(expression in shEP300 and shEP300 Tx cells / expression in shev cell). The three major 
clusters are shown. Some of the individual genes with greater relevance to EP300 functioning 
are shown near an approximate position in the clusters. Cluster 1 includes the genes that are 
significantly (fold change <5) down-regulated whereas, Cluster 2 and 3 comprises the up-
regulated (fold change >5) genes in all of the EP300 knocked-down lines. 
shev shEP1 shEP2 shEP1 Tx shEP2 Tx 
CAPN9 
BMP4 
CEACAM5 
BMP7 
EP300 
SASH1 
DUSP4 
TGFB2 
ITGA3 
BCL2 
ABCG2 
ITGA2 
TNFRSF11B 
NPY1R Cluster 3 
Cluster 2 
Cluster 1 
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Table 5.20: Gene/gene set overlap matrix for the most up-regulated genes  
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Gene Description 
7042 TGFB2 √ √ √ √ √   √ transforming growth factor, beta 2 
9547 CXCL14 √  √ √  √   chemokine (C-X-C motif) ligand 14 
3354 HTR1E √     √   5-hydroxytryptamine (serotonin) receptor 1E 
8839 WISP2 √     √   WNT1 inducible signaling pathway protein 2 
4311 MME √        membrane metallo-endopeptidase 
5297 PI4KA √        phosphatidylinositol 4-kinase, catalytic, α 
3673 ITGA2   √  √   √ integrin, α2 (CD49B, α2 subunit of VLA-2 receptor) 
7035 TFPI   
√ 
     
tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor) 
3912 LAMB1  √   √   √ laminin, beta 1 
8519 IFITM1  √    √   interferon induced transmembrane protein 1 (9-27) 
27244 SESN1  √       sestrin 1 
8621 CDK13  √       cyclin-dependent kinase 13 
57834 CYP4F11   √      cytochrome P450, family 4, subfamily F, polypeptide 11 
596 BCL2    √ √  √  B-cell CLL/lymphoma 2 
799 CALCR    √  √   calcitonin receptor 
9429 ABCG2    √   √  ATP-binding cassette, sub-family G (WHITE), member 2 
2263 FGFR2     √    fibroblast growth factor receptor 2 
4982 TNFRSF11B      √  √ TNF receptor superfamily, member 11b 
4886 NPY1R      √   neuropeptide Y receptor Y1 
5592 PRKG1      √   protein kinase, cGMP-dependent, type I 
3547 IGSF1      √   immunoglobulin superfamily, member 1 
2043 EPHA4      √   EPH receptor A4 
8825 LIN7A       √  lin-7 homolog A (C. elegans) 
10652 YKT6       √  YKT6 v-SNARE homolog (S. cerevisiae) 
8645 KCNK5       √  potassium channel, subfamily K, member 5 
1836 SLC26A2       √  solute carrier family 26 (sulfate transporter), member 2 
6509 SLC1A4       
√ 
 
solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 
6445 SGCG        
√ sarcoglycan, gamma (35kDa dystrophin-associated 
glycoprotein) 
1303 COL12A1               √ collagen, type XII, alpha 1 
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Table 5.21: Gene/gene set overlap matrix for the most down-regulated genes  
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Gene Description 
2033 EP300 √  √ √ √ √  √ E1A binding protein p300 
3397 ID1 
√ 
 
√ √ √ √ 
 
√ inhibitor of DNA binding 1, dominant negative 
helix-loop-helix protein 
655 BMP7 √  √ √ √ √   bone morphogenetic protein 7 
3400 ID4 
√ 
 
√ √ √ √ 
  
inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
602 BCL3  √ √ √ √ √  √ B-cell CLL/lymphoma 3 
6469 SHH  √ √  √    sonic hedgehog 
2261 FGFR3  √     √  fibroblast growth factor receptor 3 
56896 DPYSL5  √       dihydropyrimidinase-like 5 
1846 DUSP4  √     √  dual specificity phosphatase 4 
6237 RRAS  √     √  related RAS viral (r-ras) oncogene homolog 
10451 VAV3  √       vav 3 guanine nucleotide exchange factor 
5734 PTGER4  √       prostaglandin E receptor 4 (subtype EP4) 
7424 VEGFC  √       vascular endothelial growth factor C 
4680 CEACAM6  
√ 
      
carcinoembryonic antigen-related cell adhesion 
molecule 6 
9022 CLIC3  √       chloride intracellular channel 3 
2627 GATA6   √ √ √ √   GATA binding protein 6 
3159 HMGA1   √ √ √ √   high mobility group AT-hook 1 
8912 CACNA1H       
√ 
 
calcium channel, voltage-dependent, T type, 
alpha 1H subunit 
8399 PLA2G10       √  phospholipase A2, group X 
222537 HS3ST5         
heparan sulfate (glucosamine) 3-O-
sulfotransferase 5 
 
Pathway enrichment analysis helps in the identification of potential signalling 
pathways and aids in the determination of the putative function of the protein of 
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interest. Thus, in order to further identify specific signalling pathways that are 
involved in EP300- mediated functions in breast cancer, gene ontology (GO) 
analyses were undertaken using the DAVID (Database for Annotation, 
Visualization and Integrated Discovery, v6.7) online tool (Huang da, Sherman 
et al. 2009).  
The GO category enrichment (Table 5.22) for the up-regulated genes identified 
multiple pathways that are related to epithelial cell migration, cell growth, 
positive regulation of cell migration, motion and locomotion and proliferation, 
and response to endogenous and exogenous stimulus, drugs, nutrients, oxygen 
and hypoxia levels. All these significant GO biological processes were found to 
be highly enriched processes potentially regulated by EP300. 
For the down-regulated genes, the GO enrichment showed (Table 5.23) highly 
enriched biological processes, viz., PPAR binding, regulation of intracellular 
protein transport, regulation of transcription factor activity, positive regulation 
of cellular differentiation and developmental process, positive regulation of 
cellular protein metabolic process, regulation of cell development, membrane 
anchoring, blood vessel morphogenesis and development, angiogenesis and 
vasculature development, etc. Overall, in the EP300 down-regulated MCF-7 
cells, the potentially EP300-regulated genes were specially enriched for 
processes implicated in cellular differentiation and proliferation, drug response, 
transcriptional regulation, protein transport and metabolism. 
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Table 5.22: Gene Ontology (GO) enrichment analysis for the most up-regulated genes 
Term No. of 
genes 
(%)* 
P-Value Genes (examples) Fold 
Enrichment 
Positive regulation of epithelial cell 
migration 
2 (2.82) 0.0246 ITGA2, TGFB2 79.11 
Regulation of epithelial cell 
migration 
2 (2.82) 0.0286 ITGA2, TGFB2 67.81 
Cell growth 3 (4.23) 0.0264 FGFR2, BCL2, TGFB2 11.67 
Positive regulation of cell migration 4 (5.63) 0.0059 BCL2, ITGA2, LAMB1, TGFB2 10.67 
Positive regulation of locomotion 4 (5.63) 0.0077 BCL2, ITGA2, LAMB1, TGFB2 9.69 
Positive regulation of cell motion 4 (5.63) 0.0077 BCL2, ITGA2, LAMB1, TGFB2 9.69 
Response to estrogen stimulus 4 (5.63) 0.0093 TNFRSF11B, BCL2, NPY1R, MMP13 9.04 
Response to hypoxia 4 (5.63) 0.0180 BCL2, ITGA2, MMP13, TGFB2 7.08 
Response to nutrient 4 (5.63) 0.0202 TNFRSF11B, KYNU, BCL2, ITGA2 6.78 
Response to oxygen levels 4 (5.63) 0.0206 BCL2, ITGA2, MMP13, TGFB2 6.73 
Extracellular matrix 9 (12.68) 0.0001 TNFRSF11B, HMCN1, EFEMP1, 
COL12A1, MMP16, LAMB1, 
MMP13, COL4A5, TGFB2 
5.75 
Growth 4 (5.63) 0.0400 FGFR2, BCL2, BMP5, TGFB2 5.19 
Wound healing 4 (5.63) 0.0445 HMCN1, TFPI, ITGA2, TGFB2 4.97 
Positive regulation of multicellular 
organismal process 
5 (7.04) 0.0182 DDX58, BCL2, ITGA2, NPY1R, 
TGFB2 
4.86 
Cytokine activity 4 (5.63) 0.0473 TNFRSF11B, CXCL14, BMP5, 
TGFB2 
4.84 
Response to nutrient levels 4 (5.63) 0.0480 TNFRSF11B, KYNU, BCL2, ITGA2 4.82 
Response to drug 4 (5.63) 0.0601 TNFRSF11B, BCL2, ITGA2, ABCG2 4.40 
Response to extracellular stimulus 4 (5.63) 0.0628 TNFRSF11B, KYNU, BCL2, ITGA2 4.32 
Response to endogenous stimulus 7 (9.86) 0.0064 CALCR, TNFRSF11B, BCL2, ITGA2, 
TGFB2, NPY1R, MMP13,  
4.10 
Positive regulation of cell 
proliferation 
6 (8.45) 0.0279 FGFR2, BCL2, ITGA2, LAMB1, 
CDK13, TGFB2 
3.44 
Negative regulation of cell 
proliferation 
5 (7.04) 0.0620 WISP2, IFITM1, BCL2, SESN1, 
TGFB2 
3.29 
Cell-cell signaling 8 (11.27) 0.0115 SLC1A4, WISP2, CXCL14, PI4KA, 
MME, HTR1E, TGFB2, LIN7A 
3.16 
Regulation of cell proliferation 9 (12.68) 0.0151 FGFR2, WISP2, IFITM1, BCL2, 
ITGA2, LAMB1, SESN1, CDK13, 
TGFB2 
2.71 
Cell adhesion 8 (11.27) 0.0247 WISP2, PGM5, BCL2, SDK1, ITGA2, 
COL12A1, LAMB1, CDH11 
2.71 
Biological adhesion 8 (11.27) 0.0249 WISP2, PGM5, BCL2, SDK1, ITGA2, 
COL12A1, LAMB1, CDH11 
2.71 
Response to organic substance 8 (11.27) 0.0284 CALCR, TNFRSF11B, KYNU, BCL2, 
ITGA2, NPY1R, MMP13, TGFB2 
2.63 
Protein amino acid phosphorylation 7 (9.86) 0.0566 FGFR2, EPHA4, BCL2, PRKG1, 
TRIB2, CDK13, TGFB2 
2.49 
Phosphorylation 8 (11.27) 0.0460 FGFR2, EPHA4, BCL2, PI4KA, 
PRKG1, TRIB2, CDK13, TGFB2 
2.37 
*Percentage shown is calculated based on the 71 genes annotated, when all the up-regulated genes were submitted to DAVID, and after species selection (H. sapiens) 
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Table 5.23: Gene Ontology (GO) enrichment analysis for the most down-regulated genes 
Term No. of 
genes 
(%)* 
P-Value Genes (examples) Fold 
Enrichment 
Peroxisome proliferator activated 
receptor binding 
2 (3.33) 0.010 EP300, HMGA1 192.34 
Regulation of protein import into 
nucleus 
3 (5.00) 0.010 BCL3, PKIA, SHH 19.62 
Regulation of intracellular protein 
transport 
3 (5.00) 0.014 BCL3, PKIA, SHH 16.29 
Regulation of nucleocytoplasmic 
transport 
3 (5.00) 0.017 BCL3, PKIA, SHH 14.89 
Regulation of intracellular transport 3 (5.00) 0.024 BCL3, PKIA, SHH 12.16 
Regulation of protein transport 4 (6.67) 0.007 VEGFC, BCL3, PKIA, SHH 10.10 
Regulation of DNA binding 4 (6.67) 0.008 EP300, ID1, BCL3, SHH 9.52 
Regulation of establishment of 
protein localization 
4 (6.67) 0.008 VEGFC, BCL3, PKIA, SHH 9.52 
Regulation of transcription factor 
activity 
3 (5.00) 0.048 EP300, ID1, SHH 8.38 
Regulation of protein localization 4 (6.67) 0.011 VEGFC, BCL3, PKIA, SHH 8.34 
Response to estrogen stimulus 3 (5.00) 0.050 CA2, BMP7, SHH 8.22 
Positive regulation of cell 
differentiation 
6 (10.00) 0.001 VEGFC, PLA2G10, GATA6, CA2, 
BMP7, SHH 
7.54 
Regulation of binding 4 (6.67) 0.015 EP300, ID1, BCL3, SHH 7.52 
Positive regulation of developmental 
process 
7 (11.67) 0.0003 VEGFC, PLA2G10, GATA6, HEY2, 
CA2, BMP7, SHH 
7.25 
Epithelium development 5 (8.33) 0.007 VEGFC, GATA6, CA2, BMP7, SHH 6.34 
Positive regulation of cellular protein 
metabolic process 
5 (8.33) 0.008 VEGFC, EP300, PLA2G10, BCL3, 
BMP7 
6.18 
Response to steroid hormone 
stimulus 
4 (6.67) 0.027 EP300, CA2, BMP7, SHH 6.00 
Regulation of locomotion 4 (6.67) 0.027 VEGFC, HS3ST5, RRAS, SHH 6.00 
Positive regulation of protein 
metabolic process 
5 (8.33) 0.009 VEGFC, EP300, PLA2G10, BCL3, 
BMP7 
5.92 
Cell morphogenesis involved in 
differentiation 
5 (8.33) 0.009 PLA2G10, DPYSL5, BMP7, 
SLITRK6, SHH 
5.90 
Positive regulation of multicellular 
organismal process 
5 (8.33) 0.009 HEY2, BCL3, CA2, BMP7, SHH 5.90 
Angiogenesis 3 (5.00) 0.090 VEGFC, ID1, SHH 5.83 
Regulation of cellular localization 5 (8.33) 0.010 VEGFC, BCL3, RAB27B, PKIA, SHH 5.80 
Regulation of cell development 4 (6.67) 0.032 VEGFC, ID4, BMP7, SHH 5.62 
Anchored to membrane 4 (6.67) 0.033 CEACAM6, CEACAM5, RAB27B, 
SHH 
5.53 
Blood vessel morphogenesis 4 (6.67) 0.035 VEGFC, ID1, HEY2, SHH 5.46 
Blood vessel development 4 (6.67) 0.050 VEGFC, ID1, HEY2, SHH 4.70 
Vasculature development 4 (6.67) 0.053 VEGFC, ID1, HEY2, SHH 4.59 
Regulation of cellular protein 
metabolic process 
7 (11.67) 0.005 VEGFC, EIF4EBP1, EP300, 
PLA2G10, BCL3, BMP7, SHH 
4.25 
Cell motion 7 (11.67) 0.005 VEGFC, VAV3, SHH PLA2G10, ID1, 
DPYSL5, BMP7 
4.24 
Enzyme linked receptor protein 
signaling pathway 
5 (8.33) 0.028 VEGFC, EIF4EBP1, FGFR3, ID1, 
BMP7 
4.21 
Response to hormone stimulus 5 (8.33) 0.036 EIF4EBP1, EP300, CA2, BMP7, SHH 3.92 
Positive regulation of transcription 
from RNA polymerase II promoter 
5 (8.33) 0.037 EP300, GATA6, BCL3, BMP7, SHH 3.88 
Positive regulation of transcription, 
DNA-dependent 
6 (10.00) 0.022 EP300, GATA6, BCL3, BMP7, 
HMGA1, SHH 
3.62 
*Percentage shown is calculated based on the 60 genes annotated, when all the down-regulated genes were submitted to DAVID and after species selection (H. sapiens) 
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Table 5.23: Gene Ontology (GO) enrichment analysis for the most down-regulated genes 
(contd.) 
Term No. of 
genes 
(%)* 
P-Value Genes (examples) Fold 
Enrichment 
Positive regulation of RNA metabolic 
process 
6 (10.00) 0.023 EP300, GATA6, BCL3, BMP7, 
HMGA1, SHH 
3.59 
Positive regulation of transcription 7 (11.67) 0.012 EP300, GATA6, BCL3, BMP7, SHH 
CITED4, HMGA1  
3.57 
Regulation of transcription from 
RNA polymerase II promoter 
9 (15.00) 0.003 EP300, ID1, GATA6, HEY2, BCL3, 
ID4, BMP7, PKIA, SHH 
3.56 
Response to endogenous stimulus 5 (8.33) 0.048 EIF4EBP1, EP300, CA2, BMP7, SHH 3.55 
Positive regulation of gene 
expression 
7 (11.67) 0.013 EP300, GATA6, BCL3, BMP7, SHH 
CITED4, HMGA1  
3.47 
Negative regulation of gene 
expression 
6 (10.00) 0.027 ID1, HEY2, BCL3, ID4, UPK3B, 
PKIA 
3.43 
Transcription factor binding 6 (10.00) 0.029 EP300, GATA6, BCL3, ID4, CITED4, 
HMGA1 
3.37 
Positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolic process 
7 (11.67) 0.018 EP300, GATA6, BCL3, BMP7, SHH 
CITED4, HMGA1 
3.23 
Negative regulation of 
macromolecule biosynthetic process 
6 (10.00) 0.037 EIF4EBP1, ID1, HEY2, BCL3, ID4, 
PKIA 
3.16 
Negative regulation of 
macromolecule metabolic process 
8 (13.33) 0.011 EIF4EBP1, ID1, HEY2, BCL3, ID4, 
UPK3B, PKIA, SHH 
3.14 
Negative regulation of transcription 5 (8.33) 0.070 ID1, HEY2, BCL3, ID4, PKIA 3.14 
Positive regulation of nitrogen 
compound metabolic process 
7 (11.67) 0.021 EP300, GATA6, BCL3, BMP7, SHH 
CITED4, HMGA1  
3.13 
Positive regulation of macromolecule 
biosynthetic process 
7 (11.67) 0.023 EP300, GATA6, BCL3, BMP7, SHH 
CITED4, HMGA1 
3.08 
Negative regulation of cellular 
biosynthetic process 
6 (10.00) 0.041 EIF4EBP1, ID1, PKIA HEY2, BCL3, 
ID4  
3.08 
Positive regulation of macromolecule 
metabolic process 
9 (15.00) 0.008 EP300, VEGFC, PLA2G10, GATA6, 
BCL3, BMP7, SHH, CITED4, 
HMGA1 
3.02 
Negative regulation of biosynthetic 
process 
6 (10.00) 0.044 EIF4EBP1, ID1, PKIA HEY2, BCL3, 
ID4 
3.01 
Positive regulation of cellular 
biosynthetic process 
7 (11.67) 0.028 EP300, GATA6, BCL3, BMP7, SHH 
CITED4, HMGA1  
2.94 
Positive regulation of biosynthetic 
process 
7 (11.67) 0.029 EP300, GATA6, BCL3, BMP7, SHH 
CITED4, HMGA1  
2.90 
Response to organic substance 7 (11.67) 0.034 DUSP4, EIF4EBP1, EP300, ID1, CA2, 
BMP7, SHH 
2.79 
Regulation of transcription, DNA-
dependent 
13 (21.67) 0.013 ZNF347, ZNF320, HMGA1, PKIA, 
SHH, EP300, GATA6, ID1, HEY2, 
BCL3, ID4, ZNF732, BMP7 
2.11 
Regulation of RNA metabolic 
process 
13 (21.67) 0.016 ZNF347, ZNF320, HMGA1, PKIA, 
SHH, EP300, GATA6, ID1, HEY2, 
BCL3, ID4, ZNF732, BMP7 
2.06 
Regulation of transcription 15 (25.00) 0.046 ZNF347, ZNF320, HMGA1, CITED4, 
PKIA, SHH, EP300, ID1, GATA6, 
HEY2, BCL3, ZNF732, ID4, BMP7, 
ZNF385A 
1.66 
*Percentage shown is calculated based on the 60 genes annotated, when all the down-regulated genes were submitted to DAVID and after species selection (H. sapiens) 
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Positive regulation of epithelial cell migration (fold enrichment = 79.11) 
emerged as one of the most significant GO biological processes for the EP300-
regulated genes (ITGA2 and TGFB2).  
An analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, 
included the terms pathways in cancer (Table 5.24) and TGF-β and MAPK 
signaling pathways (Table 5.25). 
 
Table 5.24: KEGG pathway enrichment analysis for the most up-regulated genes 
Term No. of 
genes (%)* 
P-Value Genes (examples) Fold 
Enrichment 
Small cell lung cancer 3 (4.23) 0.073 BCL2, ITGA2, 
LAMB1 
6.49 
Hypertrophic cardiomyopathy 
(HCM) 
3 (4.23) 0.074 SGCG, ITGA2, 
TGFB2 
6.41 
Dilated cardiomyopathy 3 (4.23) 0.085 SGCG, ITGA2, 
TGFB2 
5.92 
Pathways in cancer 5 (7.04) 0.092 FGFR2, BCL2, 
ITGA2, LAMB1, 
TGFB2 
2.77 
*Percentage shown is calculated based on the 71 genes annotated, when all the up-regulated genes were submitted to DAVID and after species selection (H. sapiens) 
 
Table 5.25: KEGG pathway enrichment analysis for the most down-regulated genes 
Term No. of 
genes (%)* 
P-Value Genes (examples) Fold 
Enrichment 
TGF-β signaling pathway 4 (6.67) 0.0051 EP300, ID1, ID4, 
BMP7 
10.63 
MAPK signaling pathway 5 (8.33) 0.0219 DUSP4, FGFR3, 
PLA2G10, 
CACNA1H, RRAS 
4.33 
*Percentage shown is calculated based on the 60 genes annotated, when all the down-regulated genes were submitted to DAVID and after species selection (H. sapiens) 
 
 
228 
 
5.3.10 Down-stream targets of EP300 are potentially related to apoptosis, 
adhesion and stem cell pluripotency pathways 
As shown in the GSEA analyses (section 5.3.9), deletion of EP300 in MCF-7 
leads to significant up- and down-regulation of genes involved in an wide 
spectrum of biological pathways. An online database search for known EP300 
interacting proteins identified a total of 7870 genes 
(http://www.genecards.org/Search/Keyword?startPage=0&queryString=ep300&
pageSize=-1). When these were compared with the investigated 4044 genes that  
 
Figure 5.11: EP300 regulated genes overlapping with the interacting proteins. A search 
in the GeneCards for “EP300” yielded a total of 7870 hits. These are known to interact with 
EP300 either directly or indirectly. When these hits were compared with the list of the EP300-
regulated genes (n = 2056) as obtained from the array, 1523 genes were found to be common 
in both group shown in the Venn diagram. These 1523 (~38%) common genes are either 
direct or indirect targets of EP300 in the whole transcriptome of MCF-7 cell. 
(http://www.genecards.org/Search/Keyword?startPage=0&queryString=ep300&pageSize=-1) 
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are likely to be regulated either directly or indirectly by EP300 in MCF-7, 1523 
genes appeared to be common (Figure 5.11). These 1523 genes are the potential 
genes regulated by EP300. 
Based on the data from the GSEA analyses, pathway-specific search were 
performed next using PathCards, an integrated database of human biological 
pathways and their annotations (http://pathcards.genecards.org/). This 
demonstrated that in MCF-7, EP300 mainly regulates genes in biological 
 
Figure 5.12: EP300 regulates genes in the apoptosis pathway. After a search in the 
PathCards for “Apoptosis”, a total of 33 genes were found to be common in the EP300- MCF-
7. The common genes are shown at the right. The apoptosis pathway was accessed from the 
URL: http://pathcards.genecards.org/card/apoptosis_pathway?term=apoptosis. The Venn 
diagram was produced using Venny® ver. 2.0 (http://bioinfogp.cnb.csic.es/tools/venny/). 
Among the common genes overlapping in the investigated gene sets (EP300- MCF-7 
transcriptome and the “Apoptosis Pathway”) include BCL2 and CAPN9, which were found to 
be up- and down-regulated, respectively.  
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processes related to apoptosis (Figure 5.12 and 5.13), cell adhesion (Figure 
5.14) and mammalian epithelial stem cell (ESC) pluripotency (Figure 5.15). It is 
interesting to note that CDH1 did not appear in the list of genes regulated by 
EP300, although other mesenchymal cadherins, such as CDH2 and CDH11 
were represented (Fig. 5.14). As CDH1 mRNA levels were confirmed to be 
down-regulated in both sets of shEP300 and shEP300Tx cells, we have to infer 
that this represents a false negative data in the array. 
 
 
Figure 5.13: EP300 regulates genes in the KEGG apoptosis pathway. After a search in the 
PathCards for “KEGG Apoptosis”, a total of 23 genes were found to be common in the 
EP300- MCF-7. The common genes are shown at the right. Among the common genes 
overlapping in the investigated gene sets (EP300- MCF-7 transcriptome and the “KEGG 
Apoptosis Pathway”) include genes that are involved in both extrinsic and intrinsic apoptosis. 
The apoptosis pathway was accessed from the URL: 
http://pathcards.genecards.org/card/apoptosis_%28kegg%29?term=apoptosis. The Venn 
diagram was produced using Venny® ver. 2.0 (http://bioinfogp.cnb.csic.es/tools/venny/). 
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Interestingly, analyses for the apoptosis pathway (Figure 5.12 and 5.13) resulted 
genes implicated in both extrinsic as well as intrinsic apoptosis mechanism of 
cell death. This is more elaborated in the discussion following the results 
section. 
 
Figure 5.14: EP300 regulates genes related to the adhesion pathway. After a search in the 
PathCards for “Adhesion Pathway”, a total of 23 genes were found to be common in the 
EP300- MCF-7. The common genes are shown at the right. The adhesion pathway was 
accessed from the URL: http://pathcards.genecards.org/card/adhesion?term=adhesion. The 
Venn diagram was produced using Venny® ver. 2.0 
(http://bioinfogp.cnb.csic.es/tools/venny/). Among the common genes overlapping in the 
investigated gene sets (EP300- MCF-7 transcriptome and the “Adhesion Pathway”) include 
CEACAM5, which was observed to be remarkably down-regulated in all EP300
-
 MCF-7 lines. 
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Figure 5.15: EP300-regulated genes overlapping with the Nanog in mammalian ESC 
pluripotency. After a search in the PathCards for “Nanog in Mammalian ESC Pluripotency”, 
a total of 28 genes were found to be common in the EP300- MCF-7. The common genes are 
shown at the right. The adhesion pathway was accessed from the URL: 
http://pathcards.genecards.org/card/nanog_in_mammalian_esc_pluripotency. The Venn 
diagram was produced using Venny® ver. 2.0 (http://bioinfogp.cnb.csic.es/tools/venny/). 
Among the common genes overlapping in the investigated gene sets (EP300- MCF-7 
transcriptome and the “Nanog in Mammalian ESC Pluripotency”) include BMP4 and BMP7, 
which was observed to be remarkably down-regulated and TGFB2, as found to be 
significantly up-regulated in all EP300
-
 MCF-7 lines. 
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5.3.11 Validation of differentially expressed putative target genes up- or 
down-regulated in EP300 knocked down lines 
Based on the findings of the GSEA and pathway analyses, as well as a very low 
p-value, we selected a total of ten genes (Table 5.26) for array validation 
(Yague, Arance et al. 2007) by RT-qPCR. 
 
Table 5.26: List of genes selected for validation 
A. Genes up-regulated 
Transcript  
ID 
Gene  
Symbol 
shEP1 vs. 
Control 
shEP1 Tx vs. 
Control 
shEP2 vs. Control shEP2 Tx vs. 
Control 
p-value* FC p-value* FC p-value* FC p-value* FC 
16855673 BCL2 3.40E-10 11.43 1.20E-07 9.36 4.16E-09 14.35 1.68E-07 10.04 
16977868 ABCG2 1.14E-07 7.14 4.94E-05 5.39 2.19E-06 7.72 0.00034 3.45 
16677556 TGFB2 3.40E-10 6.23 1.68E-08 10.65 3.89E-09 8.69 6.20E-09 16.12 
17080486 TNFRSF11B 2.99E-08 4.59 6.31E-05 2.84 1.13E-07 8.11 6.62E-07 10.13 
16984689 ITGA2 2.29E-07 2.50 0.000525 1.78 2.94E-06 2.74 7.32E-06 3.59 
16835672 ITGA3 7.30E-08 2.22 1.76E-05 2.13 1.26E-06 2.34 8.63E-06 2.50 
B. Genes down-regulated 
Transcript  
ID 
Gene  
Symbol 
shEP1 vs. 
Control 
shEP1 Tx vs. 
Control 
shEP2 vs. Control shEP2 Tx vs. 
Control 
p-value* FC p-value* FC p-value* FC p-value* FC 
16862548 CEACAM5 7.88E-09 -32.67 2.95E-06 -25.09 5.91E-07 -20.62 0.000292 -4.59 
16920585 BMP7 2.41E-11 -5.88 1.68E-08 -4.60 6.26E-10 -6.22 1.21E-06 -2.31 
16678651 CAPN9 1.26E-09 -5.34 3.19E-07 -5.02 1.50E-07 -3.90 1.28E-06 -4.11 
16793129 BMP4 6.27E-07 -3.00 1.97E-05 -4.05 1.13E-05 -3.12 0.000153 -2.80 
*FDR-adjusted P-value 
 
Down-regulation of EP300 has been found to up-regulate genes, viz. ABCG2, 
BCL2, ITGA2, ITGA3, TGFB2 and TNFRSF11B (Figure 5.16) and down-
regulate genes, viz. BMP4, BMP7, CAPN9 and CEACAM5 as confirmed from 
both the array and the qRT-PCR in MCF-7 (Figure 5.17). Consistent results 
were also obtained in MTMEC cells (Figure 5.18 and Figure 5.19). For 
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example, BCL2, ABCG2 and TGFB2 were also up-regulated in MTMEC 
shEP300 cells (Figure 5.18) indicating that key molecules in pathways related to 
apoptosis, stemness and metastasis are shared in these two cell models. In the 
HCT-116 model, up-regulation of ABCG2 and BCL2 (Figure 5.20) confirms 
that these two genes are regulated by EP300 irrespective of the tissue-type. 
Other selected genes from the MCF-7 signature (Table 5.26) were not validated 
in the HCT-116 model and this may represent variations due to the nature of the 
cells, i.e., breast versus intestine. However, a full transcriptome profiling in 
HCT-116 EP300 knocked-out cells should determine the extent of pathways 
shared by both types of cells. 
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Figure 5.16: Validation of genes that are up-regulated upon knocking down EP300 in 
MCF-7 cells. Six genes were selected for validation by quantitative real time PCR (qRT-
PCR) in shev (first bar in each set) and EP300 knocked down lines. The top panel for each 
gene shows the normalized fluorescence from the Affymetrix array expression data. The 
lower panel for each gene indicates qRT-PCR data relative to the expression value obtained 
in MCF-7 cells. Data represent the mean ± SD from at least three replicates. All qRT-PCR 
data is statistically significant (P<0.05) for the comparison with shev. 
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Figure 5.17: Validation of genes that are down-regulated upon knocking down EP300 in 
MCF-7 cells. Four genes were selected for validation by quantitative real time PCR (qRT-
PCR) in shev (first bar in each set) and EP300 knocked down lines. The top panel for each 
gene shows the normalized fluorescence from the Affymetrix array expression data. The 
lower panel for each gene indicates qRT-PCR data relative to the expression value obtained 
in MCF-7 cells. Data represent the mean ± SD from at least three replicates. All qRT-PCR 
data is statistically significant (P<0.05) for the comparison with shev. 
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Figure 5.18: MTMECs and MCF-7 cells share a common set of genes up-regulated upon 
EP300 knock-down. Six up-regulated genes in shEP300 MCF-7 cells and derivatives were 
selected for validation by quantitative real time PCR (qRT-PCR) in shev (first bar in each set) 
and EP300 and E-cadherin knocked down MTMECs. Data represent the mean ± SD from at 
least three replicates and are statistically significant (P<0.05) for the comparison with shev.  
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Figure 5.19: MTMECs and MCF-7 cells share a common set of genes down-regulated 
upon EP300 knock-down. Four down-regulated genes in shEP300 MCF-7 cells and 
derivatives were selected for validation by quantitative real time PCR (qRT-PCR) in shev 
(first bar in each set) and EP300 and E-cadherin knocked down MTMECs. Data represent the 
mean ± SD from at least three replicate and are statistically significant (P<0.05) for the 
comparison with shev.  
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Figure 5.20: ABCG2 and BCL2 are also up-regulated in EP300-deleted HCT-116 cells as 
in MTMECs and MCF-7 cells. These two genes in EP300 knocked-out HCT-116 cells and 
two paclitaxel resistant derivatives were selected for validation by quantitative real time PCR 
(qRT-PCR) in shev (first bar in each set) and EP300 knocked down MTMECs. Statistical 
analysis was performed using a one-way ANOVA test and comparing control (wild type) cell 
to KOEP and KOEP 30/40 cells. Data represent the mean ± SD from at least three biological 
replicates and are statistically significant (*P<0.05, **P<0.01) for the comparison with the 
naive cell.  
 
240 
 
5.4 Brief discussion 
5.4.1 EP300 regulates genes related to apoptosis and drug resistance 
Apoptosis is a highly complex process from the mechanistic point of view and 
involves mainly extrinsic and intrinsic pathways (Elmore 2007) that are 
triggered by various signaling cascades. These depend on the dynamic interplay 
of the apoptosis pathway-related molecules as depicted in the figure 5.21. The 
extrinsic and intrinsic pathways are known to be regulated by initiator caspases, 
specifically caspase-8 and caspase-9, respectively. Both pathways ultimately 
converge into the execution pathway mediated by effector or executioner 
caspases (caspase-3, -6 and -7). The extrinsic apoptotic signals involve 
transmembrane interactions between death receptors of the tumour necrosis 
factor (TNF) receptor gene superfamily, abbreviated as TNFRSF (Locksley, 
Killeen et al. 2001). In MCF-7, EP300 deletion altered the gene expression of 
some of the receptors of this TNFR family. Of particular significance includes 
FAS, TNFRSF10A, TNFRSF10B (Table 5.27) and most importantly, 
TNFRSF11B, the gene encoding osteoprotegerin, a decoy receptor. 
TNFRSF11B binds TNF-related apoptosis-inducing ligand (TRAIL) resulting in 
reduced activation of the TNFR-mediated apoptotic signaling (Emery, 
McDonnell et al. 1998). In the present study, TNFRSF11B has been found to be 
up-regulated in the EP300- MCF-7, HCT-116 and MTMEC cells. Therefore, our 
data indicates that EP300 deletion might lead to drug resistance via apoptosis 
241 
 
evasion by attenuating TNFα-mediated triggering of the external death signals 
(Singh, Shankar et al. 2003, Stumm, Meyer et al. 2004). 
 
 
Figure 5.21: STRING interaction network for Apoptosis (KEGG). Apoptosis involves a 
complex process with a dynamic interaction between numerous molecules as shown. Among 
the most notable include BCL2, CASP9, CASP8, NFKB, and AKT1. 
(http://pathcards.genecards.org/card/apoptosis_%28kegg%29?term=apoptosis).  
 
In MTMEC cells, absence of EP300 led to differential expression of apoptosis-
related genes including TRAF2, TNFRSF11B, BCL2A1, BCL2L10 and CD40. 
However, the observed changes in the expression of these genes was found to 
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be unrelated to the expected outcome and of no significant relevance. Thus, 
EP300- MCF-7 model was used for a thorough transcriptome-based search. In 
this model, EP300 deletion led to remarkable increase in the expression of 
BCL2 as confirmed by qPCR validation in both breast cancer (MCF-7 and 
MTMEC) models as well as in EP300 knocked-out HCT-116 colon carcinoma 
cells. Thus, Bcl-2 expression confirms same data relating EP300 and drug 
resistance in the two breast cancer cell models and support the data shown in the 
previous chapter with HCT-116. This highlights the importance of Bcl-2 
regulation by EP300 in the three model systems from two different tissues and 
its role in the acquisition of drug resistance. 
In the chapter preceding to this, it has been confirmed that cells depleted of 
EP300 express significantly higher Bcl-2, both at the protein and mRNA levels. 
The anti-apoptotic Bcl-2 is responsible for paclitaxel resistance by apoptosis 
inhibition via caspase-9 and by inhibition of mitochondrial cytochrome c release 
and activation of IAPs (inhibitors of apoptosis) (Watanabe, Yasuhira et al. 
2013). As it has been already shown that EP300 deletion blunts caspase-9 
(intrinsic) mediated apoptosis in MCF-7, it can be inferred that this occurs via 
Bcl-2 down-stream of EP300. 
Like Bcl-2, caspase-9 is also inactivated when the PKB/Akt cell survival 
pathway is triggered. In this process, apoptosis evasion occurs via Akt 
inactivation of p27, p21, caspase-9, and Bad and by the activation of mTOR and 
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MDM2 (Hu, Guo et al. 2015). Upstream of the Akt pathway acts focal adhesion 
kinase (FAK) which is activated by ECM-receptor interaction with the 
integrins, viz., integrin-β6 (Li, Liu et al. 2015). In EP300- MCF-7 and MTMEC 
cells, the significant up-regulation of ITGA2 and ITGA3 (expression validated 
by qPCR and array), in addition to ITGB6 (encoding integrin-β6) is indicative 
of the possibility that EP300 depletion leads to apoptosis evasion via ITGA2 
and ITGA3. Since ITGA2 is linked to positive regulation of cell migration and 
adhesion, a ward of caution should be warranted and further definitive study 
confirming its role in apoptosis evasion is required. 
 
Table 5.27: Apoptosis pathway genes altered by EP300 depletion 
AIFM1 ANTXR1 BCL2 BCL2L1 CAPN10 CAPN9 
CASP3 CASP6 CFLAR CHEK2 CLSTN1 ERBB2 
ERBB4 FAS FGFR2 FGFR3 GSK3B IGF1R 
IL1R1 IL1RAP INSR ITGAV ITGB1 JUN 
MAPK6 MDM2 MTOR NRAS NTRK2 PIK3CA 
PIK3R1 PIK3R3 PPP3CB PRKAR1A PRKCA PRKCD 
PRKCI TGFBR2 TNFRSF10A TNFRSF10B TNFSF10 TRADD 
XIAP YWHAG YWHAZ       
 
Beside apoptosis evasion, drug efflux by transporters is another prominent 
mechanism of cancer drug resistance (Hu, Li et al. 2015). Various types of ABC 
(ATP binding cassette) transporters are reported and documented to pump out 
chemotherapeutic agents like 5-FU and paclitaxel from the cancer cells, thus 
inactivating them. For example, up-regulation of ABCB1 (P-glycoprotein) is the 
principal mechanism by which cells become multidrug resistant. Recently, this 
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MDR (multi-drug resistance) phenotype in breast cancer cell has been shown to 
be ABCB1 transporter-independent (Hu, Li et al. 2015) by our group. However, 
in the present study, it has been demonstrated that EP300-downregulated MCF-
7 and MTMEC cells, as well as the EP300 knocked-out HCT-116 cells, up-
regulate another transporter ABCG2, also known as BCRP (breast cancer 
resistance protein). Thus, up-regulation of ABCG2, due to the absence of 
EP300, may lead to an increase in the capacity to transport some 
chemotherapeutic agents. However, as ABCG2 does not transport paclitaxel, the 
resistance described in this study is most likely due to up-regulation of anti-
apoptotic Bcl-2.  
 
5.4.2 EP300 regulates genes related to EMT, stemness, invasion and 
metastasis 
Beside apoptosis evasion, EP300 depletion has been found to impart stem-cell 
and invasive characteristics favouring tumour cell survival and metastasis, as 
clearly demonstrated in the previous chapter. In this chapter, it has been showed 
that EP300 depletion in MCF-7 resulted in alteration of expression of potential 
target genes contributing to breast cancer drug resistance. For example, ABCG2 
and TNFRSF11B have been found to be significantly up-regulated in all EP300- 
MCF-7 cells. A recent study suggested that the overexpression of ABCG2 and 
the expression of stem cell surface markers, e.g. CD44, CD133 and EpCAM, 
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are collectively responsible for chemotherapy failure, tumour recurrence, and 
invasion in colon cancer (Xie, Lv et al. 2014). As the EP300 knocked-out HCT-
116 cells have been shown to acquire CSC characteristics (Chapter 4), ABCG2 
represents a well-known marker for stem cells, like is the case in the 2 breast 
cancer cell models studied in the thesis.  TNFRSF11B, in addition to inhibition 
of TRAIL-mediated apoptosis, can also potentiate tumour growth. Tumour-
derived TNFRSF11B (osteoprotegerin), is reported to enhance tumour growth 
in breast cancer cells (Fisher, Thomas-Mudge et al. 2006). 
Among various GO pathways that have been found highly enriched for the up-
regulated genes in the EP300-deleted MCF-7 are those associated with 
epithelial cell migration, cell growth and proliferation, extracellular matrix 
alteration, cytokine signaling and so on. Specific molecules implicated in these 
processes for example, are those encoded by genes ITGA2, ITGA3, FGFR2, 
TGFB2, BCL2, NPY1R, TNFRSF11B, etc. All of these genes are significantly 
up-regulated upon depletion of EP300. Among these genes, ITGA3 has an 
established role in cancer progression and cell survival. For example, knock-
down of ITGA3 inhibited cancer progression and invasion in prostate cancer 
cell, PCa (Kurozumi, Goto et al. 2015). Liu et al. recently demonstrated 
Neuropeptide Y receptor Y1 (NPY1R) as a novel biomarker in circulating breast 
tumour cells confirming its role in breast cancer metastasis (Liu, Xu et al. 
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2015). Elevated TGFB2 accelerates EMT via down-regulation of E-cadherin 
and vimentin in triple-negative breast cancer cells (Kim, Lee et al. 2015). 
GO enrichment analysis revealed two important KEGG pathways in the EP300 
down-regulated group of genes. These include TGF-β and MAPK signaling 
pathways. Genes that were significantly down-regulated in these two processes 
include BMP7 and DUSP4, respectively.  
Dual specificity phosphatase-4 (DUSP4) is a negative regulator of the mitogen-
activated protein kinase (MAPK) pathway. This enzyme is found to be deficient 
in highly aggressive basal-like and triple-negative breast cancers treated with 
chemotherapy, leading to resistance against taxane-induced apoptosis via 
activation of MAPK signaling. Moreover, in basal-like breast cancers DUSP4 
deficiency has been found to promote the EMT and CSC-like traits via 
increased mammosphere formation and enrichment of CD44+/CD24- population 
(Balko, Schwarz et al. 2013). In the present study, DUSP4 has been found to be 
significantly down-regulated in EP300- MCF-7 cells and their corresponding 
paclitaxel resistance derivatives. In the previous chapter, it had been shown that 
EP300 loss promotes EMT and CSC-like phenotypes by increasing both sphere 
formation efficiency and percentage of CD44high/CD24low population. 
Altogether, this indicates that EP300 depletion might promote EMT and CSC-
traits in breast cancers by down-regulating DUSP4 expression. However, 
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definite studies demonstrating the effect of DUSP4 modulation in presence or 
absence of EP300 should be performed before confirming this. 
Bone morphogenetic protein-7 (BMP7) has been shown to reduce the severity 
of injury-induced fibrosis through counteracting the fibrotic effects of 
transforming growth factor-β 1 (TGF-β1). In breast cancer cells, BMP7 has 
been recently demonstrated to significantly decrease the TGF-β1-activated 
epithelial-mesenchymal transition (EMT)-related genes. As a consequence, this 
resulted a significant reduction in TGF-β1-triggered cell growth and cell 
metastasis (Ying, Sun et al. 2015). This supports our findings that BMP7 is 
remarkably down-regulated in EP300-defiecient MCF-7 cells and that these 
cells demonstrate increased EMT and CSC-like traits. 
Among various molecules that play crucial role in cell adhesion include 
CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) and 
CEACAM6 as appeared in the GO process “anchored to membrane”. Of 
particular importance is CEACAM5, which has been found to be significantly 
down-regulated in EP300- MCF-7 and HCT-116 cells. CEACAM5 plays a 
crucial role in cell adhesion and is widely expressed in various types of cancer 
including breast cancer. It has been identified as a prominent markers for 
disseminated tumour cell (DTC) detection and is lost in metastatic episodes 
(Lacroix 2006). In the present study, qPCR validation for CEACAM5 
demonstrate the possibility that positive regulation of CEACAM5 expression by 
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EP300 might be responsible for increased stemness and EMT during metastasis, 
as evidenced in the EP300- MCF-7 and MTMEC cells. 
SASH1 (SAM and SH3 domain-containing 1) gene is recently identified as a 
tumour suppressor gene that belongs to the SLY (SH3 domain-containing 
expressed in lymphocytes) family (Zeller, Hinzmann et al. 2003). Down-
regulation of SASH1 in a lung cancer cell line has been recently documented to 
augment cell proliferation, invasion and apoptosis (Chen, Chen et al. 2012). 
Low expression of SASH1 is significantly associated with metastasis and 
reduced survival among cancer patients (Martini, Gnann et al. 2011). 
Interestingly, SASH1 expression was previously found to be reduced in breast 
cancer and knock-down of endogenous SASH1 resulted in reduced interaction of 
tumour cells with the stroma in the matrix eventually leading to aggressive 
tumour growth and invasion (Martini, Gnann et al. 2011). In our study, SASH1 
expression was significantly repressed in all shEP300 transfected MCF-7 cells 
and their paclitaxel resistant counterpart. This suggests that absence of EP300 
leads to reduced cell-matrix adhesion, increased cell migration and facilitates 
EMT and invasion via down-regulation of SASH1. However, detail studies 
seeking the effect of SASH1 on EP300-depleted breast cancer cells are 
warranted before inferring any conclusion.  
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5.4.3 Concluding remarks 
Taken together, the array targeting transcriptome of the EP300-deficient MCF-7 
opened up a new avenue for searching down-stream effectors of EP300 that 
potentially mediate drug resistance, EMT and stemness. The targets identified 
will help explore the mechanisms underlying these biological processes and 
pave the way for future drug discovery. In order to establish the involvement of 
the EP300 down-stream target genes, functional validations such as luciferase 
reporter-based and mutational assays would need to be performed. 
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Chapter 6: Correlation between EP300 and E-cadherin Expression in Breast 
Cancers 
6.1  Introduction 
6.1.1 E-cadherin as a biomarker of breast cancer diagnosis 
E-cadherin, encoded by the CDH1 gene, is an important transmembrane 
glycoprotein that mediates epithelial cell-cell adhesion in a calcium-dependent 
manner (Takeichi 1990, van Roy and Berx 2008). It is found in adherence 
junctions, sub cellular structures in the membrane of epithelial tissues that 
mediate cell-to-cell contact. In breast cancer, loss of E-cadherin represents an 
important hallmark of invasion, metastasis and epithelial-to-mesenchymal 
transition (EMT) (Pecina-Slaus 2003). In the clinical setting, E-cadherin is used 
as a biomarker for breast cancer diagnosis (Singhai, Patil et al. 2011). E-
cadherin expression becomes remarkably low or absent in a few subtypes of 
breast cancer, viz. invasive ductal carcinoma (IDC), invasive lobular carcinoma 
(ILC) and metaplastic breast carcinoma (MBC). As EP300 depletion has been 
found to be associated with enhanced invasion and EMT, it is likely that there is 
a correlation of expression between E-cadherin and its transcriptional activator 
EP300. Studying this correlation of expression is deemed to have an immense 
significance in terms of identifying a suitable of diagnostic marker for various 
breast cancer subtypes. 
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6.1.2 Histopathological subtypes of breast cancer 
Histopathologically, breast cancers are classified according to the expression of 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor (HER2) as outlined in Chapter 1. However, the invasive 
forms of breast cancers can be particularly characterised and classified based on 
E-cadherin (Figure 6.1). For example, E- cadherin is almost absent in invasive 
lobular (ILC) and ductal (IDC) carcinomas (Singhai, Patil et al. 2011). Thus, 
ILCs and IDCs are detected from the E-cadherin immunostaining. This has been 
already established clinically that the in situ forms of breast  
 
Figure 6.1: A histopathological classification and evolution of various types of breast 
cancers. Invasive breast cancers arise from the respective in-situ forms that lead to the 
metastatic versions as a consequence of metastasis (McCart Reed, Kutasovic et al. 2015)  
Metaplastic breast carcinoma, characterized by complete loss of E-cadherin (Zhang, Toy et 
al. 2012), may evolve from ductal carcinoma as an outcome of invasion and metastasis. DCIS 
= Ductal Carcinoma In-Situ, LCIS = Lobular Carcinoma In-Situ, IDC = Invasive Ductal 
Carcinoma, ILC = Invasive Lobular Carcinoma.  
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carcinomas, if left undiagnosed and untreated, eventually undergo invasion and 
metastasis and the result is metastatic breast carcinomas which are non-curable.  
Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the 
derived from their respective pre-invasive precursors, i.e., ductal carcinoma in 
situ (DCIS) and lobular carcinoma in situ (LCIS) (Buerger, Simon et al. 2000). 
DCIS and LCIS are two distinct subtypes of breast cancer that differ both 
morphologically as well as histologically. The expression pattern of E-cadherin 
segregates the lobular forms of breast carcinoma from the ductal cancer. E-
cadherin is very low almost completely absent in LCIS and ILC (Buerger, 
Simon et al. 2000). 
ILC accounts for approximately 10% of breast cancers and is characterized by 
small, round or spindle-shaped cells that grow in a characteristic single-file 
pattern and infiltrate into the adjacent stroma without causing a strong 
inflammatory response (Wasif, Maggard et al. 2010). The distinctive non-
cohesive and diffuse growth pattern, which is attributed to the loss of E-
cadherin, and the biology of ILC prevents formation of distinct palpable or 
definite identifiable masses, rendering its diagnosis difficult.  
IDC, also known as infiltrating ductal carcinoma, constitutes approximately 
80% of all diagnosed cases of breast cancer. IDC originates in the epithelial 
cells of the breast, breaks through the wall of the duct, and infiltrates into the 
surrounding adipose tissue of the breast. At this point, IDC may metastasize to 
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other parts of the body through the lymphatic system and bloodstream. Unlike 
the lobular invasive carcinomas (ILC), IDC shows good positivity for E-
cadherin immunoreactivity. Similar to ILC, IDC may also show a dispersed 
growth pattern, including infiltration around benign ducts in a targeted manner 
(Acs, Lawton et al. 2001, Singhai, Patil et al. 2011). 
Metaplastic breast carcinoma is a rare type of breast cancer which occurs in less 
than 5% of the breast cancer patients (Luini, Aguilar et al. 2007). This subtype 
of breast cancer may emerge from IDC as an outcome of further invasion and 
metastasis and undergo metaplasia into a glandular growth pattern (Gunhan-
Bilgen, Memis et al. 2002). Metaplastic breast carcinomas are clinically 
diagnosed from the absence of E-cadherin following IHC staining (Zhang, Toy 
et al. 2012) and unlike other forms of invasive breast cancer, they are not 
associated with estrogen or progesterone receptors (Luini, Aguilar et al. 2007). 
 
6.1.3 Metaplastic breast cancers are characterised by EMT core signatures 
and are enriched in CSC markers 
Microarray-based gene expression analysis revealed an EMT core signature in  
human mammary epithelial cells (HMLE) under the influence of the EMT 
inducing TFs Snail, Twist, TGF-β1 and Gsc (Goosecoid) or in absence of E-
cadherin (by siRNA). As described by Taube et al., this EMT core signatures 
comprised overlapping set of genes that are shared by up-regulation of the EMT 
254 
 
programme inducing TFs mentioned above and by down-regulation of E-
cadherin. Interestingly, the up- and down-regulated genes from the EMT core 
signature were also similarly altered in the metaplastic subtype of breast cancer 
(Taube, Herschkowitz et al. 2010). Specifically, the most commonly up-
regulated EMT genes in the metaplastic cancer included TFs like Snail, Slug, 
Zeb1, Twist and FOXC1 whereas, E-cadherin was found the most significantly 
down-regulated factor.  
Since passage through EMT is associated with the acquisition of CSC-like 
traits, it is suggested that the metaplastic subtype of breast tumours contain 
relatively high proportion of the stem cell markers (Mani, Guo et al. 2008). As 
reported by Zhang et al., primary metaplastic breast carcinomas characterised 
by high ZEB1 and low E-cadherin, were associated with an acquisition of breast 
cancer stem cell marker proteins ALDH1 (aldehyde dehydrogenase 1) and 
CD44+/ CD24−/low (Zhang, Toy et al. 2012). They proved that the EMT inducers 
and tumour-initiating or CSC-like cells are present specifically in the non-
glandular part of metaplastic carcinomas. 
 
6.2  Background information 
In epithelial cancers, the initiation of the cancer metastatic cascade is 
accompanied by a series of cellular and molecular events termed epithelial to 
mesenchymal transition (EMT). Epithelial cells undergoing EMT lose their 
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characteristic morphology and acquire a fibroblast-like shape, increased motility 
and the ability to degrade the extracellular matrix and invade other tissues and 
organs. At the molecular level, the EMT programme is characterized by loss of 
epithelial markers, such as E-cadherin, and expression of mesenchymal 
markers, such as fibronectin, vimentin or N-cadherin. E-cadherin is a 
transmembrane protein with both endo- and ecto-domains. Adjacent cells 
contact via E-cadherin ectodomains, in addition to other structures such as gap 
junctions. The cytoplasmic domain of E-cadherin is linked via β-catenin and 
several other molecules to the actin cytoskeleton, thus helping to keep the 
epithelial architecture. Loss of E-cadherin from the plasma membrane liberates 
β-catenin molecules, which can then accumulate in the cytoplasm, migrate to 
the nucleus, associate with Tcf/LEF and other transcription factors and induce 
the expression of genes orchestrating the EMT programme. EMT inducers, such 
as TGF-β or receptor tyrosine kinase ligands, trigger changes in gene expression 
by complex signalling networks, many of which are still not well understood. 
However, down-regulation of E-cadherin by transcriptional repressors such as 
those belonging to the Snail family (Snail, Slug), the two-handed zinc factors 
Zeb1 and Zeb2, as well as the bHLH factors Twist and E47, is well-studied. 
Importantly, the EMT programme generates cancer cells with stem cell-like 
characteristics (cancer stem cells, CSCs), adult stem cells which have acquired 
tumourigenic properties and drive tumour growth and progression due to their 
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unlimited proliferative potential. These two phenomena, EMT and CSCs, are 
often associated with the acquisition of drug resistance (Mani, Guo et al. 2008, 
Scheel and Weinberg 2012).  
We have recently described a novel EMT regulatory axis controlled by the miR-
106b~25 cluster down-regulating the E-cadherin transcriptional activator EP300 
(Figure 6.2) (Zhou, Hu et al. 2014, Hu, Li et al. 2015). EP300 targets the E-
cadherin gene promoter (Liu, Lee et al. 2005) and functions as a histone 
acetyltransferase that regulates transcription via chromatin remodelling, 
acetylating all four core histones in nucleosomes. Loss of EP300 heterozygosity 
has been described in colon, breast and ovarian carcinomas (Bryan, Jokubaitis 
et al. 2002). In addition, somatic mutations in EP300 have been identified in 
several malignancies (Gayther, Batley et al. 2000). Importantly, EP300-
deficient colon carcinoma HCT-116 cells show phenotypic changes 
characteristic of EMT (Krubasik, Iyer et al. 2006), in line with the results 
reported recently by us. 
 
 
 
Figure 6.2: The miR-106b~25 cluster regulates EMT. MiRs in the miR-106b~25 cluster 
target the E-cadherin transcriptional activator EP300 and activate the EMT programme which 
is characterized by an increase in drug resistance and gain of CSC properties. The cartoon is 
based on work recently published by our group (Zhou, Hu et al. 2014). 
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6.3  Hypothesis of the study 
In last chapter (Chapter 5), it has been demonstrated that EP300 down-
regulation leads to drug resistance (by genes associated with apoptosis), EMT 
and CSC phenotypes, particularly in MCF-7 cells. It has been also shown 
(Chapter 3) that EP300 positively regulates E-cadherin in the same cell line. 
Since E-cadherin loss is a hallmark of EMT, we next hypothesised that in breast 
cancer EP300 contributes positively to the expression of E-cadherin. Therefore, 
we aimed to study whether loss of E-cadherin expression in a variety of breast 
cancer subtypes correlates with loss of EP300.  
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6.4  Materials and methods 
In order to study the correlation between EP300 and E-cadherin expression, we 
aimed to collect FFPE breast cancer samples from the Imperial College 
Healthcare Tissue Bank for immunohistochemical (IHC) staining using 
commercially available antibodies against EP300 and E-cadherin (CDH1). 
 
6.4.1 Tissue bank application  
We applied to Imperial College Healthcare Tissue Bank for clinical samples as 
described below. After approval was obtained (Imperial College Hospital Tissue 
Bank approval no. R14086, as approved on 20th September, 2014), we retrieved 
the corresponding FFPE blocks from the bank and 10 μm-thick microtomic 
sections were cut (3 slides per sample).  
 
6.4.2 Sample description 
As a preliminary study, we aimed to obtain 70 FFPE samples (Table 6.1) from 
various types of breast cancer with expected low E-cadherin levels. As controls, 
we used normal breast tissue and from those with expected high levels of E-
cadherin.  
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Table 6.1: Description of clinical samples  
Type Sample Description E-cadherin 
levels 
No. of 
samples 
Control 
Normal/benign breast tissue normal 
(physiological) 
10 
E-cadherin positive invasive 
breast carcinomas 
high 20 
Study Group I 
(E-cadherin 
negative breast 
cancer) 
Invasive lobular carcinoma 
(ILC) 
low 20 
Non-invasive, in-situ lobular 
neoplasia (LCIS) 
low 10 
Study Group II 
(E-cadherin low 
breast cancer) 
Invasive, E-cadherin low 
metaplastic breast carcinoma 
low 10 
Total 70 
 
6.4.3 Antibody used 
The antibodies used for EP300 and E-cadherin staining are described in Table 
6.2. E-cadherin antibody is routinely used, and has previously been validated in 
the Histopathology Lab at Charing Cross Hospital, where this study was 
performed. Staining for EP300 is not routinely used in the clinic, although we 
chose a commercial antibody used in the generation of data for the Human 
Protein Atlas. 
 
Table 6.2: Description of antibody used 
Antibody  Source 
(Manufacturer) 
Cat. No. Species 
(Host) 
Clonality Dilution 
Anti EP300 Sigma Life Sciences HPA003128 Rabbit Polyclonal 1:200 
Anti E-cadherin BD Biosciences 610181 Mouse Monoclonal 1:200 
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6.4.4 Staining for EP300 and E-cadherin by immunohistochemistry 
Before staining for EP300, the anti-EP300 antibody was validated for its 
specificity by a protocol as outlined below in Section 6.4.5. For staining, we 
followed the SOP for immunohistochemical staining routinely used in the 
Charing Cross Histopathology Lab (Q-Pulse index Code: CEL-LP-172-X, Ver. 
1.6, 2013), with a slight modification. We used the Bond® Polymer Refine 
Detection Kit (catalog no. DS9800) from Leica Biosystems (Newcastle, UK) for 
the detection of antigen-binding sites. All sections were visualized with 
diaminobenzidine (DAB), counterstained with haematoxylin, and mounted in 
PERTEX®. All the staining and detection steps were followed as outlined 
briefly in Table 6.3. 
 
Table 6.3: Staining and detection protocol 
A. Deparaffinization  
1. In Xylene - for 30 min 
2. In Xylene - for another 30 min 
3. In 100% ethanol - for 10 min 
4. In 90% ethanol - for 10 min 
5. In 70% ethanol - for 10 min 
6. In distilled water - for 5 min 
B. Antigen Retrieval 
1. Preheating the chamber of a water bath for approx. 30 min. 
2. Heating in the presence of citrate buffer (pH 6.0) for 30 min. 
3. Cooling down to room temperature. 
4. Washing in PBS (1 quick wash followed by 2 subsequent washes, each for 5 min.). 
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Table 6.3: Staining and detection protocol (contd.) 
C. Antibody Treatment 
1. Preparing the antibody working solution by appropriate dilution in PBS. 
2. Marking the area of the slide containing the tissue with an Immedge® hydrophobic pen (Vector H-
1007). 
3. Adding the diluted antibody solution drop-by-drop from top of the slide to cover the area marked. 
4. Incubating the slides at 4°C (in a freeze) kept in a slide tray (soaked with wet tissue paper to ensure 
proper hydration to avoid drying out) for overnight. 
D. Washing 
1. A quick rinse in PBS followed by 2 subsequent washes, each for 5 min. 
E. Peroxide Block 
1. Adding H2O2 solution, 3-4% (w/v), after a quick rinse with PBS. 
2. Incubating at room temperature for 30 min. with the lid on. 
3. A quick rinse off with PBS followed by 2 washes, each for 5 min. 
F. Post-primary Treatment 
1. Applying on top of the slides the post-primary solution containing rabbit anti-mouse IgG (<10 
µg/mL) in 10% (v/v) animal serum in tris-buffered saline (0.09% ProClin ™ 950). 
2. Incubating at room temperature for 20 min. with the lid on. 
3. A quick rinse off with PBS followed by 2 washes, each for 5 min. 
G. Polymer Treatment 
1. Adding the polymer solution, containing anti-rabbit Poly-HRP-IgG (<25 µg/mL) in 10% (v/v) 
animal serum in tris-buffered saline (0.09% ProClin ™ 950). 
2. Incubating at room temperature for 30 min. with the lid on. 
3. A quick rinse off with PBS followed by 2 washes, each for 5 min. 
H. DAB Treatment 
1. Adding the premixed DAB solution containing DAB Part A (66 mM DAB in a stabilizer solution) 
DAB Part B (containing ≤0.1% v/v of H2O2 in a stabilizer solution). 
2. Waiting for the colour to develop (not more than 3 min.) as observed under the microscope.  
3. Counterstaining in hematoxylin (< 0.1%) solution followed by an acid-alcohol solution. 
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Table 6.3: Staining and detection protocol (contd.) 
I. Dehydration 
1. Switching on the down flow work station. 
2. Dipping the slides (not more than 1-2 dip) in 50%, 70% and then in 100% alcohol. 
3. Dipping the slides (not more than 1-2 dip) in 2 containers containing xylene. 
J. Mounting and Cover-slipping 
1. Adding the PERTEX® solution (1-2 drop) on top of a cover slip. 
2. Putting the slide with the stained side down on to the cover slip. 
 
6.4.5 Validation of anti-EP300 antibody by a peptide competition binding 
assay 
The specificity of the polyclonal anti-EP300 antibody was determined by a 
peptide competition assay. For this blocking experiment, we used a recombinant 
human PrEST (Protein Epitope Signature Tag) antigen EP300 (APrEST73567) 
from Atlas Antibodies® as the blocking agent for the corresponding anti-EP300 
antibody (HPA003128) as recommended by the manufacturer (Table 6.4). 
 
Table 6.4: Blocking conditions 
Condition Description 
Control Only secondary antibody, and no primary antibody   
Anti-EP300 Antibody Only anti-EP300 antibody, and no antigen  
+ 10X competing peptide The competing peptide at a 10X anti-EP300 concentration along 
with the antibody 
+ 100X competing peptide The competing peptide at a 100X anti-EP300 concentration 
along with the antibody 
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In brief, the blocking assay was carried out by following the steps as described 
below: 
i. The amount required for 10x and 100x molar excess of the PrEST 
Antigen was calculated based on concentrations and MWs of antibody 
(13,800 Da) and PrEST Antigen (31,000 Da). 
ii. The calculated amount of the respective antibody and the PrEST antigen 
were mixed in 1.5ml tubes and adjust total volume to 30 - 50 μl with 
PBS. 
iii.  The tubes containing antibody/PrEST antigen were incubated at 4°C 
overnight with gentle shaking in a rotary shaker. As a control, the 
primary anti-EP300 antibody was used without the antigen.  
iv. All the tubes with the antibody/PrEST antigen mix were centrifuged for 
15 minutes at max speed (15,000 rpm) to pellet any immune complex. 
v.  The supernatants were transferred into new tubes to prepare working 
solutions for immunostaining. Since the antibody was diluted 4 - 12 
times, the volumes of antibody diluent were adjusted accordingly. 
vi. Finally, the IHC experiments were carried out according to the protocol 
outlined in Section 6.4.4 using 2 samples for each condition (Table 6.4). 
 
 
264 
 
6.4.6 Immunohistochemical scoring 
The average intensity of positively stained cells was scored independently by 
myself, Dr. Yagüe (breast cancer scientist) and Prof. Shousha (professional 
pathologist) and blinded to the clinico-pathological data of the cases in order to 
remove bias. The cases were further verified by Prof Coombes (clinical 
oncologist), who scored representative cases from each group used in the study.  
The IHC scoring was performed semi-quantitatively on a scale of 0 to 3 (0, not 
stained; 1, weak; 2, intermediate; and 3, strong) based on the staining intensity 
(Liu, Jiang et al. 2010), and for both EP300 and E-cadherin. Representative 
examples are shown in Supplementary Table S6.1. More than six representative 
fields of each slide were analyzed for determining EP300 and E-cadherin 
expression levels. IHC score ≥2 and <2 were considered high and low EP300, 
respectively. For E-cadherin, IHC score >1 and ≤1 were taken as high and low 
expression, respectively. 
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6.5  Results 
6.5.1 High EP300 levels are associated with better survival 
A Kaplan-Meier Plot comparing breast cancer specific survival among breast 
cancer patients in a large cohort comprising a total of 4142 patients using an 
online tool (http://kmplot.com/analysis/index.php?p=service&cancer=breast) 
confirmed that high EP300 and high E-cadherin are good prognostic indicators 
(Figure 6.3). Therefore, we decided to explore if there was any correlation 
between the expression levels of E-cadherin and its transcriptional activator 
EP300 in breast tumours.  
 
 
Figure 6.3: Kaplan–Meier curves comparing breast cancer specific survival in breast 
cancer patients. Entire analyzed cohort (n = 4142) for A. EP300 (P = 3.2e-07) and B. E-
cadherin (P = 1.7e-09). Patient population was split at the median for each gene. The plots 
were generated using KM Plotter by excluding the all redundant samples and all biased arrays 
from the entire database (2014 version). 
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6.5.2 Immunohistochemical staining of EP300 and E-cadherin in various 
subtypes of breast cancer 
In order to find out whether there was a correlation between EP300 and E-
cadherin expression in breast cancer patients, we stained three equivalent FFPE 
sections of each case for H&E, EP300 and E-cadherin. We first validated the 
anti-EP300 antibody by using a peptide competition assay. A 10-fold molar 
excess of the antigen did suffice to cancel most of the antibody binding signal, 
and a 100-fold molar excess ablated it completely (Figure 6.4). This confirms 
the specificity of the EP300 antibody and its suitability for IHC. 
 
 
Figure 6.4: Validation of anti-EP300 antibody for immunostaining. Pre-incubation with a 
competing peptide PrEST EP300 antigen in presence or absence of the antibody in 2 different 
samples confirmed the specificity of the antibody. The upper panel (A, C, E, G and I) and the 
lower panel (B, D, F, H and J) represents the corresponding images from the 2 samples. H&E 
staining (A, B), only secondary and no antibody (C, D), EP300 staining (E, F), antibody + 
10X peptide (G, H) and antibody + 100X peptide (I, J) are shown. Bar represents 200 µm. 
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In normal breast tissues, both EP300 and E-cadherin staining showed, as 
expected, intense signals (IHC score 3; Figure 6.5). 
 
Figure 6.5: EP300 and E-cadherin Expression in normal breast tissues. Strong IHC 
staining for both EP300 and E-cadherin in normal and benign breast tissues. All staining 
images including H&E staining are shown at 3 different magnifications (20X, 40X and 60X). 
The images are representative examples from one of the nine cases from the normal breast 
tissue. Bar represents 200 µm for the left (20X) and middle (40X) panels and 100 µm for the 
right (60X) panel. 
 
When invasive ductal carcinoma (IDC) cases were analysed, their IHC score 
varied from 1 to 3, indicating low (Figure 6.6) to moderate (Figure 6.7) 
expression for both EP300 and E-cadherin. 
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Figure 6.6: EP300 and E-cadherin expression in invasive ductal carcinoma (IDC). IHC 
staining for both EP300 and E-cadherin showing low expression of these 2 proteins. All 
staining images including H&E staining are shown at 3 different magnifications (20X, 40X 
and 60X). The images are representative examples from one of the IDC cases with low 
expression. Bar represents 200 µm for the left (20X) and middle (40X) panels and 100 µm 
for the right (60X) panel. 
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Figure 6.7: EP300 and E-cadherin expression in invasive ductal carcinoma (IDC). IHC 
staining for both EP300 and E-cadherin showing moderate expression of these 2 proteins. All 
staining images including H&E staining are shown at 3 different magnifications (20X, 40X 
and 60X). The images are representative examples from one of the IDC cases with moderate 
expression. Bar represents 200 µm for the left (20X) and middle (40X) panels and 100 µm 
for the right (60X) panel. 
 
 
In invasive lobular carcinoma (ILC), however, most of the cases had low 
expression of both EP300 and E-cadherin (Figure 6.8) with a few exceptions 
where these two proteins were expressed relatively at a moderate level (Figure 
6.9). The IHC scores for these ILC cases varied mostly from 0 to 2, with 
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exceptions of 2 cases for which IHC scores were 3 for both EP300 and E-
cadherin.  
 
Figure 6.8: EP300 and E-cadherin expression in invasive lobular carcinoma (ILC). IHC 
staining for both EP300 and E-cadherin showing low expression of these 2 proteins. All 
staining images including H&E staining are shown at 3 different magnifications (20X, 40X 
and 60X). The images are representative examples from the ILC cases with low expression. 
Bar represents 200 µm for the left (20X) and middle (40X) panels and 100 µm for the right 
(60X) panel. 
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Figure 6.9: EP300 and E-cadherin expression in invasive lobular carcinoma (ILC). IHC 
staining for both EP300 and E-cadherin showing moderate expression of these 2 proteins. All 
staining images including H&E staining are shown at 3 different magnifications (20X, 40X 
and 60X). The images are representative examples from the ILC cases with high or moderate 
expression. Bar represents 200 µm for the left (20X) and middle (40X) panels and 100 µm 
for the right (60X) panel. 
 
 
Both EP300 and E-cadherin levels were low (Figure 6.10) in lobular carcinoma 
in situ (LCIS) with IHC scores varying from 0 to 2. 
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Figure 6.10: EP300 and E-cadherin expression in lobular carcinoma in situ (LCIS). IHC 
staining for both EP300 and E-cadherin in showed low expression profile for these 2 proteins. 
All staining images including H&E staining are shown at 3 different magnifications (20X, 
40X and 60X). The images are representative examples from one of the LCIS cases. Bar 
represents 200 µm for the left (20X) and middle (40X) panels and 100 µm for the right (60X) 
panel. 
 
 
Metaplastic breast carcinoma (MBC) is a rare form of the disease and only a 
few cases could be found in the Charing Cross Hospital archives. Nonetheless, 
all cases studied cases all had very low expression of both EP300 and E-
cadherin (Figure 6.11) with IHC scores varying between 0 and 1. 
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Figure 6.11: EP300 and E-cadherin expression in metaplastic breast carcinoma (MBC). 
IHC staining for both EP300 and E-cadherin in showed low expression profile for these 2 
proteins. All staining images including H&E staining are shown at 3 different magnifications 
(20X, 40X and 60X). The images are representative examples from one of the MBC cases. 
Bar represents 200 µm for the left (20X) and middle (40X) panels and 100 µm for the right 
(60X) panel. 
 
6.5.3 EP300 expression correlates with E-cadherin expression in breast 
cancers 
We analysed a total of 63 samples for EP300 and E-cadherin expression by 
IHC. These comprised nine normal or benign breast tissues, as well as twenty 
IDC, twenty one ILC, six LCIS and seven metaplastic cases. In all of these 
samples, we observed some distinct patterns in terms of expression of both 
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EP300 and E-cadherin. Normal tissues showed a consistent strong expression of 
both EP300 and E-cadherin (Figure 6.12). Interestingly, when all cancer 
samples were considered, and a Fisher’s exact probability test was performed 
using the 2x2 contingency table (Table 6.5), we observed a highly significant 
concordance between EP300 and E-cadherin (P < 0.00001). This strongly 
supports our laboratory studies (Zhou, Hu et al. 2014, Hu, Li et al. 2015) and 
previous literature (Liu, Lee et al. 2005) regarding E-cadherin control by 
EP300. However, we also found (Table 6.5 and 6.6) some cases of in situ 
lobular (LCIS) and invasive ductal (IDC) and lobular (ILC) types with a 
negative correlation, either EP300high/E-cadherinlow (n = 10, 16%) or 
EP300low/E-cadherinhigh (n = 4, 6%). Importantly, we found positive correlation 
(Table 6.6) in 78% of cases. Although we only had a small number of samples, 
we found 100% correlation in the metaplastic breast carcinoma cases (n = 7) in 
which all samples were very low for both EP300 and E-cadherin and in the 
normal breast tissues (n =9) in which all samples were strongly positive for 
both. The other subtypes of breast cancer used in the study also had remarkable 
positive correlation (Table 6.6 and Figure 6.12). 
 
Table 6.5: Correlation between EP300 and E-cadherin among breast carcinoma patients  
  E-cadherinhigh E-cadherinlow  Fisher’s Exact Test 
EP300high 27 10 
P<0.00001 
EP300low 4 22 
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Among the positively correlated cases, the distribution of various subtypes of 
breast cancer cases for EP300high/E-cadherinhigh and EP300low/E-cadherinlow 
categories (Figure 6.13) show that all the metaplastic carcinoma cases belong to 
the EP300low/E-cadherinlow category. 
 
Table 6.6: Pattern-wise distribution of cases among tumour subtypes types showing 
correlation of expression between EP300 and E-cadherin 
Breast Cancer Subtypes  
(No. of Cases) 
Pattern, No. (%) 
  
Percentage 
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with positive 
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IDC (20) 10 (50) 6 (30) 2 (10) 2 (10) 80 
ILC (21) 7 (33) 6 (29) 7 (33) 1 (5) 62 
LCIS (6) 1 (17) 3 (50) 1 (17) 1 (17) 67 
Metaplastic Breast Carcinoma (7) 0 (0) 7(100) 0 (0) 0 (0) 100 
Normal and Benign (9) 9 (100) 0 (0) 0 (0) 0 (0) 100 
Total (63) 27 (43) 22 (35) 10 (16) 4 (6) 78 
Positive Correlation (49) Y Y N N 
IDC = Invasive Ductal Carcinoma, ILC = Invasive Lobular Carcinoma, LCIS = Lobular Carcinoma in situ, Y = yes, N = 
no. Due to the small sample numbers in each subtype, no statistical analysis was performed.  
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Figure 6.12: Distribution of cases having positive correlation for EP300 and E-cadherin 
expression. Each bar represents the percentage of positively correlated cases for the 
respective subtypes of breast cancer. It is noticeable that all the normal and metaplastic cases 
showed positive correlation between EP300 and E-cadherin expression (EP300high/E-
cadherinhigh and EP300low/E-cadherinlow, respectively). Other subtypes showed variable yet 
strong correlations. 
 
 
In order to better understand the correlation between EP300high/E-cadherinhigh 
and EP300low/E-cadherinlow categories from the clinical and histopathological 
point of view, patients’ data were accessed from the NHS CTIS (Cancer 
treatment information system) of Imperial College London, Charing Cross 
Hospital. These data included patient age, receptor (ER/PR/HER2) status, 
tumour type, grade and stage. Representative examples for the IDC cases are 
shown in Supplementary Table S6.2. A comparison on patients’ characteristics, 
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tumour type and biomarkers between EP300high/E-cadherinhigh and EP300low/E-
cadherinlow groups are shown in Table 6.7.  
 
Table 6.7: Patients' characteristics and biomarkers showing EP300 and E-cadherin 
expression 
Variable/Biomarker EP300 vs. E-cadherin (CDH1) expression P-value 
  High EP300 vs. high 
CDH1 (%) 
Low EP300 vs. low 
CDH1 (%) 
Total 28 (57.1) 21 (42.9)  
Patient's age (years)      
 ≤50 13 (50) 3 (15) 
0.0001 
 >50 13 (50) 17 (85) 
Grade      
1 2 (10.5) 2 (9.5) 
 
2 12 (63.2) 11 (52.4) 
3 4 (21.2) 6 (28.6) 
Not known 1 (5.3) 2 (9.5) 
Stage      
1 9 (47.4) 6 (28.6) 
 
2 7 (36.8) 3 (14.3) 
3 1 (5.3) 4 (19.0) 
Not known 2 (10.5) 8 (38.1) 
Tumour type      
Normal and benign 9 (32.1) 0 (0) 
 
Metaplastic 0 (0.0) 7 (33.3) 
IDC 10 (35.7) 6 (28.6) 
ILC  7 (25.0) 6 (28.6) 
LCIS 1 (3.6)   3 (14.3) 
Estrogen receptor      
Positive 13 (68.4) 10 (47.6)  
Negative 3 (15.8) 5 (23.8)  
Not known 3 (15.8) 6 (28.6)  
Progesterone receptor      
Positive 13 (68.4) 7 (33.3)  
Negative 3 (15.8) 8 (38.1)  
Not known 3 (15.8) 6 (28.6)  
HER2 receptor      
Positive 2 (10.5) 1 (4.8)  
Negative 14 (73.7) 14 (66.7)  
Not known 3 (15.8) 6 (28.6)  
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Normal and Benign
LCIS
IDC
ILC
Metaplastic
Tumor type High vs high Low vs low
EP300 vs E-cadherin
Figure 6.13: Distribution of subtypes of breast cancers in EP300high/E-cadherinhigh and 
EP300low/E-cadherinlow categories. Note that metaplastic cases had low expressions for both 
EP300 as well as E-cadherin, as compared to the normal and benign cases, expressing these 
two proteins at higher proportion. 
 
It is noteworthy that cases with low EP300 and low E-cadherin (EP300low/E-
cadherinlow) had a higher mean age (67 year) as compared to those having high 
EP300 and high E-cadherin (EP300high/E-cadherinhigh). Strikingly, the 
differences in age distributions between the two groups was highly significant, 
as indicated by the Mann-Whitney U test (Table 6.7 and Figure 6.14). No 
apparent correlations were observed among the cases in terms of either tumour 
grade (Figure 6.15) or tumour stage (Figure 6.16). However, due to the small 
number of samples in each cancer subtype, we could not perform any 
meaningful statistical analysis to determine correlations between EP300 and E-
cadherin levels in the individual types. 
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Figure 6.14: Distribution of patients according to age in EP300high/E-cadherinhigh 
(depicted as High vs. high) and EP300low/E-cadherinlow (mentioned as Low vs. low) 
categories. Note that the later category had a significantly high mean age, as shown in the 
box plot and that the age distribution shown here is irrespective of the subtypes. Data in each 
box represent Mean±SEM, and the whiskers show minimum to maximum ages, for the 
respective category. Mann-Whitney U-test indicated that the difference between the 
parameters of both distributions was statistically highly significant (P = 0.0001). 
 
Since this was an exploratory study and as very few samples from various sub 
group were selected, intensive studies including more samples from each sub-
groups is required to establish EP300 and E-cadherin as independent prognostic 
factors. However, we found a strong association between EP300 and E-cadherin 
co-expression with age of the patients. Due to the small sample size, cox 
regression could not be done. 
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Figure 6.15: Distribution of patients according to tumour grade in EP300high/E-
cadherinhigh and EP300low/E-cadherinlow categories.  
 
 
 
Figure 6.16: Distribution of patients according to tumour stage in EP300high/E-
cadherinhigh and EP300low/E-cadherinlow categories.  
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6.6  Brief discussion 
In this chapter we have investigated the correlation between EP300 and E-
cadherin expression among the major histopathological subtypes of breast 
cancer. This was based on the findings that absence of EP300 triggers EMT, a 
hallmark for the invasive, metastatic cancers and that the membrane-bound E-
cadherin levels are gradually lost with the progression of the invasion and 
metastasis. Among the various subtypes of invasive breast cancers, IDC (50-
80%) occurs most frequently, whilst ILC (5-15%) is much rarer, whereas, 
metaplastic breast carcinoma (<5%) is present as a distinct yet very rare 
histological subtype with poor prognosis and survival rate (Weigelt, Peterse et 
al. 2005, Luini, Aguilar et al. 2007, Jagtap, Bhosale et al. 2015). In the present 
chapter, we present evidence of strongest correlation between EP300 and E-
cadherin in all metaplastic cases, with a low expression for both of the proteins. 
Morphologically, metaplastic breast carcinoma (MBC) may be either purely 
epithelial or mixed epithelial-mesenchymal with a triple negative component 
(McKinnon and Xiao 2015). As an aggressive type of breast carcinoma (Zhang, 
Lv et al. 2015), MBC generally expresses CD44 but not CD24 antigen, 
suggesting the presence of CSC-like features (Hennessy, Gonzalez-Angulo et 
al. 2009). In Chapter 4, it has been clearly demonstrated that absence of EP300 
leads to an EMT-like feature with concomitant loss of E-cadherin and a CSC-
like phenotype characterised by the presence of high CD44 and low CD24 
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antigens. Thus, it might be possible that in addition to E-cadherin, assessment of 
EP300 expression would provide valuable prognostic information in metaplastic 
subtype of breast cancer. Other invasive subtypes of breast cancer like IDC and 
ILC also showed good correlation for expression of EP300 and E-cadherin. 
Thus, it may be generalized that irrespective of the individual histopathological 
subtypes, all invasive forms of breast cancers can be characterized by a low 
expression of both EP300 and E-cadherin. In chapter 3, it has been shown that 
modulation of EP300 alters the expression of E-cadherin which is in line with 
previous findings (Zhou, Hu et al. 2014, Hu, Li et al. 2015). All these findings 
highlight the importance of EP300 as a prognostic marker for breast cancers, 
particularly of the invasive and the metastatic subtypes. 
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Supplementary Table S6.1: Representative examples of IHC scoring showing  
correlation between EP300 and E-cadherin 
No. Sample Type 
IHC score for  
Positive 
Correlation 
EP00 E-cadherin 
Nuclear/Total* Membrane 
1 Normal & benign 3 3 Y 
2 Normal & benign 2 2 Y 
3 Normal & benign 3 2+ Y 
4 Normal & benign 2+ 2+ Y 
5 Normal & benign 3 2+ Y 
6 Normal & benign 2 2 Y 
7 Normal & benign 2+ 1,2 Y 
8 Normal & benign 2+ 2+ Y 
9 Normal & benign 3 2 Y 
10 Metaplastic 0,1 0,1 Y 
11 Metaplastic 1,2 0,1 Y 
12 Metaplastic 1,2 1,2 Y 
13 Metaplastic 1,2 0 Y 
14 Metaplastic 1,2 0 Y 
15 Metaplastic 1,2 0 Y 
16 Metaplastic 1 1 Y 
Y = Yes, *total EP300 means staining in both nucleus and cytoplasm and are shown in italics 
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Supplementary Table S6.2: Patient histopathology data for representative cases from IDC  
No. Type Age 
(Year) 
TNM T N M Node 
positivity 
Grade Tumour 
dimension 
(mm) 
ER PR HER2 
1 IDC 66 pT2N2a 2 2a Y Y(5/43) 3 30 7(8) 3(8) - 
2 IDC 58 pT1cN1a 
(sn) 
1c 1a Y Y(1/3) 2 17 8(8) 5(8) - 
3 IDC 74 pT2N0 
(sn) 
2 0 N N(0/1) 2 25 8(8) 6(8) - 
4 IDC 59 pT1cN0 
(sn) 
1c 0 N N(0/2) 2 18 8(8) 7(8) 1+ (-) 
5 IDC 57 pT1cN0 
(sn) 
1c 0 N N(0/2) 2 16.8 8(8) 8(8) - 
6 IDC 73 pT2N2a 2 2a Y Y(4/28) 2 26 7(8) 0(8) - 
7 IDC 68 pT1cN1a 
(sn) 
1c 1a Y Y(3/4) 2 44 8(8) 4(8) - 
8 IDC 67 pT2N0 
(sn) 
2 0 N N(0/1) 1 25 8(8) 8(8) - 
9 IDC 73 pT2N0 
(sn) 
2 0 N N(0/1) 2 38.8 8(8) 5(8) 3+ 
10 IDC 66 pT2N0 
(sn) 
2 0 N N(0/1) 2 39 8(8) 7(8) - 
11 IDC 71 pT2N0 
(sn) 
2 0 N N(0/2) 2 40 8(8) 6(8) - 
12 IDC 60 pT1cN0 
(sn) 
1c 0 N N(0/1) 1 18 2(8) 0(8) - 
13 IDC 73 pT2N2a 2 2a Y Y(6/24) 3 40 5(8) 0(8) 3+ 
IDC = Invasive Ductal Carcinoma; TNM = Tumour, Node, Metastases; T = Tumour Size; N = Node (lymph nodes); M = Metastases; 
ER = Estrogen Receptor; PR = Progesterone Receptor; HER2 = Human Epidermal Receptor 2 
 
 
 
 
 
 
285 
 
Chapter 7: Discussion and Future Directions 
 
In breast cancer, treatment failure due to emergence of drug resistance has 
always been a concern for the clinicians and researchers as this has a profound 
impact on patient relapse and morbidity. Resistance to chemotherapy is 
multifactorial but the greatest emphasis is given upon the so-called ‘axis of evil’ 
(Figure 7.1), that comprises drug resistance (DR), epithelial-to-mesenchymal-
transition (EMT) and cancer stem-cell (CSC) which are tightly interlinked 
(Singh and Settleman 2010). 
 
Figure 7.1: The so-called ‘axis of evil’ connecting drug resistance (DR), epithelial-to-
mesenchymal-transition (EMT) and cancer stem cell (CSC). In cancer, these phenotypes 
are interconnected to each other (Singh and Settleman 2010). 
 
Regardless of the fact that tumours are histologically heterogeneous, subsets of 
cancer cells exhibiting distinct molecular profiles (Gupta, Chaffer et al. 2009) 
within the same tumour respond differently to anticancer therapeutics, leading 
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to drug resistance (Zhou, Zhang et al. 2009). In epithelial cancers, adaptive 
changes following therapy involve epithelial to mesenchymal transitions (EMT) 
as the first step in the metastatic cascade, although the reverse process, 
mesenchymal to epithelial transitions (MET), is crucial for those metastatic 
cells to generate secondary tumours, which are normally drug resistant. 
Interestingly, EMT elicits reversion to a CSC-like phenotype in a variety of 
systems (Mani, Guo et al. 2008, Polyak and Weinberg 2009). However, 
although this is well-established in breast cancer, recent data on mouse models 
of breast and pancreatic cancers indicate a stronger role for EMT in the 
generation of drug resistance than in the metastatic process (Fischer, Durrans et 
al. 2015, Zheng, Carstens et al. 2015).  
The present study aimed to evaluate drug resistance markers that are potentially 
implicated in breast cancers and investigate their potential roles in 
chemotherapy resistance via CSC- and EMT-like processes. Nicastrin, an 
integral part of the complex multi-component γ-secretase enzyme, was our first 
candidate. Previous work in our laboratory indicated that  nicastrin has crucial 
roles in tumour growth and invasion (Lombardo, Filipovic et al. 2012) as well 
as  the ability to alter the sensitivity of the basal-like breast cancer cells to the 
anti-proliferative effects of EGFR inhibition (Dong, Li et al. 2010).  
In order to assess the role of nicastrin in breast cancer chemoresistance, two 
stably transfected cell line models in which nicastrin expression was 
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experimentally modulated were used, MCF-7 cells over-expressing nicastrin 
and HCC-1806 cells stably expressing shRNA targeting nicastrin. As a 
preliminary test, short-term drug sensitivity and long-term drug resistance 
assays were employed to investigate whether the effect of experimental 
nicastrin modulation can alter the sensitivity to three chemotherapy agents: 
doxorubicin, etoposide and paclitaxel. Nicastrin modulation could not initiate 
any observable change in behaviour toward the selected chemotherapy agents. 
In this context, it is worth mentioning that nicastrin overexpression has been 
previously shown to confer resistance against tamoxifen via EMT (Lombardo, 
Faronato et al. 2014). Tamoxifen as an anti-estrogen agent, has a different mode 
of action when compared with conventional chemotherapeutic agents. 
Doxorubicin (Adriamycin®) is a cytotoxic agent with a complex mechanism of 
action, although it is well established for its DNA damage capacity, whereas 
etoposide exerts its anti-cancer effect by inhibition of topoisomerase II. 
Paclitaxel, unlike the other two drugs mentioned, acts as a mitotic poison and 
elicits its anti-tumour effects by mitotic arrest and induction of apoptosis. Thus, 
it is likely that nicastrin-mediated drug resistance is context-dependent and, 
although nicastrin modulation is important in modifying sensitivity toward 
endocrine therapy, it does not offer any benefit in altering chemosensitivity 
toward conventional agents. This is reinforced further from the fact that 
combination of a γ-secretase inhibitor (GSI) with doxorubicin, etoposide or 
288 
 
paclitaxel does not alter the cell survival in nicastrin overexpressed MCF-7 
cells. Intriguingly, nicastrin stable knock-down in aggressive, basal and triple-
negative line HCC-1806 had slightly more reduction in the cell survival but 
without any potential benefit of combining the GSI agent. However, nicastrin 
regulates breast cancer stem cell propagation and invasion in vitro and tumour 
growth in vivo (Lombardo, Filipovic et al. 2012). Thus, although nicastrin 
controls some of the characteristic associated with the "axis of evil" (Figure 
7.1), its partial control on drug resistance did not make it worth further studies 
at this stage. 
As mentioned earlier, chemotherapy resistance is often accompanied by 
acquisition of an EMT phenotype and by exhibition of CSC-like property. 
Recently it has been shown by our group that EP300, a transcriptional co-
activator of E-cadherin expression is involved in mediating doxorubicin, γ-
radiation (Zhou, Hu et al. 2014) and paclitaxel (Hu, Li et al. 2015) resistance via 
evasion of drug-induced senescence and apoptosis, respectively. These findings 
led to the investigation of the effect of EP300 modulation on drug resistance, 
EMT and CSC phenotypes and to uncover the underlying mechanisms. 
One of the cardinal features of EMT is loss of E-cadherin, an epithelial adherens 
junction protein. As a transcriptional co-activator of E-cadherin, EP300 has 
been found to positively regulate its expression. This was confirmed using 
EP300-depleted MCF-7 and HCT-116 cells where E-cadherin levels were 
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significantly reduced. Moreover, re-expression of E-cadherin was detected 
when the triple-negative breast cancer cells CAL-51 and MDA-MB231 were 
overexpressed with EP300. 
In order to assess the role of EP300 in drug resistance, short-term drug 
sensitivity and long-term drug resistance assays were performed using 
paclitaxel. Modulation of EP300 was found to alter paclitaxel sensitivity. To be 
specific, EP300 down-regulation led to increased resistance against paclitaxel. 
Many drug resistant cells acquire cancer stem-cell (CSC)-like properties 
(Voulgari and Pintzas 2009, Singh and Settleman 2010), and we confirmed that 
EP300-depleted cells, as well as their corresponding paclitaxel resistant 
derivatives and E-cadherin down-regulated cells, displayed increased sphere 
forming capacity. Reassuringly, ectopic expression of EP300 led to a significant 
reduction in sphere forming capacity. Similar findings were observed with soft 
agar clone formation assays. These findings confirm the role of EP300 in 
stemness in breast cancer cells. 
CSC-like populations in breast cancers express a CD44high/CD24low sub-
population (Sheridan, Kishimoto et al. 2006, Jaggupilli and Elkord 2012). In 
order to characterize the CSC-like population in EP300-modulated breast cancer 
cells, expression of CD44 and CD24, as the breast cancer CSC markers (Al-
Hajj, Wicha et al. 2003), was evaluated. Of particular interest, EP300 down-
regulation was associated with remarkably high enrichment of the 
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CD44high/CD24low sub-population. On the contrary, EP300 overexpressed 
MDA-MB231 cells had diminished proportion of this sub-population. However, 
CAL-51 cells overexpressing EP300 do not show that phenotype, probably due 
to the fact that CAL-51 has very low expression of CD44 (Kao, Salari et al. 
2009). It will be important to detect other CSC markers such as ALDH (Awad, 
Yustein et al. 2010) or ABCG2 in order to generalize these results. Overall, 
these findings highlight the role of EP300 in the acquisition of stemness, in 
tumour progression and in mediating drug resistance via CSC-like populations. 
The CD44high/CD24low antigenic phenotype is displayed by most of the CSC-
like cells that have undergone EMT (Liao, Zhang et al. 2007). EMT is not only 
accompanied by increased tumour invasion and metastasis, but is also 
associated with poor outcome, drug resistance and an increase in the number of 
cancer stem cell-like cells (Thiery, Acloque et al. 2009, Chen, Beetham et al. 
2014). Considering these, some of the well-characterised EMT markers were 
assessed in EP300-depleted cells. Among the EMT marker proteins vimentin 
and Snail were found to be significantly up-regulated in EP300-depleted cells. 
At the mRNA level, Twist was found to be up-regulated in both MCF-7 and 
HCT-116 cells that are depleted of EP300. Twist has an established role as a 
master regulator of cellular morphogenesis and plays an essential role in tumour 
metastasis (Yang, Mani et al. 2004). In breast cancer, Twist-mediated 
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transcriptional repression of E-cadherin (Vesuna, van Diest et al. 2008) triggers 
EMT (Mironchik, Winnard et al. 2005).  
Elevated levels of the EMT associated markers along with diminished 
expression of E-cadherin strongly demonstrated that absence of EP300 can, at 
least partially, evoke the EMT process. This is further supported by the findings 
that ectopic expression of EP300 in the basal-like, triple-negative MDA-MB-
231 cells partially reverted EMT by altering Zeb2 and Snail, but not the 
mesenchymal cytoskeletal filament vimentin. Furthermore, the ectopic 
expression of E-cadherin in the same MDA-MB-231 cells did not produce any 
discernible change in the EMT marker expression. This is in consistent with 
others (Hollestelle, Peeters et al. 2013, Chen, Beetham et al. 2014) who 
demonstrated that E-cadherin is not the only factor that drive EMT. Thus, EMT-
like phenotypic changes brought about by EP300 modulation may take place in 
an E-cadherin independent manner or may be a result of direct influence of 
EP300 on its downstream targets associated with cell-matrix adhesion. In order 
to confirm the E-cadherin independent pathway leading to EMT, E-cadherin 
might be re-introduced in EP300-depleted lines and the EMT-related 
phenotypic changes be evaluated.  
In the present study, up-regulation of the anti-apoptotic protein Bcl-2 has been 
confirmed in EP300- MCF-7 and HCT-116 models, and both at protein and 
mRNA levels. This indicates a plausible effect of EP300 deletion on paclitaxel 
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resistance by way of apoptosis inhibition. Moreover, Bcl-2 is reported to 
regulate both apoptotic pathways (extrinsic and intrinsic) by blocking the action 
of caspase-8 and -9 and this occurs via reduction of cytochrome c release (by 
decreasing mitochondrial permeability) from mitochondria (Li, Nijhawan et al. 
1997). This led to the investigation whether EP300 deletion can affect the 
apoptotic pathways by inactivation of initiator caspases. Interestingly, paclitaxel 
treatment upon EP300 depletion led to a remarkable decrease in the activation 
of both caspase-8 and caspase-9 in MCF-7 and caspase-9 in MTMEC. 
Furthermore, in MTMEC cells, EP300 silencing attenuated the effect of 
paclitaxel on cell death (as confirmed by the annexin v binding assay) and 
abrogated the effect of this drug on cell-cycle (as confirmed by the cell cycle 
profiling experiment). As paclitaxel triggers apoptosis both via intrinsic and 
extrinsic pathways (Park, Wu et al. 2004, Janssen, Pohlmann et al. 2007, 
Sprowl, Reed et al. 2012), our results suggest that paclitaxel resistance upon 
EP300 depletion may be a consequence of apoptosis evasion and is mediated by 
inactivation of both extrinsic and intrinsic pathways.   
In order to trace the paclitaxel resistance mechanism underlying apoptosis 
evasion, an apoptosis array was performed in EP300 deleted MTMEC cells. 
Among the differentially expressed genes included BCL2A1 (anti-apoptotic), 
BCL2L10 (pro-apoptotic), CASP5 (an inflammation-related caspase) and a set 
of tumour necrosis factor (TNF)-related proteins viz., CD40 (TNFRSF5), LTA 
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(TNF-β), TNFRSF11B (OPG), TNFRSF1B, TNFRSF25 and TRAF2. However, 
the array was performed once as an exploratory experiment and no firm 
conclusion can be inferred from the outcome. This necessitated a further 
comprehensive study using a transcriptome-wide analysis. 
Accordingly, sixteen whole transcriptome array were performed to identify 
potential EP300 downstream targets of drug resistance, EMT and CSC in 
EP300-depleted MCF-7 and their paclitaxel resistant descendants. Clearly, and 
as expected, cells devoid of EP300 exhibited differential gene expression 
pattern as compared to the cell carrying the empty vector. Among the 
significantly up-regulated genes included ABCG2, a drug transporter, also 
known as BCRP (breast cancer resistance protein) and prototypical stem cell 
marker; BCL2, an anti-apoptotic protein, involved in the caspase-mediated 
activation of the apoptotic pathways; ITGA2 and ITGA3, the two integrin 
receptors; NPY1R, encoding the Neuropeptide Y receptor Y1; TGFB2, a 
member of the transforming growth factor beta (TGF-β) family of cytokines; 
and TNFRSF11B, that belongs to the tumour necrosis factor receptor (TNFR) 
superfamily of receptors. The transcriptome profiling also identified potentially 
relevant and significantly down-regulated genes likely to be involved in the 
EP300-mediated biological effects. Among these were, two bone 
morphogenetic proteins (BMPs), namely, BMP4 and BMP7, the multi-
functional growth factors belonging to the TGF-β superfamily (Chen, Zhao et 
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al. 2004); CAPN9, encoding calpain-9 of the calpain family of cysteine 
proteases that are implicated in cell signalling, motility, apoptosis and survival 
(Davis, Martin et al. 2014); CEACAM5 and CEACAM6, the carcinoembryonic 
antigen-related cell adhesion molecules that play crucial roles in cell adhesion 
(Lacroix 2006); DUSP4, encoding the dual specificity phosphatase 4; and 
SASH1, which encodes for the SASH1 (SAM And SH3 Domain Containing 1), 
a potential tumour suppressor protein that prevents growth and invasion in 
breast cancer (Martini, Gnann et al. 2011).  
As discussed in Chapter 5, all of the above genes are likely to be involved in 
EP300-mediated drug resistance and are associated with EMT and CSC 
phenotypic changes (Table 7.1). Pathway enrichment analyses also revealed the 
potential roles of the proteins encoded by the above mentioned differentially  
Table 7.1: EP300-regulated genes involved in drug resistance, EMT and CSC 
Gene Symbol Phenotype Involved Potential/Proposed Mechanism  
ABCG2 Drug Resistance Drug transport or Efflux and stem cell marker 
BCL2 Drug Resistance Anti-apoptosis or Apoptosis evasion 
ITGA2 Drug Resistance Apoptosis evasion 
ITGA3 Drug Resistance Apoptosis evasion 
TGFB2 EMT Induction of EMT 
TNFRSF11B Drug Resistance Apoptosis evasion, tumour growth 
NPY1R EMT and CSC Facilitating growth and invasion  
BMP7 EMT and CSC Inhibition of TGFβ1-activated EMT 
CAPN9 Drug Resistance Evasion of TNF-α mediated apoptosis 
CEACAM5 CSC Loss of cell contact 
CEACAM6 CSC Loss of cell contact 
DUSP4 Drug Resistance, EMT 
and CSC 
Activation of MAPK signalling, promoting 
EMT and CSC 
SASH1 Drug Resistance, CSC Apoptosis evasion, tumour growth and 
invasion 
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regulated genes. Importantly, the up-regulated genes were highly enriched for 
pathways involving – response to drugs (ABCG2, BCL2, ITGA2 and 
TNFRSF11B), extracellular matrix (e.g. COL12A1, MMP16, TGFB2, 
TNFRSF11B, etc.), epithelial cell migration (ITGA2 and TGFB2), growth 
(BCL2, FGFR2 and TGFB2) and proliferation (e.g. BCL2, ITGA2, FGFR2, 
TGFB2, etc.) pointing to the role of EP300 in these processes. Among the 
down-regulated genes, BMP7 appeared to be involved in multiple processes 
including epithelium development, regulation of cell development and 
differentiation. Other down-regulated genes worth mentioning are CEACAM5 
and CEACAM6, involved in membrane anchoring; DUSP4, implicated in 
MAPK signalling; and SASH1 with a putative role in regulating apoptosis, 
tumour growth and invasion. Overall, the differentially regulated genes in the 
EP300-silenced MCF-7 transcriptome are likely to facilitate EP300 mediated 
drug resistance, stemness and EMT. Importantly, key molecules in the signature 
obtained in EP300-depleted MCF-7 cells, such as Bcl-2 and ABCG2, were also 
confirmed in EP300 knocked-out HCT-116 colon carcinoma cells. 
Experimental down-regulation of EP300 in another breast cancer epithelial line, 
such as T47D, using a similar strategy will undoubtedly help in the 
generalization of the results obtained here. 
In case of cancer cells that have undergone EMT, E-cadherin loss is prominent. 
The present study clearly demonstrates the concomitant loss of E-cadherin in 
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EP300-depleted epithelial cells (MCF-7) that displayed EMT-like traits. In 
breast cancer, E-cadherin loss is accompanied by invasion and metastasis and its 
expression is a guide for determining the histopathologic type of breast cancer. 
For example, E-cadherin level is low in IDC and almost absent in ILC and 
metastatic breast cancers. Thus, we decided to investigate whether there was 
any correlation between EP300 and E-cadherin in various forms of breast 
cancers. Interestingly, immunohistochemical staining for EP300 and E-cadherin 
revealed a positive correlation between expression of these two proteins in IDC, 
ILC and metaplastic breast cancer. The strongest correlation was observed in 
case of metaplastic breast carcinoma where E-cadherin level is virtually absent. 
However, further confirmatory studies with a larger number of metaplastic 
cases are required before drawing any firm conclusion. In this respect, we have 
applied to the Breast Cancer Now Tissue Bank to access its 10 metaplastic 
samples (Dr. Yagüe, personal communication). Metaplastic breast carcinoma is 
a rare subtype and the EMT core signatures associates closely with this 
particular subtype. Low E-cadherin levels have been linked to clinical 
presentation of metaplastic breast cancers (Taube, Herschkowitz et al. 2010). 
Since passage through EMT is associated with acquisition of stem cell 
characteristics, cancer cells in metaplastic subtype are likely to contain 
relatively high proportions of cancer stem cells (Taube, Herschkowitz et al. 
2010). It will be interesting to study whether other EMT markers are also 
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differentially regulated in metaplastic samples. Thus, immunohistochemical 
staining for EP300, in addition to that for E-cadherin may serve as a guide to the 
prognosis of metaplastic breast carcinoma considering also the data supporting 
the role of EP300 in regulating EMT and stemness, via regulation of E-cadherin 
expression.  
Further work may include definitive proof of the involvement of Bcl-2 in drug 
resistance in EP300-depleted cell models by using selective Bcl-2 inhibitors, 
such as ABT-737® (Abott) (Muqbil and Mohammad 2015), ABT-199® 
(Venetoclax, Abott) (Vaillant, Merino et al. 2013) and Bcl-2 antisense 
oligonucleotide, G3139®, also known as oblimersen (Genasense®, Genta) 
(Moulder, Symmans et al. 2008). Determination of other CSC markers by flow 
cytometry, such as ALDH Aldefluor assay and ABCG2 (as this is up-regulated 
following EP300 depletion), would broaden the spectrum of markers studied. 
Equally, motility and migration assays would offer functional proof for the 
acquisition of metastatic properties in vitro. Further confirmation of the 
globality of the pathways controlled by EP300 would also benefit from the 
establishment of another breast cancer epithelial cell line with EP300 either 
down-regulated by expression of stable hairpins or knocked-down using 
CRISPR-Cas9 (Sander and Joung 2014). Further in vivo assays in mouse 
models using xenografts will also be crucial to establish the validity of these 
findings in vitro. 
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Taken together, the data from the present study encourages further investigation 
to decipher the underlying mechanisms for EP300 mediated pathways in breast 
cancer related to drug resistance, EMT and stemness. Overall, the findings 
provide a strong evidence for considering EP300 as a marker of breast cancer 
drug resistance, EMT and CSC phenotypes and a putative role in the prognosis 
of breast cancer aiding in diagnosis. In conclusion, the data can be utilized to 
carry out further in-depth study for establishing the translational value of EP300 
as a mediator of breast cancer drug resistance, EMT and stemness, from the 
laboratory to the clinical setting. 
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Chapter 9: Appendices 
Appendix I 
List of primary antibodies used for Western blotting 
Antibody Species Dilution Manufacturer/Supplier 
Anti-EP300 Anti-rabbit 1: 5,000 Abcam, Cambridge, UK 
Anti-CDH1 Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-Bcl-2 Anti-mouse 1:500 Santa Cruz, Texas, USA 
Anti-vimentin Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-snail Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-twist Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-zeb1 Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-slug Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-β-catenin Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-N-cadherin Anti-rabbit 1: 1,000 Cell signalling, Hertfordshire, UK 
Anti-nicastrin Anti-rabbit 1:1,000 Sigma-Aldrich, Dorset, UK 
Anti-SGK1 Anti-rabbit 1:500 Αbcam, Cambridge, UK 
Anti- β-actin Anti-mouse 1: 20,000 Αbcam, Cambridge, UK 
Anti- lamin-B Anti-mouse 1: 20,000 Santa Cruz, Texas, USA 
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Appendix II 
List of primers used for RT-qPCR 
Target gene Fwd/Rev Primer sequence in 5'→3' 
GAPDH 
Fwd TGAAGGTCGGAGTCAACGGATTT 
Rev GCCATGGAATTTGCCATGGGTGG 
RPS6 
Fwd AGGGTTATGTGGTCCGAATCA 
Rev TGCCCCTTACTCAGTAGCAGG 
RPS14 
Fwd 5TCACCGCCCTACACATCAAACT 
Rev CTGCGAGTGCTGTCAGAGG 
RPLO 
Fwd GCAGCATCTACAACCCTGAAG 
Rev CACTGGCAACATTGCGGAC 
NCT 
Fwd CAAAGCACCTTCAGCATCAA 
Rev GGTCACATCAGGTGCCTTTT 
RUNX1 
Fwd GGCTGGCAATGATGAAAACT 
Rev TGATGGCTCTGTGGTAGGTG 
FOXA1 
Fwd GTGGCTCCAGGATGTTAGGA 
Rev GCCTGAGTTCATGTTGCTGA 
EP300 
Fwd AAAAATAAGAGCAGCCTGAG 
Rev AGACCTCTTTATGCTTCTTCC 
CDH1 
Fwd GATTCTGCTGCTCTTGCT 
Rev GTCAAAGTCCTGGTCCTC 
BCL2 
Fwd GATTGTGGCCTTCTTTGAG 
Rev GTTCACAAAGGCATCC 
ABCG2 
Fwd TGGCTGTCATGGCTTCAGTA 
Rev GCCACGTGATTCTTCCACAA 
TGFB2 
Fwd AGATTTGCAGGTATTGATGG 
Rev ATTTCTAAAGCAATAGGCCG 
ITGA2 
Fwd GGTGGGGTTAATTCAGTATG 
Rev ATATTGGGATGTCTGGGATG 
ITGA3 
Fwd GGAAACAGCTACATGATTCAG 
Rev CCCAATATAGAGGTTTCCTTG 
TNFRSF11B 
Fwd ATAGATGTTACCCTGTGTGAG  
Rev AAGACACTAAGCCAGGTTAGG  
BMP4 
Fwd AGAACATCTGGAGAACATCC 
Rev AATGTTTATACGGTGGAAGC 
BMP7 
Fwd TGGTCCACTTCATCAACC 
Rev TTCTGTATTTCTTCAGGATGAC 
CEACAM5 
Fwd TCATCCTGAATGTCCTCTATG 
Rev GTGATGTTGGAGATAAAGAGC 
CAPN9 
Fwd CAAGCTAAATGGGAGCTATG 
Rev CTCTTTAGTTTGGAAGGTCTC 
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List of primers used for RT-qPCR (contd.) 
Target gene Fwd/Rev Primer sequence in 5'→3' 
VIM 
Fwd AGTCCACTGAGTACCGGAGAC 
Rev CATTTCACGCATCTGGCCGTTC 
SNAI1 
Fwd AGGCCATGTCCGGACCCACA 
Rev GTGGAGCAGGGACATTCGGGA 
ZEB2 
Fwd CAAGAGGCGCAAACAAGCC 
Rev GGTTGGCAATACCGTCATCC 
TWIST 
Fwd CGGAGACCTAGATGTCATTG 
Rev ACGCCCTGTTTGTTTGAAT 
BCL2A1 
Fwd GAAGAAACTTCTACGACAGC  
Rev AAGCCATTTTCCTCTTCTTG  
CD40 
Fwd GTGAAAGCGAATTCCTAGAC  
Rev AGATGGTTCTGTTTCTGAG  
TNFRSF1B 
Fwd ACCAGGTGGAACTCAAG  
Rev TTTCAGTTCCTGGTCTGG  
TNFRSF25 
Fwd AGCAGTTCACCCTTCTAC  
Rev CAGTATCTCTGCGGGAAC  
TRAF2 
Fwd GGACCAAGACAAGATTGAAG  
Rev AGTCTGAGATCTTCCAGATG  
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Appendix III 
Reagents for Western blotting 
No. Description Vol./Pack Supplier/Manufacturer Ref# 
1 4X Protogel Resolving Buffer 
(1.5 M Tris HCl, 0.4% SDS, pH 
8.8) 
450 mL/1Lt National Diagnostics EC-892 
2 Protogel Stacking Buffer (0.5 M 
Tris HCl, 0.4% SDS, pH 6.8) 
200 mL National Diagnostics EC-893 
3 Ultra pure ProtoFLOWGel (30% 
w/v Acrylamide: 0.8% w/v) 
450 mL/1Lt Flowgen Bioscience H17009 
H16996 
4 Odyssey Nitrocellulose 
Membrane 
1 VWR P/N 66485 
5 Spectra Multicolor Broad Range 
Protein  
10X250 μL Thermo Scientific 26623 
 
Gel composition for WB 
Reagent Running Gel (20 ml) Stacking Gel 
(10 ml) 6% gel 10% gel 
Water 10.8 ml 8 ml 6.1 ml 
ProtoFLOWGel 4.0 ml 6.7 ml 1.3 ml 
Resolving/Stacking 
buffer 
5.0 ml 5.0 ml 2.5 ml 
APS (10%) 200 µl 200 µl 50 µl 
TEMED 20 µl 20 µl 10 µl 
APS = Ammonium peroxydisulfate, TEMED = Tetramethylethylenediamine 
 
Other reagents used 
Reagent Name Composition  
1xTBST 50 mM Tris-HCl, 150 mM NaCl and 0.1% (v/v) Tween-20, pH 7.5 
5xLaemmli buffer 0.3 M Tris-HCl pH 6.8, 15% (w/v) SDS, 50% (v/v) glycerol, 16% 
(v/v) β-mercaptoethanol, 0.05% (w/v) bromophenol blue 
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Appendix IV 
Publications associated to the thesis findings 
1. Research Article 
Title: miR-106b~25 cluster regulates multidrug resistance in an ABC 
transporter-independent manner via downregulation of EP300. 
Authors: Yunhui Hu, Kaiyong Li, Muhammad Asaduzzaman, Raquel Cuella, 
Hui Shi, Selina Raguz, Raoul Charles Coombes, Yuan Zhou and Ernesto Yagüe 
Journal: Oncology Reports, Volume 35 Issue 2 
Published online on: Thursday, November 12, 2015  
DOI: 10.3892/or.2015.4412 
Publication URL: http://www.spandidos-publications.com/or/35/2/1170  
 
2. Database submitted 
Title: Gene Expression Pattern in EP300 knocked-down MCF-7 cells and 
corresponding paclitaxel resistant derivatives.  
Submitted to: National Center for Biotechnology Information (NCBI), Gene 
Expression Omnibus 
GEO accession no. GSE76200 
Database release date: December 19, 2018. 
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3. Conference Proceeding (Poster presentation) 
Abstract Title: Role of EP300 in mediating drug resistance, EMT and stemness 
in breast cancers 
Authors: Muhammad Asaduzzaman, Stephanie Constantinou, Haoxiang Min, 
Charles Coombes and Ernesto Yagüe 
Conference on: “Breast Cancer – Bridging Gaps in our Knowledge to Improve 
Patient Outcome” 
Venue: SAGE Newcastle/Gateshead 
Date: October 7 – 9, 2015 
Conference Organizer: British Association for Cancer Research (BACR) 
Conference Sponsor: Breast Cancer Now  
 
 
 
 
 
